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Abstract-The role of Slit/Robo signalling in peripheral nerve regeneration. 
 
Slit/Robo chemorepulsive signalling has been shown to play a role in axon 
pathfinding during the development of the central nervous system. There is evidence 
that Slit/Robo are expressed in the adult intact and injured peripheral nervous 
system. Owing to their role in axon pathfinding during development it is plausible that 
Slit/Robo signalling could also play a role in axon pathfinding following peripheral 
nerve transection injury where axons must find their way across the newly-formed 
nerve bridge. This project aimed to study the expression pattern of Slit and Robo 
family members in both the intact and injured adult peripheral nervous system to 
establish a potential role for Slit/Robo signalling in peripheral nerve repair.  
A range of methods were employed to look at the expression of Slit/Robo’s at both 
the mRNA and protein levels. These included RT-PCR and in situ hybridisation to 
look at mRNA levels and immunohistochemistry and western blotting to determine 
protein levels. Staining was carried out on both mouse adult intact sciatic nerves and 
transected sciatic nerves. To establish the role of Slit/Robo during peripheral nerve 
regeneration, Slit/Robo mutant mice underwent a sciatic nerve transection to 
replicate a peripheral nerve injury; nerves were removed and underwent whole 
mount staining to establish axon regeneration patterns. 
Our results revealed a diverse expression pattern of Slit/Robos in the intact mouse 
sciatic nerve at both the mRNA and protein levels. Slit/Robos were expressed in a 
range of cells in the sciatic nerve including Schwann cells, axons, endothelial cells, 
fibroblasts and the cell bodies of sciatic nerve neurons. During peripheral nerve 
regeneration, Slit3 was expressed strongly in macrophages surrounding the nerve 





The Slit2, Slit3 and Robo1 single adult mutants show normal sciatic nerve 
morphology, but Slit3 and Robo1 single and double mutants had severely disrupted 
axon trajectories following sciatic nerve transection. However, Robo1 mutants did 
not have any apparent defects in recovery following a crush injury.  
Slit and Robos family members are expressed in the adult mouse sciatic nerve, and 
this signalling pathways presence is likely linked to maintenance of the peripheral 
nerve structure. Slit3-Robo1 signalling plays a crucial role in correct cell trajectory 
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VEGF  vascular endothelial growth factor  
Wld slow Wallerian degeneration  













Chapter 1 Introduction 
Peripheral nerve damage due to an injury or pathology can lead to reduced or no 
motor or sensory innervation to the affected region, ultimately leaving that person 
with a reduced quality of life. 2.8% of trauma patient are left with life changing side 
effects due to peripheral nerve injuries [Houschyar et al., 2016]. The most debilitating 
type of nerve injury is a cut injury where the nerve is completely severed, and 
recovery rates remain poor [Seddon, 1943; Sunderland, 1951]. The gold standard to 
repair a cut nerve remains a nerve graft from another region of the body [White et al., 
2012]. Nerve grafting, however, leads to sensory loss from the innervation site of the 
grafted nerve and does not always have the best outcome for the patient [White et 
al., 2012]. To make progress in an optimal treatment for peripheral nerve injury 
patients, that does not require a nerve graft; more research needs to be undertaken 
to understand the underlying mechanisms that control nerve regeneration. 
1.1 Slit/Robo signalling 
1.1.1 Roundabout 
During the development of the central nervous system, in insects and vertebrates, a 
large proportion of axons from both sides of the brain and spinal cord project towards 
the midline. The axons then cross the midline into the opposite side of the CNS they 
originate from, these axons are referred to as commissural axons. These axons only 
cross the midline once [Kidd et al., 1998a]. 
In a large-scale screen in Drosophila, a mutation in the gene Roundabout (Robo) 
was identified as affecting midline crossing during the development of the CNS. 
Robo was upregulated in axon growth cones after midline crossing to stop them re-
crossing, whereas in Robo mutants growth cones would aberrantly cross the midline 





The sequence of Robo1 was characterised elucidating its structure and expression 
pattern in Drosophila. Robo had a conserved structure of five immunoglobin-like 
domains, followed by three fibronectin type three domains, a single span 
transmembrane domain and conserved cytoplasmic domains 0-3 (CC0-3). Robo1 
was established as a receptor upregulated in growth cones after midline crossing 
and that Robo-like protein sequences were identifiable in rats and humans. [Kidd et 
al., 1998a].  
At a similar time, Zallen et al., (1998) identified Robo’s homolog, Sax3, in C.elegans. 
Sax3 was identified as a receptor that had a similar structure to Robo and was part 
of an immunoglobin superfamily. Sax3 was also expressed in axon growth cones 
and involved in axon pathfinding, Sax3 mutants also displayed aberrant axon 
projections [Zallen et al., 1998].  
Robo2 and Robo3 were further identified in Drosophila [Rajagopalan et al., 2000a]. 
These two receptors are also involved in midline crossing of commissural axon 
crossing during Drosophila development. However, Robo2 and Robo3 expression 
were determined to be primarily involved in lateral positioning of the axon away from 
the midline, rather than inhibiting axon recrossing [Rajagopalan et al., 2000a; 
Rajagopalan et al., 2000b]. Robo2 is also involved in expelling axons out of the 
midline to stop them remaining within the midline [Rajagopalan et al., 2000b].  
Robo1-3 were also sequenced in zebrafish, zRobo1 and zRobo2 had an 80% 
sequence homology with hRobo1 and hRobo2, while zRobo3 had a 68% homology 
with mRobo3. The structure of zRobo2 and 3 was the same structure previously 
observed in Drosophila [Challa et al., 2001; Lee et al., 2001].  In zebrafish, the 





axons along the dorsoventral axis of the forebrain [Devine and Key, 2008]. These 
findings further confirm the conserved nature of the Robo receptors.   
Robo1-4 have been identified in mammals, mammalian Robo1 and 2 have a 
conserved structure to that observed in Drosophila [Kidd et al., 1999a; Huminiecki et 
al., 2002; Long et al., 2004; Sabatier et al., 2004]. Robo1 and 2 are both expressed 
in distinct populations of commissural axons, with expression of both significantly 
increasing in axons that had crossed the floorplate. Furthermore, in Robo1 and 
Robo2 single mutants’ axons crossing the floor plate were severely misguided, 
confirming that Robo1 and Robo2 are involved in axon pathfinding during 
development [Long et al., 2004]. 
Robo1 is also involved in the guidance of various axon populations of several  
forebrain tracts. Robo1 is required for the correct formation of the corpus callosum 
(CC) and the hippocampal commissure (HC); in Robo1 knockouts axons of the CC 
and HC became segregated rather than migrating as a single bundle. In Robo1 
knockouts axons of the CC also projected into the septum instead of crossing the 
midline and became mixed with axons from the HC [Andrews et al., 2006]. These 
results further ratify Robo’s role in axon pathfinding during development.   
Robo1 and Robo2 have also been reported to be expressed on endothelial cells and 
in other blood vessel-associated cell types in mice. Slit2-Robo1/Robo2 signalling is 
involved in promoting ocular neovascularisation during development by driving 
angiogenic sprouting and endothelial cell migration. Both Slit2 and Robo1/Robo2 
inducible knockouts show a severe lack of blood vessel formation in the retinas of 
postnatal day seven mice [Rama et al., 2015]. Robo1 has also been reported to 





activation of Robo is essential in endothelial migration, and blocking Robo results in 
a reduction of vasculature formation [Rama et al., 2015; Wang et al., 2003].  
Robo3 shares a 40% homology with Robo1 and Robo2, sharing the same 
extracellular domain [Yuan et al., 1999; Sabatier et al., 2004]. However, the 
intracellular domain of Robo3 differs as it does not contain a CC1 domain. Robo3 is 
also expressed in commissural axons, but in stark comparison to Robo1 and 2 is 
expressed in pre-crossing axons rather than post-crossing axons. In Robo3 mutants, 
axons were unable to enter the floor to cross the midline, suggesting that Robo3 
attenuated the chemorepulsive effects of normal Slit/Robo signalling allowing 
commissural axons to cross the midline [Sabatier et al., 2004].  Mutations in human 
Robo3 have also been documented, these mutations were identified in patients with 
horizontal gaze palsy with progressive scoliosis. MRI images and 
electrophysiological data indicated a conserved role for Robo3 in enabling axons of 
the hindbrain to cross the midline [Jen et al., 2004].  
Robo4 was identified using bioinformatic mining, it shares homology with the Robo 
family members. However, it is much smaller. Robo4 differs in both its intracellular 
and extracellular domain compared to other Robo’s. Robo4 has only two of the five 
immunoglobulin-like domains and two of the three fibronectin domains [Huminiecki et 
al., 2002]. The intracellular domain of Robo4 only possesses CC0 and CC2 of the 
potential four domains that are present in Robo1 [Park et al., 2003]. Robo4 is 
expressed during angiogenesis in endothelial cells during mouse development, and 
also in the quiescent endothelium [Huminiecki et al., 2002, Park et al., 2003; Okada 
et al., 2008]. In the quiescent endothelium, Robo4 has been shown to inhibit 
angiogenesis but is important for the maintenance of endothelial permeability [Cai et 








Following Robos discovery Slit was then identified as the ligand that interacted with 
the Robo receptor [Kidd et al., 1999; Brose et al., 1999; Li et al., 1999]. Slit had been 
previously identified in Drosophila (dSlit) [Rothberg et al., 1988; Rothberg et al., 
1990]. dSlit was characterised as containing leucine-rich repeats (LRR), seven 
epidermal growth factor (EGF)-like repeats, a variable domain and a cysteine knot. 
Due to the lack of a transmembrane domain and presence of LRR, it was 
hypothesised that dSlit was likely a secreted protein. They determined that dSlit was 
expressed by midline glial cells involved in commissural axon development, and 
reduced Slit expression resulted in disrupted development of the midline [Rothberg 
et al., 1990; Rothberg et al., 1988].  
Three mammalian Slit proteins (Slit1-3) were identified with sequence homology to 
dSlit (44%). The three mammalian Slits share a high sequence homology between 
one another (60-66%), all having a general structure of four tandem arrays of LRR, 
nine EGF repeats, an Agrin-Laminin-Perlecan-Slit (ALPS) conserved spacer motif, 
and a cysteine knot. The mammalian Slits differ from dSlit due to the addition of an 
LRR in the third tandem array and two EGF-like domains [Holmes et al., 1998; Itoh 
et al., 1998; Nakayama et al., 1998; Brose et al., 1999].  
In early experiments, hSlit2 was shown to have both a chemoattractive and 
chemorepellent effect [Brose et al., 1999; Wang et al., 1999]. Brose et al., (1999) 
showed that hSlit2 had a chemorepellent effect on spinal motor axons. In 
comparison, Wang et al., (1999) determined that sensory axons exposed to hSlit2 





Both Brose et al., and Wang et al., also determined that full-length hSlit2 had a 
molecular weight of around 190kDa. During purification assays, both groups 
identified that hSlit2 was likely cleaved due to the presence of two fractions at 
140kDa and 60kDa. Slit2-N was an amino acid cleavage product of 140kDa whereas 
Slit2-C, 60kDa in weight, was a carboxyl-terminal cleavage product [Brose et al., 
1990; Wang et al., 1999].  
Moreover, in mice, all three mammalian Slits were identified and expressed during 
the development of the floor plate, like that documented during Drosophila 
development [Yuan et al., 1999]. Furthermore, it was determined that the expression 
of Slit is required for the repulsion of commissural axons away from the midline after 
crossing it [Zou et al., 2000]. Slit triple mutants had disorganised commissural axons 
with many axons lingering in the midline or recrossing the midline, confirming Slits 
role in central nervous system development [Long et al., 2004].  
Slit is not only involved in chemorepulsion of commissural axons but is also involved 
in branching and arborisation. When sensory axons in the central nervous system of 
mice encountered Slit2, they branched and arborised, when Slit2 activity was 
blocked these effects were attenuated [Özdinler and Erzurumlu, 2002; Yeo et al., 
2004]. Slit has also been shown to influence neuronal migration during development 
in a chemorepulsive manner [Hu, 1999; Wu et al., 1999]. In addition to its roles in 
axon guidance, Slit is also capable of inhibiting leukocyte chemotaxis induced by 
chemokines; Slit-dependent signalling had similar effects on several types of 
leukocytes including lymphocytes, monocytes and neutrophils [Wong et al., 2002]. 
1.1.3 Slit-Robo interaction and downstream signalling pathways 
After the identification of Slit as the ligand for Robo, a more in-depth analysis was 





interacted. It was determined that the LRR of Slit were sufficient to elicit downstream 
signalling events by Robo [Figure 1.1] [Chen et al. 2001; Battye et al. 2001]. Further 
analysis revealed that in all 3 Drosophila Robos, the first Ig domain competed for the 
same region of dSlit, the concave face of the second leucine-rich repeat [Howitt et al. 
2004; Hohenester 2008]. As mammalian Slit/Robo have a high sequence homology 
with Drosphilia Slit/Robo, it was unsurprising that the same interaction was observed 
in mammals [Liu et al. 2004; Morlot et al. 2007]. 
Many papers have shown that the Slit/Robo interaction leads to chemorepulsion. 
Chemorepulsion is controlled through changes in actin dynamics primarily controlled 
by the activation or inactivation of small guanosine triphosphate hydrolysing proteins 
[GTPases] of the Rho family including RhoA, Cdc42 and Rac1 [Van Aelst and 
D’Souza-Schorey, 1997]. These GTPases can cycle from an active GTP-bound state 
to an inactive GDP-bound state under the influence of GTPase activating proteins 
(GAPs) and Guanine nucleotide-Exchange Factors (GEFs) [Bustelo et al., 2007].  
Slit-Robo GAPs 1, 2 and 3 (srGAP) have been identified in mice, and these proteins 
interact with the CC3 domain of Robo. The interaction between srGAP1 and the CC3 
domain of Robo1 was significantly increased upon the binding of Slit to Robo, and 
this effect was dose-dependent. srGAP1 activity increases the number of inactive 
Cdc42, ultimately leading to growth cone collapse through reduced actin 
polymerisation [Figure 1.1] [Wong et al., 2001].  
In Drosophila the Cross GTPase-activating protein (CrossGap)/Visle protein can 
interact with the cytoplasmic domain of Robo and is a GAP that is specific for the 
Rac GTPase. The inactivation of Rac via CrossGAP contributes to the control of cell 
migration [Figure 1.1] [Lundström et al., 2004; Hu et al., 2005]. Abelson tyrosine 





Slit/Robo signalling in Drosophila [Figure 1.1]. Both Ena and Abl can bind to the 
cytoplasmic domain of Robo. The binding of Ena to Robo has shown to be involved 
in chemorepulsion during midline crossing. In comparison, Abl is an antagonist of 
Robo, and it is likely Abl phosphorylates part of the cytoplasmic domain of Robo 
attenuating downstream signalling pathways [Bashaw et al. 2000].  
Slit/Robo signalling can also silence chemoattractive cues. Slit binding to Robo1 
inhibited the chemoattractive effects of deleted in colorectal cancer (DCC). The 
CC1F domain of Robo1 interacted with the P3 intercellular domain of DCC and was 
able to inhibit the attractive force of netrin-1 signalling [Stein and Tessier-Lavigne, 
2001]. 
There is evidence to suggest that both Slit and Robo can be cleaved and this may 
have an influence on downstream signalling events. Extra-cellular immobilised Slits 
have been shown to bind to Robo1 leading to decreased molecular tension in the 
Robo1 receptor [Barak et al., 2014]. This leads to the exposure of the 
juxtamembrane region containing a metalloproteinase cleavage site. This cleavage 
site has been shown to be involved in the ectodomain shedding of Robo1, which in 
drosophila is a requirement for the recruitment of downstream signalling factors 
[Coleman et al., 2010]. In drosophila, the cleavage fragment can be transported to 
the nucleus where its function is unknown [Seki et al., 2010]. 
Slit is also able to be cleaved into an n-terminal and a c-terminal fragment, and this 
process is conserved between drosophila and vertebrates. Both full length Slit and 
the n terminal Slit stay associated with the cell surface and are able to bind Robo’s 
unlike the c-terminal fragment which resides mostly in the extracellular space and 
has the ability to bind dystroglycan and plexins [Brose et al., 1999; Delloye-





determined that the n-terminal fragment of Slit2 was the only stable form of Slit and 
the c-terminal quickly degraded [Jordan et al., 2015]. However, this has not yet been 
determined in vertebrates.  
Slit and Robo have also been implicated in tumour metastasis through regulating cell 
motility through actin dynamics. Slit2-Robo1 signalling has been shown to regulate 
actin dynamics and therefore cell motility by inhibiting the activity of Cdc42 through 
srGAP1, the dysfunction of this pathway in colorectal, oesophageal and breast 
cancer has a poor prognosis [Wong et al., 2001; Tseng et al., 2015; Bhattacharya et 














































Leucine rich repeat Epidermal growth factor (EGF)-like repeats 
Agrin-Laminin-Perlecan-Slit (ALPS) conserved spacer motif Cysteine knot  
Immunoglobin-like domains Fibronectin type three domains 






































Figure 1.1: Slit/Robo signalling. Slit is composed of four leucine rich repeats, 
nine epidermal growth factor-like repeats, a single ALPS domain and a cysteine 
knot. Slit interacts with the first immunoglobin-like domain (Ig) of Robo. Robos 1-3 
have an extracellular domain composed of five Ig domains and three fibronectin 
type III domains. The intracellular domain of Robo1 and Robo2 is composed of 
four conserved cytoplasmic domains 0-3 (CC0-3). Upon Slit binding to Robo1, 
CC3 recruits srGAP1 which converts Cdc42 from is active GTP bound form to its 
inactive GDP bound form.  In Drosophila CrossGap/Visle interacts with the 
cytoplasmic domain of Robo, CrossGap inhibits Rac activity by converting it into 
its inactive GDP bound form. Both Abelson tyrosine kinase (Abl) and Enabled 
(Ena) can bind to the cytoplasmic domain of Robo. Binding of Ena to Robo has a 
chemorepulsive effect. In comparison Abl is an antagonist of Robo and 





1.2 Peripheral nerve anatomy 
The peripheral nervous system encompasses all nerves outside the spinal cord and 
brain. It can be divided into the autonomic, enteric and the somatic nervous systems. 
The somatic nervous system can be subdivided further into the motor (efferent) and 
sensory (afferent) [Farley et al., 2014].  
1.2.1 Sensory and motor neurons 
Motor neurons of the peripheral nervous system comprise the lower motor neuron 
system. Cell bodies of the motor somatic nervous system reside in the ventral horn 
of the spinal cord, from which they extend an axon [Figure 1.2] [Cramer et al., 2014]. 
The cell bodies of motor axons are large, polygonal and have many dendrites. Motor 
cell bodies with axons that extend to the trunk of the body are found medially in the 
grey matter of the spinal cord. Whereas, cell bodies of axons that innervate limbs are 
found more laterally in the grey matter of the spinal cord [Farley et al., 2014].  
The cell bodies of the lower motor neurons synapse with axons from the upper motor 
neuron system. The neurons of the upper motor neuron system originate from the 
primary motor cortex; they extend axons down through the corticospinal tracts of the 
spinal cord to the appropriate spinal nerve level, where they synapse with the 
appropriate cell body of the lower motor neuron system [Kandel et al., 2013].  
In comparison, sensory neuron cell bodies reside in the dorsal root ganglia (DRG) 
and are pseudounipolar [Figure 1.2]. They extend an axon out of their cell bodies, 
which extends from the dorsal horn of the spinal cord to the innervation target 
[Cramer et al., 2014; Farley et al., 2014]. Cell bodies of the DRG can be subdivided 
into small dark and large light cell bodies, all cell bodies are surrounded and 
supported by a single layer of satellite glial cells [Hanani, 2004; Hatai, 1902; Lawson, 





mechanoreceptors, whereas small dark neurons have either unmyelinated C-fibres 
or myelinated Aδ-fibres [Zerboni and Arvin, 2015]. Axons of the sensory nervous 
system will synapse in the spinal cord or the brain, ultimately relaying information to 
the somatosensory cortex [Kandel et al., 2013]. 
1.2.2 Axon structure in the peripheral nervous system 
Axons are the longest structures in the body, and their structure is adapted to 
conduct action potentials over relatively long distances. The internal axon structure 
consists of microtubules, peripherin, α-internexin, microfilaments and three 
neurofilament sub-units including light, medium and heavy chains [Hoffman et al., 
1987; Waxman et al., 1995]. Specific organelles reside in the axon which includes 
mitochondria, axoplasmic reticulum and vesicles supporting the axons function 
[Hollenbeck, 1996; Tsukita and Ishikawa, 1980].  The axolemma is a plasma 
membrane that surrounds these aforementioned structures and is specialised to 
facilitate conduction. 
Unmyelinated axons, C-fibre axons, are small calibre axons typically ranging from 
0.1-1.2µm in size [Hursh, 1939; Lloyd, 1943]. C-fibre axons include postganglionic 
autonomic fibres, nociceptive, and thermoreceptive fibres [Georgopoulos, 1976; 
Sugiura et al., 1986]. In unmyelinated axons, the conduction of action potentials 
occurs along the entire length of the axons. Therefore, the entirety of the axolemma 
of unmyelinated axons has voltage-gated sodium channels resulting in the 
conduction velocity being relatively slow, around 0.5-1.4m/s [Harper and Lawson, 
1985; Hursh, 1939; Lloyd, 1943]. 
In comparison, myelinated axons are larger in calibre usually ranging from 1µm-
20µm and have conduction velocities that are usually around 12-70m/s [Harper and 





fibre axons can be further subdivided into α, β, γ, and δ. Group A-fibre axons include 
somatic motor axons and large sensory (e.g. proprioceptive) axons. Group B-fibre 
axons are mainly preganglionic sympathetic fibres [Erlanger and Gasser, 1968; 
Hursh, 1939]. Myelinated axons are ensheathed by myelin formed by single 
myelinating Schwann cells (SCs), the area of the axon ensheathed by a single 
myelinating SC is called an internode. Myelinating SCs are separated by nodes of 
Ranvier, which are exposed areas of the axolemma that are enriched with sodium 
and potassium channels. Propagation of the action potential occurs only at the 
nodes of Ranvier via saltatory conduction which increases the conduction velocity of 
the action potential [Hodgkin and Rushton, 1946; Hodgkin and Huxley, 1952]. 
1.2.3 Slit/Robo expression in neurons 
Slit/Robos are highly expressed in axons of neurons during development; some 
groups have therefore already begun to establish if Slit/Robos are expressed in the 
adult peripheral nervous system. Yi et al., (2006) observed Slit1 and Robo2 mRNA 
expression in the sensory cell bodies and axons of the sciatic nerve in rats.  It was 
determined that Slit1 was expressed in neuronal cell bodies and their axons, 
whereas Robo2 was only present in the sensory cell bodies. Zhang et al., (2010) 
determined that Robo2 and Slit1 mRNAs were expressed in L3-L6 cultured and 
intact rat DRGs. Bloechlinger et al., (2004) used in-situ hybridisation to determine 
that Robo2, Slit1 and Slit3 mRNA expression was observed in the neuronal cell 
bodies of the DRG [Bloechlinger et al., 2004].  
Wherle et al., (2005) documented the expression of Slits in the thoracic grey matter 
of the spinal cord where motor cell bodies reside. Slit1-3 mRNA have all been 





 Currently, there is no evidence documenting the expression of Robo1, Slit2 or Slit3 
proteins in neurons of the sciatic nerve in vivo. Furthermore, no work has currently 
been done to establish the expression pattern of Slit/Robo’s in the lumbar region of 
the spinal cord where motor cell bodies of the sciatic nerve reside.  
1.3 Schwann cells (SCs) 
SCs in the intact nerve are primarily involved in the survival and maintenance of 
axons, and secondly in facilitating correct nerve conduction velocity. SCs can be split 
into two groups; myelinating and non-myelinating. Non-myelinating SCs can be 
further subdivided into Remak, satellite and perisynaptic [Griffin and Thompson, 
2008; Pereira et al., 2012]. SCs can also adopt a pro-repair state in the adult PNS in 
response to injury. This pro-repair state is induced due to loss of axonal contact 
caused by injury, and results in the down-regulation of mature SC markers enabling 
them to respond to the peripheral nerve injury (See section 1.2.1) [Arthur-Farraj et 
al., 2012; Harrisingh et al., 2004; Jessen and Mirsky, 2008; Kristjan R. Jessen, 
Mirsky, and Arthur-Farraj, 2015; Jessen and Mirsky, 2016].  
All types of SCs are derived from neural crest cells (NCCs). NCCs delaminate from 
the neural tube and migrate throughout the body to differentiate into an extensive 
range of tissues. NCCs differentiate into both neural and glial cells of the somatic, 
autonomic, and enteric nervous systems. NCCs that become SCs go through a 
series of transitions where they become gradually fate-restricted. The transitional 
stages include SC precursors, immature SCs and finally a mature SC. These 
transitional stages can be characterised by specific molecular profiles, gene 
expression profiles and signalling responses [Douarin et al., 1991; Jessen and 






1.3.1 Myelinating Schwann cells 
Group A and B axon internodes are myelinated by a single myelinating SCs, the 
nodes of Ranvier separate internodes [Poliak and Peles, 2003a]. A myelinating SC 
produces a myelin sheath at the internode, which elongates and wraps around the 
axon [Figure 1.2]. The myelin wrap has a low capacitance which facilitates saltatory 
conduction. In myelinated axons, the cross-sectional area of the myelinating SC is 
proportional to the axon calibre, as axons increase in size the myelin layer becomes 
thicker [Donaldson and Hoke, 1905; Pannese et al., 1987; Rushton, 1951; Voyvodic, 
1989].  
The relationship of myelin thickness and axon calibre can be measured using a 
parameter called the G-Ratio. It can be defined as the ratio of the inner (axon) to the 
outer (axon plus myelin) diameter of the fibre. The optimal value for G-ratio is 
approximately 0.6 in an adult nerve, and this value is thought to provide optimal 
propagation speeds [Rushton, 1951; Waxman, 1975]. However, myelin thickness is 
not always linear to axon calibre and can change depending on factors such as the 
internodal length. As the internodal length increases the myelin thickness increases, 
this causes the G-ratio to decrease [Friede and Bischhausen, 1982].  
Myelin is composed of cholesterol, sphingolipids and proteins, the structure formed 
by these components reduces the capacitance of the myelinating SC [Figure 1.3]. 
Only 30% of myelin is composed of protein. However, their presence is imperative 
for correct myelin wrapping [Garbay et al., 2000]. Myelin protein zero (MPZ) is the 
most common protein in SC myelin, around 50-70% total protein, and contains both 
an intracellular and extracellular domain. The extracellular domain is involved in 
maintaining the intraperiod line, the line where two external surfaces of the myelin 





which bind to one another on opposing membranes [Figure 1.3] [Greenfield et al., 
1973; Shapiro et al., 1996].  
Myelin basic protein (MBP) is another protein expressed in myelinating SCs. It is 
expressed in the cytoplasmic regions of myelin in myelinating SCs and is involved in 
compaction and maintenance of the major dense line. The opposition of the plasma 
membrane of myelin forms the major dense line [Figure 1.3] [Omlin et al., 1982; 
Readhead, 1987; Roach et al., 1985].  
Myelin-associated glycoprotein (MAG) is expressed by myelinating SCs at the 
adaxonal membrane, the membrane that opposes the axon, and is important in cell-
cell communications with the axolemma [Figure 1.3] [Schnaar and Lopez, 2009]. 
MAG null mutants have altered nodes of Ranvier, progressive axon degeneration, 
and altered axon cytoskeletal architecture revealing a role in axon-glial signalling. 
MAG is believed to directly increase neurofilament spacing and neurofilament 
phosphorylation, and MAG null mice show an age dependent decrease in axon 
calibre showing its importance in the maintenance of axon structure [Yin et al., 1998; 
Kumar et al., 2002]. MAG interacts with gangliosides (GANG) that form part of the 
axolemma, GANG are glycosphingolipids containing sialic acid and are a significant 
component of the nervous system. The interaction between MAG and GANG 
increases axon stability and maintains the myelinating phenotype of myelinating SCs 
[Marcus et al., 2002; Sheikh et al., 1999].  
Neuregulin-1 type III (NRG1-3), a cell adhesion molecule, also plays a crucial role in 
the maintenance of the axon-myelinating SC relationship [Figure 1.3]. NRG1-3 is 
expressed on the axolemma of axons and interacts with an erythroblastic leukaemia 
viral oncogene homolog-2/3 (ErbB2/B3) heterodimeric receptor on myelinating SCs; 





2012]. If NRG1-3 is overexpressed in axons, it results in hypermyelination, 
conversely if NRG1-3 expression is reduced axons become hypomyelinated 
[Michailov et al., 2004; Taveggia et al., 2005]. Moreover, ErbB2 SC specific null 
mutants have similar patterns of myelination to that observed in the NRG1-3 
mutants, as they have hypomyelinated axons. This further confirms that the 
interaction between NRG1-3 and ErbB2 is involved in determining the thickness of 
myelin [Garratt et al., 2000].  
NRG1 signalling activates three major downstream signalling pathways the 
phosphatidylinositol-3-kinase (PI3K) pathway, the phospholipase C-γ (PLC-γ) Ca2+ 
signalling pathway, and the mitogen-activated protein kinase–extracellular-signal 
regulated kinase (MEK/ERK) pathway [Goebbels et al., 2010; Kao et al., 2009; 
Pereira et al., 2012]. The activation of the PLC-γ and MEK signalling pathway 
ultimately leads to the activation of the Krox20 (Egr2) gene [Goebbels et al., 2010; 
He et al., 2010].  Krox-20 is a pro-myelin transcription factor, which is imperative in 
the SC myelination programme [Decker et al., 2006; Murphy et al., 1996; Nagarajan 
et al., 2001; Topilko et al., 1994; Zorick et al., 1996]. It maintains the myelination 
phenotype by activating the myelin associated genes; periaxin and MPZ. Krox20 
also inhibits proliferation and cell death in myelinating SCs [Nagarajan et al., 2001; 
Parkinson et al., 2003; Parkinson et al., 2004; Zorick et al., 1999].  
Another pro-myelin transcription factor in myelinating SCs is Sox10. Sox10 is 
expressed in NCCs that become glial cells and is vital for this differentiation pathway, 
confirmed by mice carrying a Sox10 mutation in which the peripheral glia did not 
form [Britsch et al., 2001; Finzsch et al., 2010]. Sox10 acts a transcription factor, 
upregulating the expression of MPZ, an essential protein for correct myelin formation 





transcription factors such as Yin Yang 1 (YY1), Oct6 and Nuclear factor of activated 
T-cells (NFAT) have also been shown to play a role in SC differentiation and 
maintenance, revealing a complex network of transcription factors influencing SC 
fate [Jaegle et al., 1996; Jagalur et al., 2011; Peirano et al., 2000; Kao et al., 2009]. 
Myelinating SCs have collars of uncompacted myelin, and these areas are called 
Schmidt-Lanterman incisures (SLI). SLIs are spiralling cytoplasmic channels within 
the myelin sheath that provide a cytoplasmic channel between the inner and outer 
cytoplasmic domains; they are believed to be important in the transport of metabolic 
substances [Segura-Anaya et al., 2015]. The gap junction protein connexin 32 
(Cx32) is enriched within the SLI; gap junction proteins are important for the 
exchange of metabolites and information throughout the nervous system supporting 
the notion that SLIs play a role in the transport of metabolic substances. 
Furthermore, mutations in Cx32 leads to X-linked Charcot-Marie-Tooth disease, a 
common demyelinating peripheral neuropathy, demonstrating the importance of the 
SLIs in myelinating SC structure and myelin maintenance [Balice-Gordon et al., 
1998; Bergoffen et al., 1993; Scherer et al., 1998; Spray and Dermietzel, 1995]. 
Myelinating SCs have two specialised domains at their proximal and distal ends, 
which flank the node of Ranvier called the paranode [Figure 1.4]. At the paranode, 
myelinating SCs have multiple paranodal loops that invaginate the axon. Here 
septate-like adhesive junction’s form between the axolemma and paranodal myelin 
loops [Poliak and Peles, 2003a; Lyons and Talbot, 2008]. These junctions are 
maintained through the axolemma expressing contactin and contactin-associated 
protein (Caspr), both of which are neuronal membrane proteins involved in cell 





SCs [Boyle et al., 2001; Bhat et al., 2001; Einheber et al., 1997; Lyons and Talbot, 
2008].  
The areas directly next to the paranode are referred to as the juxtaparanodes [Figure 
1.4]. Axons at the juxtaparanodes are regions enriched with delayed-rectifier 
potassium channels. Potassium channels associate with contactin-associated 
protein 2 (Caspr2) in the axolemma and are believed to be involved in maintaining 
internodal resting potential and assisting repolarisation of the node [Poliak et al., 
2003b]. At the juxtaparanodes, myelinating SCs express Transient Axonal 
Glycoprotein-1 (TAG-1), a neuronal adhesion molecule, the expression of TAG-1 
specifically at the juxtaparanodes is essential of the maintenance of the structure by 
directly interacting with Caspr2 [Savvaki et al., 2010; Traka et al., 2002].   
At the node itself, myelinating SCs have microvilli which are in contact with the 
axolemma [Figure 1.4] [Corfas et al., 2004; Melendez-Vasquez et al., 2001]. 
Microvilli become disorganised following myelinating SC-specific ablation of 
dystroglycan, a transmembrane glycoprotein that connects the extracellular matrix to 
the cell cytoskeleton. This ablation also results in fewer sodium channels 
concentrated at the node of Ranvier suggesting that microvilli have a role in 
stabilisation of these channels [Saito et al., 2003].  
Expression of guidance cues by myelinating SCs at the node of Ranvier have also 
been implicated in controlling aberrant axonal sprouting in the adult. Deleted in 
colorectal cancer (DCC), a transmembrane protein usually involved in 
chemoattraction, is expressed on myelinating SCs at the node of Ranvier and SLI in 
the adult peripheral nervous system [Webber et al., 2011]. Although its function is 





the paranodal region and inhibits axonal sprouting, maintaining the organisation of 
oligodendroglia junctions [Jarjour et al., 2008].  
1.3.2 Remak Schwann cells 
Group C-fibre axons, which include postganglionic autonomic fibres and nociceptors, 
are unmyelinated [Murinson and Griffin, 2004]. Unmyelinated axons are surrounded 
by non-myelinating Remak SCs (RSCs), together the axons and SCs are known as 
Remak bundles and were first described by Robert Remak in 1838 [Figure 1.2]. 
RSCs typically ensheath more than one axon and can ensheath up to 20 small 
diameter axons in the sciatic nerve [Murinson and Griffin, 2004]. Along the length of 
the nerve unmyelinated axons are not found in the same Remak bundles. Axons are 
continuously being exchanged from bundle to bundle reducing the possibility of 
action potentials being passed among axons [Aguayo et al., 1976]. Unlike 
myelinating SCs, which are separated by nodes of Ranvier, RSCs form junctional 
zones with one another through interdigitation of processes [Eames and Gamble, 
1970]. 
The relationship between RSCs and C-fibre axons is imperative for the survival and 
maintenance of C-fibre axons. If Neuregulin1-ErbB signalling is disrupted between 
RSCs and C-fibre axons, C-fibre axons go through apoptosis and RSCs will begin to 
dedifferentiate [Chen et al., 2003; Taveggia et al., 2005]. Moreover, if mitochondria 
within RSCs are forced to malfunction, through the tissue-specific deletion of the 
mitochondrial transcription factor A gene (Tfam), it results in C-fibre axon loss, 
suggesting that RSCs metabolically support C-fibre axons [Viader et al., 2011]. The 
expression of the metabolic regulator LKB1, a protein kinase, in RSCs is also crucial 
in unmyelinated axon survival. When LKB1 expression is disrupted in RSCs, small 





2014]. As C-fibre axons are unmyelinated, they are energetically more demanding 
than myelinated axons [Wang et al., 2008]. Therefore, C-fibre axon loss occurs much 
faster than myelinated axon loss when metabolic support is disrupted [Beirowski et 
al., 2014; Viader et al., 2011]. C-fibres are also prone to injury in diabetes where 
metabolic support is disrupted, glucose dysmetabolism in some diabetic patients 
leads to a peripheral neuropathy [Smith et al., 2001; Stino and Smith, 2017; Sumner 
et al., 2003].  
RSCs also do not provide a myelin sheath like their myelinating counterparts 
[Remak, 1838]. However, RSCs are involved in potassium buffering to maintain the 
homeostasis of the axonal environment. RSCs possess a sodium/potassium pump, 
this actively pumps potassium out of the axon, maintaining potassium homeostasis 
of the axon microenvironment ensures correct functioning of the cell and ensures the 
axons ability to propagate an action potential [Robert and Jirounek, 1994].  
Moreover, unlike myelinated axons, unmyelinated axons have a higher degree of 
plasticity than their counterparts. This plasticitiy enables C-fibre axons to respond to 
injury and reinnervate their target faster, which is essential in an injury prone organ 
such as the skin which C-fibre axons innervate [Griffin and Thompson 2008; Hsieh et 
al., 1996; Sugiura et al., 1986].    
1.3.3 Satellite glial cells  
Satellite glial cells (SGCs) are another form of non-myelinating SCs. SGCs surround 
and support both small dark and large light cell bodies of the DRG [Figure 1.2] 
[Lawson, 1992]. Many SGCs ensheath a cell body forming a distinct functional unit, 
connective tissue then surrounds these units binding the cell bodies together to form 
the DRG [Pannese, 1981]. The SGC layer does not form an impenetrable layer over 





providing a slight protective mechanism [Arvidson, 1979; Hanani, 2005; Shinder and 
Devor, 1994; Ten Tusscher et al., 1989].  
SGCs do not myelinate cell bodies. However, they do ensheath them and provide a 
homeostatic environment. They contribute to the homeostasis of the cell body by 
possessing potassium pumps. The potassium pumps are involved in regulating 
extracellular potassium during nerve activity, which is critical for correct cell function 
and the ability to propagate an action potential [Konishi, 1996; Gola et al., 1993]. 
SGCs have also shown to inhibit dendrite sprouting of DRG neurons in vitro, 
suggesting a role in structural maintenance [De Koninck et al., 1993].  
1.3.4 Slit/Robo expression in Schwann cells 
Wang et al., (2013) established that Slit2, Slit3, Robo1 and Robo2 mRNA is present 
in cultured SCs and reported that Slit1 mRNA was not present [Wang et al. 2013].  
Slit1 expression was observed in axons of the sciatic nerve and myelin and cell 
bodies of SCs [Yi et al., 2006]. However, this finding is contradictory to Wang et al., 
work but could suggest that Slit1 was not present in cultured SCs which resemble an 
injury model but was present in vivo.  
Tanno et al., [2005] used semi-quantitative PCR weak expression of Slit1, Slit2, 
Robo1 and Robo2 mRNA expression was observed in the sciatic nerve, which would 
suggest that these are being produced by SCs. Furthermore, immunolabelling 
revealed Slit2 was expressed in SCs, confirming the presence of Slit2 protein in SCs 
[Tanno et al., 2005].  
It remains unknown whether Slit3 protein is present in SCs in the PNS. It remains 
unknown which SCs Robo1, Robo2, Slit1 and Slit2 are expressed in as there was no 





the function of Slit/Robo expression in SCs in the PNS and whether there are any in 
defects in SCs formation in Slit/Robo mutants. 
 
1.4 The connective layers of the peripheral nerve 
The basal lamina consists mainly of laminins and collagens and surrounds the 
axon/SC unit, combined they make up a functional unit [Figure 1.2]. The basal 
lamina expresses laminin-2, a glycoprotein that forms the extracellular matrix, on the 
surface that opposes a SC which expresses integrins and dystroglycan, both 
laminin-2 receptors, on its abaxonal membrane [Colognato and Yurchenco, 2000; 
Scherer and Arroyo, 2002; Tsiper and Yurchenco, 2002]. Laminin-2 and 
dystroglycan interaction results in the recruitment of dystroglycan related protein-2 
(DRP2) which forms a complex with periaxin, a scaffolding protein. When this 
complex is disrupted it results in hypermyelination [Figure 1.3] [Sherman et al., 
2001]. Furthermore, disruption of laminin-2 leads to demyelination, revealing the 
importance of the basal lamina in maintaining the axon/SC relationship [Scherer and 
Arroyo, 2002; Sunada et al., 1995]. 
The endoneurium adheres to the basal lamina and surrounds functional axons 
[Figure 1.5] [Peltonen et al., 2013]. The endoneurium is formed from collagen type I 
and III and is populated by fibroblasts and endoneurial fibroblast-like cells [Causey 
and Barton, 1959; Shellswell et al., 1979; Richard et al., 2012]. The endoneurium 
has multiple functions, one of which is to promote basal lamina deposition by SCs 
[Obremski et al., 1993]. The endoneurium also inhibits axonal sprouting through the 
expression of chondroitin sulphate proteoglycans, which are proteoglycans usually 





Functional units surrounded by the endoneurium are bundled together in nerve 
fascicles and surrounded by the perineurium [Figure 1.5] [Peltonen et al., 2013]. The 
perineurium is formed of multiple layers of perineurial cells, the number of layers of 
perineurial cell layers depends on the fascicle size, with large fascicles having up to 
15 layers. These layers are separated by an extracellular matrix composed of 
collagens and fibronectin; this equips the perineurium with the ability to modulate 
external stretching forces to maintain structural integrity during nerve compression 
[Mizisin and Weerasuriya, 2011; Peltonen et al., 1990; Sunderland and Bradley, 
1952].    
The perineurium forms a metabolically active diffusion barrier, of which the primary 
function is to maintain the blood-nerve barrier [Allt and Lawrenson, 2000; Mizisin and 
Weerasuriya, 2011; Reale et al., 1975]. The perineurium maintains the blood-nerve 
barrier in several ways, one of which is that pericytes form tight junctions with one 
another through the expression of tight junction-associated proteins including Zonula 
occludins-1, occludin and claudins which are all involved in forming a diffusion 
barrier to the components of blood [Ghabriel et al., 1989; Kristensson and Olsson, 
1971; Pummi et al., 2004; Todd et al., 2000].  
Each layer of perineural cells is coated with a basement membrane; this basement 
membrane is formed of collagen type IV and laminin but also contains heparin 
sulphate proteoglycans, which are believed to function to filter out molecules larger 
than 12 nm in diameter [Gamble and Eames, 1964; Peltonen et al., 2013]. The 
presence of pinocytotic vesicles in pericytes supports the notion that perineural cells 
perform transcytoses to transport material across the blood-nerve barrier [Bertossi et 





The epineurium is an outer layer of connective tissue that binds fascicles together 
[Figure 1.5]. Two layers of the epineurium can be distinguished, the deeper layer of 
the epineurium is composed of a dense layer of collagen types I and III, interspersed 
with elastin fibres enabling the epineurium to contribute to the tensile strength of the 
nerve [Gamble and Eames, 1964; Salonen et al., 1985; Stolinski, 1995; Tassler et 
al., 1994]. The outer layer is composed of a vascular network and areolar connective 
tissue with some collagen fibres, while both layers have epineurial fibroblasts 
[Gamble and Eames, 1964; Salonen et al., 1985]. 
The mesoneurium is the final layer of connective tissue surrounding the epineurium 
and is responsible for loosely connecting the nerve to the underlying muscle [Millesi 
et al., 1995]. 
Currently, no research has been done into the expression of Slit/Robo in the cells 
that form the structural layers of the peripheral nerve. There is current research that 
implicates Slit/Robo in fibroblast dynamics which are essential cells in maintaining 
the structural integrity of the nerve. One group reported that human fibroblasts 
expressed and secreted Slit2 which inhibits fibroblasts differentiation [Pilling et al., 
2014]. Furthermore, it has been suggested that Slit2-Robo4 control fibroblast 
repulsion and locomotion through srGAP2 which controls Rac1 activity [Dominik et 
al., 2015]. 
1.5 Vasa nervorum 
The vasa nervorum describes the blood supply of peripheral nerves. The nerve is 
supplied along its length in segments; these segments can be supplied by various 
vessels. These vessels permeate the mesoneurium and run longitudinally in the 
epineurium, here they form several anastomoses with one another forming a plexus 





epineurium and form a longitudinal plexus associated with the perineurium. 
Endoneurial microvessels then branch off from this plexus to invaginate the area 
surrounding the endoneurium [Mizisin and Weerasuriya, 2011]. The endoneurial 
microvessels are covered by a sleeve of pericytes to maintain the blood-nerve 
barrier. The epithelial cells of the endoneurial microvessels form tight junctions with 
one another forming another barrier within the blood-nerve barrier [Sano et al., 2007; 
Kanda, 2013; Olsson and Kristensson, 1971].  
1.5.1 Slit/Robo in blood vessels 
The expression of Slit2 and Slit3 has been confirmed in endothelial cells, smooth 
muscle cells and pericytes [Zhang et al., 2009; Guijarro-Munoz et al., 2012]. The 
Robo receptors are also expressed in endothelial cells, Robo4 has been shown to be 
expressed in all endothelial cells while Robo1 is expressed in endothelial cells at 
lower levels in comparison [Zhao et al., 2014]. Furthermore, the level of expression 
of Robo1 in these cells may depend on the expression of Slit2 and Slit3 genes which 
can inhibit Robo1 expression through miR-218 which is located on intron 15 of Slit2 
and Slit3 [Davidson et al., 2010; Small et al., 2010].  
Functional studies of Slit/Robo signalling has determined that Slit2/Robo4 signalling 
has been shown to reduce vascular permeability and stabilise endothelial barriers, 
thus helping to maintain the endothelial barrier [Jones et al., 2008; Jones et al., 
2009; London et al., 2010]. Currently, these studies are not focused in the peripheral 
nerve, this is an important difference due to it having to maintain the blood-nerve 










































Figure 1.2: The basic structure of the peripheral nervous system. A. Sensory 
neurons are pseudounipolar, the dorsal root ganglia (DRG) lies outside the spinal 
cord and project an axon both to the spinal cord and target organ. The DRG cell 
body is surrounded by supporting satellite glial cells (SGCs). Non-myelinated 
axons are surrounded by non-myelinating Remak Schwann cells (RSCs). The 
basal lamina (BL) surrounds both myelinated fibres and non-myelinated fibres. B. 
Motor neurone cell bodies (CB) reside in the grey matter of the spinal cord. Axons 
are myelinated by myelinating Schwann cells (MSC), which are surrounded by a 
BL. C. Transverse view of a RSC. The RSC envelops and supports many small 
calibre axons, the RSC and axons are surrounded by the BL. D. Transverse view 
of a MSC. The MSC surrounds a single axon with many layers of myelin, the 












































Figure 1.3: The structure of compact myelin. Compact myelin has a complex 
structure, it is mainly composed of lipids (70-80%) such as galactosylceramide. 
Proteins, which make up around 15-30% of myelin, are inserted into the lipid 
bilayers and are vital in maintaining the structure of compact myelin. Myelin 
protein zero (MPZ) has both an intracellular and extracellular domain, the 
extracellular domain maintains the intraperiod line. Myelin basic protein (MBP) 
is another protein present in myelin. MBP is expressed in the cytoplasmic regions 
and is involved in the compaction and maintenance of the major dense line. The 
abaxonal membrane is the outermost layer of myelin that interacts with the 
basal lamina (BL). The BL expresses laminin-2 which interacts with two types of 
receptors on SCs; dystroglycan and integrins. This signalling is important for the 
maintenance of the myelinating phenotype of the SC. SCs express myelin 
associated protein (MAG) at the adaxonal membrane which interacts with 
gangliosides (GANG) on the axolemma. This interaction increases axon stability 
and maintains the myelinating phenotype of SCs. Neuregulin-1 type III (NRG1-3) 
is expressed on axons and interacts with an erythroblastic leukaemia viral 
oncogene homolog-2/3 (ErbB2/B3) receptor on SCs. This interaction is a rate-







Figure 1.4: Structure of the node of Ranvier, paranodes and 
juxtaparanodes. The axolemma at the node of Ranvier is enriched with sodium 
channels that are involved in the propagation of an action potential. Myelinating 
Schwann cell microvilli (MSC MV) surround the node of Ranvier and are 
important in the stabilisation of the structure at the node. At the paranode, loops 
of uncompact myelin invaginate the axon. SCs express neurofascin 155 while the 
axolemma expresses its receptors contactin-associated protein (Capsr) and 
contactin. This signalling maintains the SC-axon relationship at the paranode. 
The juxtaparanodes are regions of the axon enriched with potassium channels, 
which are involved in maintaining internodal resting potential and assisting 
repolarisation. At the juxtaparanodes the SCs express transient axonal 
glycoprotein-1 (TAG-1), which directly interacts with contactin-associated protein 
2 (Caspr2), and is believed to be involved in maintenance of the SC-axon 














































Figure 1.5: The structure of the epineurium, perineurium and endoneurium. 
The endoneurium surrounds functional axons and is formed of collagen types I 
and III and is populated by fibroblasts and endoneurial fibroblast-like cells. The 
perineurium bundles axons together in nerve fascicles and is formed of multiple 
layers of perineurial cells; layers are separated by an extracellular matrix 
composed of collagens and fibronectin. The perineurium’s main function is to 
maintain the blood nerve barrier. The epineurium is the outermost layer of 
connective tissues and binds nerve fascicles together. The epineurium is formed 
of areolar connective tissue, collagen fibres and epineurial fibroblasts. Both the 
epineurium and perineurium have a dense network of blood vessels embedded 
within them, the blood supply of the nerve is termed the vasa nervorum. 
Branches from the blood vessels surrounding the perineurium invaginate the 






1.6 Peripheral nerve injuries  
In America, 2-5% of trauma patients sustained a peripheral nerve injury, with around 
100,000 people every year undergoing peripheral nerve repair surgery [Chhabra et 
al., 2014].  Peripheral nerve injuries can be classified according to their severity; this 
classification was first described by Seddon in 1943 and later elaborated on by 
Sunderland. Seddon classified the nerve injuries into three separate groups; 
neurotmesis, axonotmesis and neurapraxia [Seddon, 1943; Sunderland, 1951].  
Neurapraxia, also described by Sunderland as a first-degree injury, is the mildest 
type of nerve injury with no interruption in the continuity of the axon. Neurapraxia is 
the compression of a nerve leading to focal demyelination; it is characterised by 
functional motor loss due to disrupted saltatory conduction across the demyelinated 
segment. Following a neurapraxic injury, local SCs and resident macrophages will 
clear myelin debris from the focal demyelination. Following the clearance of myelin 
debris, neighbouring SCs will proliferate and remyelinate the segment that has 
undergone demyelination. Neurapraxic injuries have a good prognosis with full 
function returning within a matter of weeks [Table 1.1] [Ochoa et al., 1972; Seddon, 
1943; Sunderland, 1951]. 
Axonotmesis, described by Sunderland as a second-degree injury, is where the 
continuity of the axon and supporting myelin are disrupted but the surrounding 
perineurium and epineurium stay intact. These types of injuries usually occur due to 
the nerve being crushed and generally have a good prognosis due to the 
maintenance of the basement membrane. This enables SCs distal to he injury site to 
form Bands of Büngner through the basement membrane, which elongating axons 






In comparison, neurotmesis is the most severe type of injury and has a poor 
prognosis. Seddon et al., (1943) first described neurotmesis as a complete 
severance of all the structures of the nerve. Sunderland et al., (1951) further sub-
divided neurotmesis into third, fourth and fifth-degree injuries. Sunderlands third-
degree injury describes disruption of axon, myelin and endoneurium, while a fourth-
degree injury describes the disruption in continuity of all structures apart from the 
epineurium. Sunderland's fifth-degree injury resembles Seddon’s neurotmesis injury, 
with complete transection of all structures [Table 1.1] [Seddon, 1943; Sunderland, 
1951]. 
Neurotmesis injuries result in three distinct sites consisting of the proximal nerve 
stump, the nerve bridge and the distal nerve stump. The proximal nerve stump is the 
part of the axon still in connection with the cell body, the nerve bridge is the area 
between the nerve stumps where newly generated tissue forms and the area 
regenerating axons must cross, and the distal nerve stump is part of the axon still in 
contact with the effector site.  
Nerve injuries can have variable outcomes regarding motor and sensory recovery. A 
meta-analysis study demonstrated that, following median or ulnar nerve repair 
surgery after a neurotmesis injury, only 51.6% achieved satisfactory motor recovery 
and only 42.6% were experiencing satisfactory sensory recovery. Younger patients 
and more distal injuries experienced a greater return of sensation and motor function 
[Ruijs et al., 2005].  
The reduction in the capability of nerves to regenerate due to ageing also occurs in 
mice. Elegant work by Painter et al., (2014) revealed that this decrease in capacity of 
axons to regenerate is not due to changes in axons, but a decrease in the capability 





transcriptional machinery to push them into a pro repair state to clear myelin debris 








































2nd degree  • Continuity of the axon and supporting 
myelin are disrupted  






3rd degree  • Disruption of axon, myelin and 
endoneurium 
4th degree  • Disruption in the continuity of all 
structures apart from the epineurium 










Table 1.1: Nerve injury classifications. Table 1.1 shows how nerve injury 






1.7 The neuronal response to injury 
After a transection injury, proximal stump axons degenerate retrogradely back to the 
first node of Ranvier that is located closest to the injury site; this initiates WD in the 
proximal stump in the same region. A wave of intracellular calcium into the proximal 
nerve stump axons causes microtubule reorganisation and swelling at the proximal 
axon tip in the proximal nerve stump [Bradke et al., 2012; Hill, 2017].  Microtubule 
reorganisation leads to the formation of two “traps”; these two traps are termed the 
plus-end trap and minus-end trap. The plus end trap is where plus-end-oriented 
molecular motors and cargo accumulate, whereas, in the minus-end trap, minus-
end-oriented molecular motors and cargo accumulate [Erez and Spira, 2008]. These 
traps form due to the defective turnaround of material, leading to a build-up of 
axoplasmic material and swelling of the axonal tip [Hill, 2017].  
Also following injury, peripheral neurons shifts from a steady-state transmitting mode 
to a regenerative response mode. The cell body undergoes structural changes 
termed chromatolysis once an injury to a peripheral axon has been detected. This 
leads to an enlargement of the cell body, break-up and dispersal of Nissl granules 
and the migration of the nucleus to the periphery of the cell. It is believed these 
changes occur due to a buildup of cytoskeletal material in the cell body as a result of 
transection [McIlwain and Hoke, 2005].   
It is imperative for the cell body of the peripheral axon to be able to detect that it is 
injured, this enables the cell body to elicit a regenerative response. One way the cell 
body detects an injury has occurred is due to a build-up of intracellular calcium in the 
axon and cell body. When the calcium influx is blocked, regeneration of the axon 
fails [Abe and Cavalli, 2008; Stoll and Müller, 1999]. The interruption of nerve growth 





cell body to injury, triggering a regenerative response [Verge et al., 1995]. This 
regenerative response is dependent upon neuron-intrinsic transcription of 
regenerative associated genes (RAGs), which enables the neuron to respond to the 
injury. However, the ability of the axon to regenerate is highly dependent on a 
permissive environment [Ma and Willis, 2015].  
The release of neurokines at the injury site by SCs is also important to promote 
transcriptional changes in the neuronal cell bodies, to push them into a pro-
regenerative state. Neurokines including IL-6, ciliary neurotrophic factor (CNTF) and 
leukaemia inhibitory factor (LIF) bind to the gp130 receptor expressed on axons of 
the proximal stump; one downstream effect of this interaction is the phosphorylation 
of STAT3. STAT3 is a transcription factor, one of many that play a role in peripheral 
nerve regeneration. STAT3 is responsible for the upregulation of GAP-43; GAP-43 is 
expressed on the growth cone and is vital for axonal extension [Cafferty et al., 2001; 
Heinrich et al., 2003; Kirsch et al., 2003; Liu et al., 2014].  
Up-regulation of c-Jun terminal kinase (JNK) in axons following axotomy also plays a 
role in the cell body response to injury. JNK forms a complex with the Sunday driver 
motor protein which transports JNK retrogradely, JNK then phosphorylates c-Jun in 
the cell body. Blocking c-Jun activity leads to reduced axonal outgrowth, as it is 
involved in switching on the regenerative machinery [Cavalli et al., 2005; Raivich et 
al., 2004; Ruff et al., 2012]. 
1.8 Wallerian degeneration 
Following both an axonotmesis “crush” injury or a neurotmesis “cut” injury, the distal 
stump becomes deinnervated and will undergo a process called Wallerian 
degeneration [Figure 1.6]. Wallerian degeneration describes the series of events that 





(1850). One of the first events to happen during Wallerian degeneration is the 
degradation of the axolemma and axoplasm of the distal stump caused by a calcium 
influx and activation of calpain and E3/E4 ubiquitin ligase after injury [Figure 1.7] 
[George et al., 1995].  
However, due to the discovery of the slow Wallerian degeneration mutant mouse 
(Wlds), the process of distal fragmentation and degradation was determined to be 
more complex than a calcium influx alone [Lunn et al., 1989]. In Wlds mice the distal 
stump survives ten times longer in comparison to its wild-type counterparts. When 
the distal stump degenerates in Wlds mice, it is a much slower process than that 
seen in a wild-type mouse. Wlds mice vary from wild-type mice through the presence 
of the Wld protein [Coleman and Freeman, 2010]. This protein is a fusion of the 
complete protein sequence of nicotinamide mononucleotide adenylyltransferase 1 
(Nmnat1), 70 amino acids (N70) from the N-terminus of Ube4b and a unique 18 
amino acid sequence [Mack et al., 2001]. 
Work to elucidate how the presence of the Wld protein inhibits distal axon 
fragmentation determined that the presence of Wld in axons was responsible for this 
effect, rather than the expression of Wld in glia or immune cells [Glass et al., 1993; 
Perry et al., 1990]. This work also indicated that short-term survival of axons is 
independent of the cell body [Glass et al., 1993; Perry et al., 1990]. How the Wld 
protein inhibits Wallerian degeneration remains unclear. However, one plausible 
theory is that Nmnat1 is an endogenous axon survival factor, when Nmnat1 is fused 
with part of Ube4b, it becomes more stable, and its presence perseveres in the distal 
nerve stump, which inhibits axon fragmentation [Gilley and Coleman, 2010]. 
However, axon regeneration is not inhibited in Wlds mice, suggesting that distal 





1.8.1 Schwann cell response to injury. 
Losing axonal contact caus myelinating SCs to undergo reprogramming, which 
results in the downregulation of pro-myelin markers and the upregulation of markers 
of immature SCs such as Sox2, ERK 1/2, c-Jun and p38 MAPK [Arthur-Farraj et al., 
2012; Clemments et al., 2017; Harrisingh et al., 2004; Kim et al., 2013; Le et al., 
2005; Napoli et al., 2012; Parkinson et al., 2008; Yang et al., 2012]. SCs then rapidly 
proliferate reaching peak proliferation rates at four days post-injury [Figure 1.6] [Liu 
et al., 1995; Murinson et al., 2005]. Myelinating SCs must also shed their myelin 
sheath and break it down, this enables the myelinating SCs to take on a pro-
regenerative state, and remove myelin that inhibits nerve regeneration [Filbin, 2003; 
Gomez-Sanchez et al., 2015; Schäfer et al., 1996]. Myelinating SCs fragment their 
myelin at SLIs and the nodes of Ranvier through actin polymerisation, fragmented 
myelin then forms small ovoids [Figure 1.6] [Jung et al., 2011; Stoll et al., 1989]. SCs 
break down their myelin through autophagy, also known as myelinophagy, and for 
the first five days after injury SCs are the predominant force in myelin clearance, 
breaking down around 40-50% of the total myelin [Figure 1.6] [Gomez-Sanchez et 
al., 2015; Jung et al., 2011; Perry et al., 1995].  
1.8.2 The immune response following injury. 
Following a cut injury, neutrophils are the first inflammatory leukocytes to invade the 
nerve bridge and do so around eight hours post injury. By 24 hours post-injury 
neutrophil numbers in the nerve bridge have peaked, they are primarily responsible 
for the phagocytosis of nerve debris but have also been implicated in the early 






SCs also recruit macrophages to assist in the clearance of myelin. SCs secrete 
monocyte chemoattractant protein-1 (MCP-1), LIF, tumour necrosis factor-α (TNF-α), 
and multiple toll-like receptors to recruit macrophages to the injury site [Goethals et 
al., 2010; Tofaris et al., 2002]. During this second stage of myelin breakdown, both 
SCs and macrophages phagocytose myelin and axonal debris [Gomez-Sanchez et 
al., 2015]. Macrophages adopt an opsonin-dependent mechanism to break down 
myelin and axonal debris, with phagocytic macrophage numbers reaching their peak 
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Figure 1.6: Wallerian degeneration. A. Following an axotomy injury three 
distinct areas are formed, the proximal and distal nerve stumps and the nerve 
bridge. Calcium influx in axons of the distal nerve stump and up to the node of 
Ranvier closest to the injury site, in the proximal stump causes axon 
fragmentation. Fibronectin, fibrinogen and fibrin fill the nerve bridge. B. SCs 
dedifferentiate and proliferate, ovoids form within the SCs filled with myelin debris. 
SCs begin clearing axonal debris and neutrophils infiltrate the injury zone to assist 
with axonal debris clearance. C. Macrophages are recruited to the injury zone by 
SCs to assist with axonal and myelin debris clearance. SCs continue to clear 
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Figure 1.7: Cell body response to injury.  The cell body of neurons have 
multiple ways of detecting that an injury has occurred to an axon. A. Injury 
causes an influx of calcium that travels retrogradely to the cell body where it is 
detected. B. Inhibition of retrogradely transported nerve growth factor (NGF) 
alerts the cell body of an injury to an axon. C. The release of neurokines, such as 
IL-6, CNTF and LIF at the injury site activate the upregulation of regeneration 
associated genes such as the phosphorylation of STAT3. c-Jun terminal kinase 
(JNK) is released at the injury site and forms a complex with Sunday driver 
protein which transports JNK retrogradely. JNK then phosphorylates c-Jun in the 
cell body. Both the phosphorylation of STAT3 and c-Jun are important in the 







1.9.1 Crossing the nerve bridge 
2-3 hours after a neurotmesis injury the nerve bridge will fill with serum. In the 
following 48 hours after injury, the serum is replaced with fibrin, fibrinogen and 
fibronectin which forms a solid matrix [Geuna et al., 2009]. 
Two days following a sciatic nerve transection, macrophages make up around 50% 
of the total number of cells within the nerve bridge, and at this time point are hypoxic. 
Hypoxia induces the expression of transcription factor hypoxia inducible factor 1α 
(HIF-1α) in the macrophages, leading to upregulation of vascular endothelial growth 
factor-a [VEGF-A] expression [Figure 1.8]. The expression of VEGF-A stimulates the 
migration and proliferation of endothelial cells into the nerve bridge at two days post-
injury. By day three post-injury in rats, a new network of blood vessels has formed 
that traverses the nerve bridge. In comparison, this process appears to start later in 
mice, with completed blood vessel formation across the bridge visible at five days 
post-injury. The endothelial cells migrating into the nerve bridge all incorporate EdU, 
confirming that these were newly generated cells [Figure 1.8] [Cattin et al., 2015; 
Dun and Parkinson, 2015; Hobson et al., 2000; Sondell et al., 1999].  
Furthermore, the blood vessel network forms in a polarised manner across the nerve 
bridge, connecting the proximal tip and distal tip of the nerve stumps [Figure 1.8]. 
SCs migrating into the nerve bridge physically interact with the blood vessel network 
and use them as a scaffold to migrate across the nerve bridge. VEGF-A, expressed 
by macrophages, has also shown to be a chemoattractant for SCs, stimulating them 
to migrate into the nerve bridge along the network of blood vessels [Figure 1.8] 






1.9.2 Slit/Robo in angiogenesis 
Angiogenesis plays a central in peripheral nerve regeneration, and previous 
Slit/Robo signalling studies have shown that this signalling can both promote and 
inhibit angiogenesis. However, no studies have shown a role for Slit/Robo signalling 
in controlling angiogenesis during peripheral nerve regeneration.  
Slit2 promotes endothelial migration through the Robo1-VEGFR2-ERK1/2 pathway 
both in vivo and in vitro in mice [Li et al., 2015]. Slit2 has also been shown to interact 
with a Robo1/Robo4 heterodimer which then signals through Wiskott-Aldrich 
syndrome protein (WASP) to induce filopodia formation and increase endothelial 
motility [Sheldon et al., 2009]. Slit3 was expressed with Robo1 and Robo4 in 
endothelial cells and was shown to act in a paracrine fashion, during embryogenesis, 
promoting new vessel growth and sprouting [Zhang et al., 2009].  
In comparison, Slit2 has been shown to inhibit the VEGF-Notch signalling pathway 
thus inhibiting endothelial cell proliferation and migration [Guo-Jian et al., 2017; 
Youngblood et al., 2015]. In an induced squamous cell carcinoma cell line Slit2-Robo 
signalling also inhibited angiogenesis, however, in human malignant melanoma 
A375 cell Slit2-Robo1 signalling increased microvessel density [Wang et al., 2003; 
Wang et al., 2007]. This variable data suggests that the effect of Slit-Robo signalling 
on angiogenesis depends on the environment, and it currently remains unknown if 
Slit/Robo signalling plays a role in angiogenesis during peripheral nerve 
regeneration. 
1.9.3 Schwann cell migration across the nerve bridge 
SCs have begun to migrate into the nerve bridge at five days post injury and by 
seven days post-injury have filled the nerve bridge. SCs migrate in discrete cords, 





sort SCs into cords through the upregulation of ephrin-B2 on their surface, which 
interacts with the EphB2 receptor expressed on SCs. This interaction results in 
upregulation of the transcription factor Sox2 in SCs, which results in N-cadherin up-
regulation and relocalisation. N-cadherin relocalisation to the cell membrane results 
in the formation of adherens junctions between SCs, resulting SC to SC adhesion is 
responsible for SC cord formation during regeneration [Parrinello et al., 2010; 
Roberts et al., 2017].  
1.9.4 Slit/Robo signalling in SCs during peripheral nerve regeneration 
Wang et al., (2013) did an in-depth study on Slit/Robo expression and signalling in 
SCs of the PNS. SCs in culture replicate the SC response following a peripheral 
nerve injury. Wang et al,. determined that in vitro the application of Slit2 to cultures 
SCs caused the collapse of the leading front and soma relocation. In the same cells, 
Slit2 exposure caused activation of intracellular Ca2+-cofilin signalling resulting in 
the collapse of the leading front. Soma relocation in cultured SCs is thought to be 
controlled through RhoA-Rock-Myosin signalling pathway mediated by Slit/Robo 
signalling [Wang et al. 2013]. However, this study only analysed the effects on 
cultured SCs and did not determine if similar affects were seen in vivo, but this could 
suggest a similar response.  
Tanno et al., [2005] used semi-quantitative PCR to determine the expression pattern 
of Slit/Robo signalling in the distal nerve stump after sciatic nerve crush and 
transection followed by repair. After a sciatic nerve crush the expression of all 
Slit/Robo mRNA was unchanged at 2, 7, 14 and 21 days post-injury. No changes 
were also observed in the levels of Slit1 mRNA levels in the distal nerve stump after 
transection and repair. In comparison, they saw upregulation of Slit2, Robo1 and 





immunolabelling distal nerve stumps using the SC marker S100 and Slit2 antibodies. 
They observed co-localisation of staining with both antibodies indicating that Slit2 
was expressed in SCs of the distal nerve stump at seven days post-injury [Tanno et 
al., 2005].  
The current research suggests that the Slit/Robo mRNA expression is unaffected by 
injury in vivo and that Slit2 can control SC migration. However, the potential role of 
Slit2 in SCs and controlling SC migration in vivo has not been explored. Neither 
groups looked at the function of Slit/Robo expression in vivo in the uninjured nerve. 
N-cadherin is an important factor in controlling SC dynamics during peripheral nerve 
regeneration, and Slit/Robo signalling has been shown to influence cell-cell 
interactions and motility through controlling N-cadherin dynamics [Rhee et al., 2002; 
Rhee et al., 2007; Shiau et al., 2009]. Upon the binding of Abl kinase to a Robo 
receptor, β-catenin is phosphorylated which results in its translocation to the nucleus 
decreasing its affinity to bind N-cadherin resulting in less cell adhesion [Rhee et al., 
2002; Rhee et al., 2007]. Furthermore, Slit-Robo2 signalling downregulates N-
cadherin in cranial sensory neurons through post-translational changes to N-
Cadherin decreasing cell adhesion [Shiau et al., 2009].  
Slit-Robo signalling has not only been identified altering N-cadherin dynamics but 
also the upregulation and downregulation of E-cadherin. In colorectal cancer Slit2-
Robo1, signalling is upregulated this leading to the degradation of E-cadherin 
through a ubiquitin ligase; this leads to increased cell migration [Zhou et al., 2011].  
In comparison the down regulation Slit2-Robo1 signalling in breast cancer has also 





cell migration, showing that the cell response to Slit/Robo signalling is dependent on 
cell type and environment [Prasad et al., 2008; Tseng et al., 2010]. 
In oral cell carcinoma, Slit2-Robo3 signalling has been shown to inhibit cell migration 
through interacting with cadherins. Robo3 can interact with P-cadherin, this 
interaction is enhanced when Slit2 binds to Robo3. P-cadherin has been shown to 
disrupt E-cadherin and promote cell motility and that the interaction with Robo3 
alleviates this and stops cell migration [Bauer et al., 2011]. This data suggests a 
strong relationship between cadherins and Slit/Robo signalling; this could suggest 
that Slit/Robo signalling plays a role in SC sorting during peripheral nerve 
regeneration through controlling cadherin dynamic. However, this remains unknown. 
1.9.5 Axon regeneration  
During development of the nervous system the distal end of elongating axons forms 
a growth cone, this is the exploratory hand of the axon and can respond to 
environmental cues which guide the axon. The growth cone can be split into three 
distinct areas the central, peripheral and transtiion zones. The central domain, this 
area encloses stable bundled microtubules, whereas the peripheral zone is formed 
by the finger-like filopodia and web-like lamellipodia which are mainly composed of 
actin filaments, the transition zone which sits at the interface between the peripheral 
and central domains [Bradke et al., 2012;  Hill, 2017; Lowery and Vactor, 2009]. 
Actin dynamics in the filopodia and lamellipodia can control whether the growth cone 
elongates, turns or collapses. The Rho family of GTPases which includes Cdc42, 
RhoA and Rac, play an important role in growth cone steering by regulating actin 
dynamics. They can induce actin polymerisation, causing filopodia and lamellipodia 





depolymerisation which results in growth cone stalling or growth cone collapse 
[Dickson, 2001; Hall and Lalli, 2010; Rajnicek et al., 2006].  
However, during the regeneration of mature peripheral nerves, a classical growth 
cone has not been observed. Nevertheless, regenerating axons must still elongate 
and respond to environmental cues like their developmental counterparts. At the 
distal tip of elongating axons a structure develops that resembles that of a growth 
cone, however, this “regenererative growth cone” is smaller with fewer filopodia 
[Kumagai et al., 1990; Okajima et al., 2000]. The “regenererative growth cone” 
appears to have less F-actin bundles and the extension of the axon is less reliant on 
F-actin polymerisation, and more reliant on microtubule tip polymerisation [Jones et 
al., 2006]. Regenerating axons also elongate more slowly and are less responsive to 
growth factors, such a brain-derived neurotrophic factor and glial derived 
neurotrophic factor [Blizzard et al., 2007]. These axons retain a close relationship 
with SCs and their basement membranes, 4-5 days following sciatic nerve 
transection in mice SCs form ball like structures that cover the tips of regenerating 
axons. Seven days post transection SCs then extend proccesses out in front of the 
elongating axons in mice [Dun and Parkinson, 2015; Okajima et al., 2000].   
Axon elongation speed is dependent on the injury type. Following a crush injury in 
humans, axons will typically elongate at a rate of 1 mm per day. In comparison, 
axons in the nerve bridge will only elongate at a rate of 0.34/0.35 mm per day in 
mice following transection. The difference in elongation speed is thought to be due to 
the basement membrane remaining intact in crush injuries [Dun and Parkinson, 
2015; Hill, 2017; Pfister et al., 2011].  
The basement membrane of the SC is important in peripheral nerve regeneration, as 





player in supporting axon elongation [Luckenbill-Edds, 1997; Ménager et al., 2004; 
Wang et al., 1992]. Laminin may also act as a stimulator and guide for axonal 
regeneration, as when growth cones interact with laminin on a stripe assay they 
follow laminin stripes in a co-ordinated manner, this response is dependent upon 
laminin-activated integrin receptor signalling [Turney and Bridgman, 2005]. However, 
in transection injuries, the basement membrane is destroyed so axons use SC cords 
as a substrate to cross the nerve bridge from the proximal stump to reach the distal 
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Figure 1.8: Crossing the nerve bridge. A. Two days following SNT in rats, 
macrophages in the nerve bridge become hypoxic, this induces the expression of 
transcription factor HIF-1α. HIF-1α expression results in the secretion of VEGF-A 
by macrophages which induces the migration and proliferation of endothelial cells 
into the nerve bridge. B. 3-5 days post-injury a network of polarised blood vessels 
has formed that traverses the nerve bridge. C. 5-7 days post injury SCs migrate 
into the nerve bridge using the newly formed blood vessels as a scaffold. VEGF-
A, also acts as a chemoattractant for SCs stimulating them to migrate into the 
nerve bridge. SCs migrate into the nerve bridge in discrete cords, SCs are 
organised into cords by fibroblasts. Fibroblasts upregulate ephrin-B2 after injury, 
which interacts with EphB2 on SCs leading to the upregulation of Sox2 within 
SCs. The upregulation of Sox2 in SCs causes N-cadherin to relocalise to cell-cell 
adherens junctions between SCs that are involved in cord formation. As SCs 
begin to migrate into the nerve bridge axons begin to elongate across the nerve 
bridge, following the SC with which it forms a reliant intimate relationship. D. 7-10 
days post-injury SC cords are fully formed across the nerve bridge and axons 






1.9.6 Axon guidance signalling during regeneration 
Chemoattractive cues have also been shown to play a role in axon regeneration after 
a nerve transection injury. DCC is a receptor for netrin-1 and during development 
DCC and netrin-dependent signalling ochistrate potent chemoattractive effects on 
axons [Kim et al., 2015; Petit et al., 2007; Lakhina et al., 2012]. Following injury, 
DCC is upregulated in SCs and in the tips of a subset of regenerating axons. This 
upregulation is important for the extension of axons in the nerve bridge, as when 
DCC is blocked axons fail to elongate into the nerve bridge [Webber et al., 2011]. 
Furthermore, the robust upregulation of netrin-1 has been observed in SCs distal to 
the injury site after axotomy, suggesting that SCs express chemoattractive cues to 
axons to promote them to cross the nerve bridge [Madison et al., 2000].  
Semaphorin-neuropilin signalling plays a crucial chemorepulsive role in axon 
pathfinding during the development of the CNS and PNS [He and Tessier-Lavigne, 
1997; Kitsukawa et al., 1997; Zou et al., 2000]. The expression of semaphorin 
(Sema) and their receptors neuropilins (NRP) have also been identified during 
peripheral nerve regeneration. One study observed that before and after axotomy 
NRP1 mRNA was expressed, but levels remained unchanged in both sensory and 
motor neurons. This indicates that both sensory and motor neurons remain sensitive 
to the effects of Sema signalling following injury [Pasterkamp et al., 1998].  
Furthermore, an increase in Sema3A, Sema3B, Sema3C, Sema3E, Sema3F and 
NRP1 and NRP2 in the distal nerve stump has been observed [Scarlato et al., 2003; 
Ara et al., 2004]. Fibroblasts were identified as expressing semaphorin-3, whereas 
SCs expressed NRP2 [Ara et al., 2004]. When the NRP2 receptor was blocked in 
cultured SCs, they were unable to aggregate and align to form slender columns of 





deficient mice axonal regeneration was delayed, these results suggest an important 
role for semaphorin-neuropilin signalling during peripheral nerve regeneration 
[Bannerman et al., 2008].  
  
1.9.7 Slit-Robo expression in neurons during regeneration 
As Slit/Robo signalling is imperative in axon pathfinding during CNS development, it 
is interesting to consider the possibility that Slit/Robo signalling may be involved in 
axon pathfinding during peripheral nerve regeneration. Some studies have already 
investigated the expression of Slit and Robo in neurons during peripheral nerve 
regeneration.   
Yi et al., (2006) observed changes in Slit/Robo expression following sciatic nerve 
transection. Following sciatic nerve transection Slit1 mRNA levels significantly 
increased in the DRG seven days post-injury and remained elevated up to 28 days 
post-injury. Robo2 mRNA levels also became elevated in the DRG seven days post-
injury. However, Robo2 levels only remained significantly elevated 14 days post-
injury.  It was determined that Slit1 was expressed in both SGCs and neuronal cell 
bodies and that at 7, 14 and 21 days post-sciatic nerve transection Slit1 proteins 
remained elevated. In comparison, Robo2 was expressed in neuronal cell bodies 
and their axons, this expression level increased 7-14 days following sciatic nerve 
transection in the large neuronal cell bodies and remained expressed in retrograde 
degenerating axons. Following injury Slit1 continued to be expressed in the proximal 
nerve stump in both neuronal and non-neuronal cells. However, Slit1 was no longer 






Zhang et al., (2010) determined that following sciatic nerve transection, both Robo2 
and Slit1 mRNA levels were upregulated in the DRG. Robo2 expression was 
observed in neuronal cells in cultured DRG explants, whereas Slit1 was expressed in 
some neuronal cells and non-neuronal cells. Furthermore, the study determined that 
Slit1 promotes neurite formation and extension in cultured rat DRG, suggesting a 
potential role in peripheral nerve regeneration [Zhang et al., 2010].  
Data that still needs to be confirmed is the expression pattern of Robo1, Slit2 and 
Slit3 during peripheral nerve regeneration in relation to the neurons. All data that has 
been previously established concentrates on sensory cell bodies, it would, therefore, 
be interesting to establish the expression pattern of Slit-Robos in motor cell bodies 
before and after sciatic nerve transection.  
1.9.8 Expression of downstream regulators of Slit/Robo signalling during 
peripheral nerve regeneration 
Downstream regulators of Slit/Robo signalling, Slit/Robo GTPase activating proteins 
(srGAP), have been shown to be expressed in the PNS and changes to the 
expression level at both the mRNA and protein level have been observed after injury. 
Chen et al., (2012) observed the expression of srGAP 1 and 3 in the L3-L4 uninjured 
DRG of mice. However, srGAP2 could not be detected. Following sciatic nerve 
transection, a significant increase in srGAP1 and srGAP3 mRNA was observed from 
day 3 to day 14 post-injury. In comparison, only srGAP3 protein was significantly 
upregulated from day 1 to day 14 post injury. Using immunohistochemistry, srGAP1 
expression co-localised with GFAP and some neurofilament expression, determining 
that srGAP1 was expressed in both SGCs and some cell bodies. In comparison 
srGAP3 expression did no co-localise with GFAP but did with neurofilament, 





cell bodies of the DRG. Furthermore, convincing evidence shows the co-localisation 
of Robo2 and srGAP3 in the cell bodies of the DRG at seven days post-injury. These 
findings suggest that Robo2 could recruit srGAP3 in response to a peripheral nerve 
injury [Chen et al. 2012].  
Previous work has documented the expression of the Slit/Robo signalling pathway in 
the intact adult PNS and during peripheral nerve regeneration [Table 1.2, 1.3, 1.4 
and 1.5]. This expression suggests a potential role in the maintenance of the adult 
PNS and a role in regeneration.  
However, the full expression profile of the Slit/Robo in the adult PNS has not been 
obtained, and its role in regeneration has not been established. We hypothesise that 
Slit/Robos are expressed in varying cells of the intact sciatic nerve and that Slit/Robo 
signalling plays a role in axon regeneration patterns during peripheral nerve 
regeneration. We aim to map out the expression pattern of all the Slit/Robos in all 
the cells of the intact sciatic nerve and any changes to the adult intact sciatic nerve 
architecture in Slit/Robo mutants. We also aim to establish the expression pattern of 
Slit/Robos in the sciatic nerve during regeneration. We then hope to determine any 















Gene Published knowledge 
Slit1 Slit1 mRNA present in uncut sciatic nerve [Tanno et al., 2005]. 
Slit2 Slit2 mRNA present in uncut nerve [Tanno et al., 2005]. 
Slit2 mRNA and protein expressed in SCs in vitro and in vivo [Wang et al. 2013]. 
Slit2 mRNA expression confirmed in motor neurons of the facial nerve of rats [Fujiwara et al., 2008] 
Slit3 Slit3 mRNA expressed in cultured SCs [Wang et al. 2013]. 
Robo1 Robo1 mRNA expressed in nerve [Tanno et al., 2005]. 
Robo1 protein expressed in SCs [Wang et al. 2013].  
Robo2 Robo2 mRNA expressed in nerve [Tanno et al., 2005]. 
Robo2 protein expressed in SCs [Wang et al. 2013]. 
Robo2 protein expression has also been detected in adult rat primary sensory axons [Yi et al., 
2006; Zhang et al., 2010]. 
Table 1.2: Summary of Slit/Robo expression in cells of the sciatic nerve. 
 
 
Gene Published knowledge 
Slit1 Slit1 mRNA and protein expression observed in rat DRG[Yi et al., 2006; Zhang et al., 2010; 
Bloechlinger et al., 2004]. 
Slit2 No Data 
Slit3 Weak Slit3 mRNA expression observed in rat DRG [Bloechlinger et al., 2004]. 
Robo1 Robo1 mRNA and protein confirm in rat DRG [Zheng et al., 2012]. 
Robo2 Robo2 mRNA expressed in rat DRG [Yi et al., 2006; Zhang et al., 2010; Bloechlinger et al., 2004]. 
Table 1.3: Summary table of previous knowledge of Slit/Robo expression in the intact DRG. 
 
 
Gene Published knowledge 
Slit1 Slit1 mRNA expression was strong in the dorsal horn in the thoracic spinal cord [Wherle et al., 
2005].   
Slit2 Slit2 mRNA expression was strong in the ventral horn in the thoracic spinal cord [Wherle et al., 
2005].   
Slit2 mRNA was also detected in rat thoracic spinal cords using QPCR [Liu et al., 2011]. Slit2 
mRNA was expressed in the cervical spinal cord in mice [Jacobi et al., 2014].  
Slit2 was expressed in the thoracic spinal cord in rats [Li et al., 2017]. 
Slit3 Slit3 mRNA expression was strong in the ventral horn in the thoracic spinal cord [Wherle et al., 
2005].   
Slit3 mRNA detected in the cervical spinal cord of mice [Jacobi et al., 2014]. 
Robo1 Robo1 mRNA and protein has been detected in the thoracic region of the adult spinal cord of rats 
[Liu et al., 2011].   
Robo1 expressed in the cervical spinal cord of mice [Jacobi et al., 2014].  
Robo1 is expressed in motor neuron cell bodies, in the dorsal region of the thoracic spinal cord in 
rats [Li et al., 2017].   
Robo2 Robo2 mRNA in the grey matter of the cervical spinal cord in mice [Jacobi et al., 2014].  




















Gene Published knowledge 
Slit1 Slit1 is expressed before, and following a sciatic nerve transection [Yi et al., 2006] Slit1 is 
expressed in the SCs in the proximal nerve stump [Zhang et al., 2010].  
Slit1 mRNA is not present in cultured SCs [Wang et al., 2013].  
Slit1 promotes neurite formation and elongation of cultured adult rat neurons and continues to 
be expressed in the distal stump [Zhang et al., 2010].  
Slit1 mRNA levels remained unchanged in the distal stump, after either a crush or cut injury 
[Tanno et al., 2005]. 
Slit2 Slit2 mRNA expression increased in the distal stump seven days post-sciatic nerve transection 
[Tanno et al., 2005]. Slit2 was expressed in SCs in the distal nerve stump seven days post-
injury [Tanno et al., 2005].  
Slit2 can repel cultured SCs in vitro [Wang et al., 2013]. 
Slit3 No data for any injury model 
Robo1  Robo1 mRNA was upregulated 7 and 14 days post injury in the distal nerve stump [Tanno et 
al., 2005]. 
Robo1 mRNA expression in nerve unchanged following a nerve crush [Tanno et al., 2005]. 
Robo1 is upregulated in large calibre axons after axotomy in rats [Yi et al., 2006]. 
Robo1 is expressed in SCs of the sciatic nerve and can control SC migration in vitro [Wang et 
al., 2013].  
Robo2 Robo2 mRNA expression in nerve unchanged following nerve crush [Tanno et al., 2005]. 
Robo2 mRNA upregulation following sciatic nerve 7 and 14 days post injury in the distal nerve 
stump [Tanno et al., 2005]. 
Large diameter sensory neurons upregulated Robo2 following axotomy and smaller calibre 
sensory axons continued to express Robo2 [Yi et al., 2006].  
Slit1-Robo2 signalling promoted neurite outgrowth in DRG explants [Zhang et al., 2010].  
Seven days post-axotomy Robo2 mRNA was upregulated in the distal stump. [Tanno et al., 
2005]. 






Materials and Methods 
2.1 Mouse Lines  
All work involving animals was carried out according to Home Office regulations 
under the UK Animals (Scientific Procedures) Act 1986 (ASPA). Ethical approval for 
all experiments was granted by Plymouth University Animal Welfare and Ethical 
Review Board.   
Robo1 global null mutants were created at University College London by Bill 
Williams [Williams et al., 2005].  They used the Cre/loxp system to target exon 5 of 
Robo1 and then positively selected for these cells using a neomycin selection 
cassette and negatively selected for these cells using a thymidine kinase cassette. 
Loss of exon 5 led to the decay of the Robo1 mRNA and a null phenotype. A 
C57BL/6 background was used in the production of these mutants, the line was 
maintained on a C57BL/6 mouse background. Mixed sex mice were used throughout 
this experimental data. 
Robo2 global null mutants were created at the University of California by Uta 
Grieshammer [Grieshammer et al., 2004]. Robo2 null mutants were produced by 
replacing a 135 base pair sequence, which included the 3’ end of the first exon 
containing the start codon and the five end of the adjacent intron, with an IRES-
tauLacZ expression cassette and a self-excising floxed sperm-specific Cre 
recombinase/neomycin resistance expression cassette.  A CD1 background was 
used in the production of these mutants, the line was maintained on a C57BL/6 
background. Mixed sex mice were used throughout this experimental data. 
Slit1 and Slit2 global null mice were generated at the University of California by 





targeting a portion of an exon encoding the second leucine-rich repeat (LRR). This 
region was replaced by a KDEL-IRES-tauGFP and a loxp-PGK-neo selection 
cassette. To produce the Slit2 null mice the first and second exon of Slit2 was 
replaced with an IRES-tauGFP and a loxp-PGK-neo selection cassette. Although this 
left the promoter intact, it disrupted the signal sequence and a portion of the first 
LRR of Slit2. A mixed C57BL/6 and CD1 background were used in the production of 
these mutants, the line was maintained on a C57BL/6 background. Mixed sex mice 
were used throughout this experimental data. 
Slit1, Slit2, Robo1 and Robo2 null mutants breeding pairs were kindly provided by Dr 
Bill Andrews from University College London, UK. 
Slit3 global null mice were generated at the Washington University School of 
Medicine by Yuan Wenlin et al. [Wenlin et al., 2003]. The Slit3 null mice were 
generated using a targeting vector that introduced a 1kb deletion that included the 3’ 
half of exon one that contains the initiation codon and signal peptide. The deletion 
also encompassed 800 base pairs of intron one; this region was replaced by the β-
galactosidase gene and a loxp-PGK-neo selection cassette. A C57BL/6 background 
was used in the production of these mutants, the line was maintained on a C57BL/6 
background. Mixed sex mice were used throughout this experimental data. 
Myelin proteolipid protein (PLP), -EGFP mice, were generated by Barbara Mallon et 
al. at the Lerner Research Institute, Cleveland, USA [Mallon et al., 2002]. PLP-EGFP 
mice were generated using a PLP promoter in which EGFP was fused to the 3 UTR 
of PLP. A C57BL/6J and CBA/J background was used in the production of these 
mutants, the line was maintained on a C57BL/6 background. Mixed sex mice were 





 The GFAP-GFP mice were produced at the University of Wisconsin-Madison by 
Lang Zhuo et al. and bought from Jackson laboratories (stock no. #003257) [Zhuo et 
al., 1997]. These mice were produced via blunt end ligation of the GFAP promoter 
and mouse protamine gene-1 with a HindIII-Xbal fragment that contained the entire 
GFP coding region. An FVB/NJ background was used in the production of these 
mutants, the line was maintained on a C57BL/6 background. Mixed sex mice were 
used throughout this experimental data. 
C57BL/6 mice were purchased from Charles River UK limited (strain no. #027). All 
mouse strains were maintained on a C57BL/6 background. C57BL/6 animals were 
used as wild-type mice in all experiments where stated. 
2.2 Animal husbandry and peripheral nerve surgery 
All animals were maintained in a specialised animal facility, where they were under a 
12 hour light/dark daily cycle with unlimited access to food and water. Temperatures 
of 65-75°F (~18-23°C) with 40-60% humidity were the standard range. Enrichment 
activities included play tunnels, shepherd shacks and polypropylene mouse houses. 
Bedding included the use of hard wood particles and paper strand nesting material. 
For surgery, animals were firstly anesthetised using isoflurane, and the skin and 
muscle of the right rear limb were opened to reveal the sciatic nerve.  Sciatic nerve 
cut and crush were carried out according to procedures detailed in Dun and 
Parkinson. (2015). Animals were then given appropriate post-operative care and 
checked daily to ensure they showed no adverse effects (e.g. weight loss or 
autotomy). At different indicated time points post-surgery, animals were euthanised 
humanely by cervical dislocation in accordance with UK Home Office regulations 





2.3 Polymerase chain reaction 
The polymerase chain reaction (PCR) is an important technique to be able to 
determine the genotype of the mutant mice used during the duration of this project. It 
enables the amplification of a specific fragment of DNA using designed primers that 
either recognises the wild-type gene or the mutant gene. As DNA is negatively 
charged, agarose gel electrophoresis can be used to separate the negatively 
charged DNA products according to size; the DNA within the gel is visualised using 
Gel Red under ultra violet light. This band will indicate the genotype of the animal as 
the bands for mutant and wild-type genotypes will have varying sizes of amplified 
DNA product. 
Ear notches from genetically modified mice were first lysed by adding 75µl of alkaline 
lysis reagent and heating to 95°C for 1.5 hours in a thermal cycler following the 
HotSHOT protocol [Truett., 2000]. The solution was then neutralised using 75µl of 
neutralising reagent.  The solution was then stored at 4°C in preparation for PCR. 
2.0µl of the DNA sample (or water for the negative control) was added to a 23µl PCR 
mix containing 1.5mM MgCl2, 200µM deoxynucleotide triphosphates (dNTPs), 0.5 
picomoles forward and reverse primers, 5x green GoTaq® buffer and 0.125µl Taq® 
polymerase diluted in double distilled water. The PCR reaction was performed in a 
thermal cycler [For standard programme see Table 2.1 and for variations see Table 
2.2]. Following amplification, 25µl of the sample was pipetted into a 2% agarose gel 
with 1:10,000 GelRed™ submerged in 1x tris acetate EDTA (TAE) to be 
electrophoresed. The gel was run at 120V for 30 minutes, and the bands were 





2.4 mRNA extraction  
Sciatic nerve and spinal cord tissue samples were placed in 700µl QIAzol™ lysis 
reagent, and DRGs were placed in 400µl QIAzol™ lysis reagent and homogenised 
using a sonicator for 40-60 seconds. 300µl of QIAzol™ lysis reagent was then added 
to tubes containing DRGs post homogenisation. Tubes were then incubated at room 
temperature for 5 minutes. 140µl of chloroform was added to each tube which was 
then shaken vigorously for one minute. The solution was then left to stand at room 
temperature for 10 minutes. Samples were centrifuged for 15 minutes at 12,000xg at 
4ºC, and the upper aqueous phase was collected. 100% ethanol was added to each 
tube at a ratio of 1.5x the amount of the upper aqueous phase in the previous step. 
RNA was then extracted using a miRNeasy mini kit (Qiagen) following the 
manufacturer’s instructions. RNA was eluted from the mini spin column using RNA 
free ddH2O and then measured using a spectrophotometer.  
A spectrophotometer uses different wavelengths of light through the sample to 
measure how much light is absorbed; this enables us to measure how much RNA is 
in the sample, how pure the sample is and analyse the quality of RNA. The 260/280 
absorbency ratio indicates the quality of RNA, RNA absorbs light at 260nm so an 
expected ratio of good quality RNA should be bigger than 1.80. The ratio 260/230 
gives us a value of how pure our RNA sample is, and values are commonly in the 
range of 2.0-2.2. If the ratio is appreciably lower than expected, it may indicate the 
presence of contaminants which absorb at 230 nm such as EDTA, carbohydrates 
and phenol. 
2.5 Complementary DNA (cDNA) synthesis   
The synthesis of stable cDNA is extremely useful due to the unstable nature of 





as it is stable for long periods at room temperature. The mRNA extracted from 
samples undergoes reverse transcription which results in a complementary strand of 
DNA. This complementary strand can be used for many downstream processes such 
a semi-quantitative PCR and microarrays whereas mRNA would be broken down 
during these processes. 
1μg of total extracted RNA was added to a sterile RNase-free microcentrifuge tube 
with 250ng of random hexamers; this was then made up to a volume of 14μl using 
nuclease-free water. The tube was heated to 70°C in a thermal cycler for five 
minutes to melt secondary structures within the template. The solution was then 
immediately cooled on ice for five minutes to inhibit the secondary structures 
reforming. 5µl 5x Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase 
(RT) Reaction Buffer, 1.25µl dNTP, 40mM 1µl M-MLV DNA polymerase was added 
to the RNA containing tube, and the final volume was made up to 25µl using 
nuclease-free water. Tubes were then placed in a thermal cycler and heated to 24ºC 
for 10 minutes then to 50ºC for 50 minutes. cDNA was then stored -20°C. 
Synthesised cDNA was then used to look at gene expression in the different 
samples. Sequence-specific primers were used to measure gene expression (Table 
2.3) using the same principle PCR method [Section 2.4]. An example PCR 
programme is detailed in Table 2.1 for specific cycle length, and annealing 

















Step Temperature Time 
1 94ºC 5 minutes 
2 94º 30 seconds 
3 50ºC 40 seconds 
4 72ºC 40 seconds 
5 Repeat steps 2-4 x38 times 
6 72ºC 10 minutes 
7 4ºC ∞ 
Table 2.1: Typical PCR programme. Table 2.1 shows a typical PCR programme 
used during genotyping and real time PCR (RT-PCR). The first step is the initial 
denaturation, followed by a short denaturation, annealing and extension. These 
three short steps are repeated a number of times depending on the target, they 










































































































60 35 1.5 173 
 
 
Table 2.2: Primer information for genotyping PCR. Table 2.2 shows the specific 
primer sequences to establish the genotypes of different animals; also shown are 
the specific annealing temperature for each primer and how many cycles each 
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50 30 1.5 312 
 
 
Table 2.3: Primer information for real time PCR. Table 2.3 shows information 
including sequences, annealing temperature, and the number of cycles each PCR 
programme for each primer pair. These primers were specifically designed to 
recognise fragments of cDNA. This enabled the gene expression in different 





2.6 In situ hybridisation  
In situ hybridisation allows the visualisation of mRNA localisation and quantitation in 
tissue samples. This is useful as it allows us to visualise transcription rates of 
specific genes by targeting the RNA with probes that detect the antisense strand and 
the negative control, the sense strand. This allows us to see which cells within the 
tissue express the mRNA of interest and how transcription rates are affected after 
injury. 
Tissue was fixed in 4% paraformaldehyde (PFA) in 1x PBS at 4°C overnight. Tissue 
was then snap frozen using liquid nitrogen in optimal cutting temperature medium 
(OCT). Samples were stored at -80°C until further processing. Tissue was then 
mounted onto a cryostat chuck and 15µm sections cut and placed onto 
SuperFrost®Plus slides. 
The hybridisation chamber was prepared by placing filter paper at the bottom of each 
slide chamber. This was then soaked with 50ml of 50% formamide in 1x SSC DEPC 
treated buffer. The chamber was then heated to 65°C in a water bath. The 
hybridisation buffer was heated to 65°C for one hour using a thermal cycler. 3µl of 
the probe was added to 500µl of hybridisation buffer; the solution was then heated to 
75°C for five minutes using a thermal cycler to denature the probe [Probe information 
Table 2.4]. Slides were prepared by adding a Frame-Seal™ incubation chamber 
onto each slide, then 150µl of hybridisation buffer containing probe was added to 
each slide and sealed with a coverslip. Slides were placed in the heated 
hybridisation chamber which was sealed and placed overnight in a 65°C water bath.  
The following day, coverslips were removed from the slides which were then washed 





SSC at 65°C. Slides were washed 2x 30 minutes in 1x maleic acid buffer containing 
Tween®-20 (MABT) at room temperature. A PAP pen was used to draw a 
hydrophobic ring around the samples, and the samples were blocked with 500µl of 
10% FBS in 1x MABT for one hour at room temperature. Anti-DIG-AP conjugated 
second antibody 1:1000 in blocking solution was applied to the slides and left 
overnight at 4ºC in a humidified container. The slides were washed 3x15 minutes in 
1x MABT at room temperature followed by 2x five minutes in the pre-staining buffer 
at room temperature; slides were then incubated in PVA staining buffer in the dark at 
37ºC overnight [For buffer recipe refer to solutions table]. Slides were washed 3x 10 
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2.7 Scanning electron microscopy 
Scanning electron microscopy is used to study microstructures of the nerve as it 
enables the visualisation and measurement of myelin rings and axons that can then 
be analysed to produce G-ratio scores.  
Sciatic nerve tissue was fixed in 2.5% glutaraldehyde for one hour. 2x 15 minutes’ 
rinses in 0.1M pH 7.2 sodium cacodylate buffer followed the fixation. The tissue was 
then given a secondary fix with 1% osmium tetroxide in 0.1M sodium cacodylate 
buffer for one hour. Samples were then washed 2x 15 minutes in 0.1M sodium 
cacodylate buffer. Samples were dehydrated via a 6x 15 minute incremental ethanol 
concentration series of 30%, 50%, 70%, 90% and 2x100% ethanol. 
The 100% ethanol was removed and replaced with a 30% Agar low viscosity resin: 
70% absolute ethanol and left for 24 hours to allow the resin to infiltrate the tissue. 
This solution was then followed by 4x 24-hour steps with an increasing resin 
concentration of 50:50 resin:ethanol, 70:30 resin:ethanol and finally 2x 100% resin. 
The tubes were then transferred to an embedding oven where the resin was 
polymerised at 60ºC overnight. The blocks were polished using an ultramicrotome 
using a glass knife.  
2.8 G-ratio calculations 
Images of uncut sciatic nerves from Robo1Het, Robo1Cntrl, Slit2Het, Slit2Cntrl, Slit3KO 
and Slit3Cntrl were taken using a JSM-6610lV scanning electron microscope following 





ImageJ. The radius of the axon and the axon plus the myelin is measured using 
ImageJ. The g-ratio is the radius of the axon divided by the radius of the axon and 
the myelin. From this data, the average g-ratio and average axon diameter can then 
be calculated. Statistical significance was assessed using Student’s t-Test and a 
significance threshold of p value (p =<0.05).  
2.9 Static sciatic index (SSI) 
An SSI is a measurement taken pre and post-sciatic nerve crush; it measures the 
ratio of the spread of the toes in comparison to the length of the foot. It is a useful 
tool to measure functional recovery after injury as the ratio changes after injury 
[Baptista et al., 2007]. Before injury, the spread of the toes is large and the length of 
foot relatively short resulting in an almost 1:1 relationship. After injury, the toe spread 
is decreased and the foot length increases as the nerve recovers the ratio returns to 
a normal distribution and these changes can be tracked.   
Before injury the SSI of both feet are measured, this is done by placing the mouse 
into a Pyrex box that has a small amount of water in its base. The box is then placed 
on a stand and a camera placed underneath that is set to record. The mouse is then 
recorded for around one minute. Measurements were taken using the software 
BitRule; this programme is a screen measurement utility. Measurements were taken 
of the toe spread by measuring from the outer edge of the 1st toe to the outer edge 
5th. Measurements were taken of the foot length by measuring from the tip of the 3rd 
toe to the more distal part of the foot still in contact with the box.  
2.10 Western blotting 
Western blotting can be utilised to separate proteins by size from samples to look at 





buffer at a ratio of one nerve to 100µl of SDS buffer and then sonicated. Samples 
were then heated to 70ºC for 10 minutes in a heating block before loading. 
Samples were run on a 12% w/v polyacrylamide gel submerged in running buffer at 
constant 120V for 2.5 hours at room temperature. Proteins from the gel were 
transferred onto a polyvinylidene fluoride 0.45µm thickness transfer membrane 
(PVDF) using the wet transfer method. The transfer cassette was submerged in 1x 
transfer buffer at 4°C for 16 hours and set at constant 90mA. Membranes were 
blocked for two hours in 5% w/v milk powder diluted in Tris-buffered saline (TBS) at 
room temperature. Primary antibodies were diluted in the blocking solution, and the 
membranes were incubated in primary antibodies overnight at 4°C on a roller 
[Primary antibody dilutions provided in Table 2.5]. 
Following overnight incubation, with primary antibody, the membranes were washed 
3x five minutes in 1 x TBST. The membrane was then incubated with diluted 
secondary antibody, 1:2500 in 5% milk powder 1x TBST, for one hour on a roller at 
room temperature [Secondary antibody dilutions refer to table 2.4]. The membrane 
was then washed 4x 5 minutes in 1x TBS and dried slightly. Chemiluminescent 
Pierce® ECL western blotting substrate was added to the area of interest to oxidise 
the HRP and was incubated in the dark for five minutes. Amersham Hyperfilm™ ECL 
was exposed to the membranes for a varying length of time depending on the 
strength of the signal but was usually between 10 seconds – 5 minutes. The 
exposed film was then developed in a Compact X4 automatic processor which 
utilises Devalex® M X-ray developer solution to develop the film and in Fixaplus™ 
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Table 2.5: Antibody information for western blotting. Table 2.4 details the 
antibodies used during western blot experiments and their dilution in the 5% 






Immunohistochemistry (IHC) allows us to identify proteins in tissue samples from 
animals by targeting them with specific antibodies that recognise and bind to the 
protein of interest.  Multiple antibodies can be used on one sample as long as they 
are from different species and fluorophores with different wavelengths are used to 
detect the different primaries. The fluorescent signal from these antibodies can be 
visualised with a fluorescence microscope, and the location and expression of the 
protein can be determined as well as colocalisation with other proteins.  
Uninjured, cut, and crushed sciatic nerves, as well as L4-L5 DRG, and L4-L5 spinal 
cords were dissected from mice. The samples were fixed for five hours in 4% PFA at 
4ºC. Samples were then washed 3 x 10 minutes in 1x PBS and dehydrated in 30% 
sucrose overnight at 4ºC. Post dehydration samples were placed in embedding 
moulds and frozen using liquid nitrogen in OCT and stored at -20ºC. Sections were 
mounted onto a cryostat chuck and sectioned using a cryostat at 8 µm thickness for 
both DRGs and nerves and 15µm for spinal cords. Sections were placed onto 
SuperFrost®Plus slides and stored at -20ºC. 
To begin the staining procedure slides were left at room temperature for 10 minutes. 
Slides were then washed 2x 5 minutes in 1x PBS in a Coplin jar to remove OCT. A 
PAP pen was used to draw a hydrophobic ring around the sample to stop the sample 
drying and ensure maximum coverage by the antibody. Slides were then incubated 
at room temperature for 30 minutes in 1% BSA with 0.25% Triton®X-100 in 1x PBS 
to permeabilise the sample. Upon removal of this 3% BSA with 0.05% Triton®X-100 
in 1x PBS (blocking buffer) was applied for 45 minutes at room temperature to block 
the sample. Primary antibody in blocking buffer was then added to the tissue sample 





primary antibody, slides were washed 3x 10 minutes in 1x PBS, and secondary 
antibody was applied at a 1:300 dilution plus a Hoechst stain at a 1:500 dilution in 
blocking buffer for one hour at room temperature. Slides were washed 3x 10 minutes 
in 1x PBS and mounted according to standard procedure. 
2.12 Three-layer protocol immunohistochemistry 
If staining using the two-layer system did not give an adequate signal of staining a 
three-layer approach was employed. The previously stated immunohistochemistry 
protocol was used up until the primary was washed off. Biotinylated antibodies raised 
against the species of the primary were then added in 3% BSA + 0.05% Triton at a 
1:500 dilution for one hour at room temperature. The sample was then washed with 
3x 10 minutes in 1x PBS in Coplin jars. A streptavidin Alexa Fluor 568 conjugate 
acted as the tertiary layer and was added at a 1:500 dilution in 3% BSA + 0.05% 
Triton along with any other secondary antibodies used to target other primary 
antibodies.  The slides were then washed 3x 10 minutes in 1x PBS and mounted 
according to standard procedure.  
2.13 Imaging 
Confocal laser scanning microscopy was used to photograph immunohistochemistry, 
immunocytochemistry and whole mount image results. The confocal microscope 
system works by shining lasers of a specific wavelength onto the sample. The 
fluorophores, with which the sample is stained, become excited in response to the 
lasers and emit light at a lower wavelength. This emitted light is focussed through a 
pinhole unlike conventional fluorescence microscopy, which results in a much higher 
resolution image. The confocal also has the advantage of being able to distinguish 





multiple images at different focal planes called a z-stack using a Leica DMI 600 
confocal microscope.  
2.14 Whole mount staining 
Whole mount staining is the most effective way to look at axonal pathfinding after a 
peripheral nerve injury as the whole structure can be visualised and there is little 
disruption to the structure.  
Nerves are removed from animals 14 day post sciatic nerve transection and fixed in 
4% paraformaldehyde for five hours at 4ºC. Once the nerve is fixed it was then 
washed 3x 10 minutes in 1x PBS with 1%Triton® X-100 (PTX). The sample was then 
blocked overnight at 4ºC with 10% foetal bovine serum (FBS) in PTX. The nerve was 
incubated in neurofilament primary antibody at a 1:100 dilution in blocking buffer at 
4ºC for 72 hours. The primary antibody solution was removed, and the nerve was 
washed 3 x 15 minutes in PTX solution at room temperature followed by an 
overnight wash at 4ºC. Anti-Chicken 568 secondary antibody was used at a 1:300 
dilution in blocking buffer incubation in this solution for 48 hours at 4ºC. The nerve 
was then rinsed 3x 15 minutes in PTX and then left overnight in PTX at 4ºC. The 
nerve was then cleared using multiple 24-hour incubations at 4ºC using incremental 
glycerol concentrations of 25%, 50%, 75% and 2x 100%. Nerves were placed onto 
SuperFrost®Plus slides, and coverslips were mounted using Dow-Corning® high-
vacuum grease and glycerol based Citifluor. 
2.15 Calculation of positive cells in uncut and cut nerves. 
The percentage of co-localisation in uncut and cut nerves between different cell 
markers and Slit/Robos was counted to establish how many cells Slit/Robo was 





different samples and co-localisation determined in each for Schwann cells and 
macrophages. The nuclei of neurons are located far away from the axons; this 
makes using nuclei as an indicator for the cell count an ineffective tool. In transverse 
sections of the individual nerve axons can be identified easily using the marker 
neurofilament. In longitudinal sections, axons of the proximal stump were counted 
again using the axon marker neurofilament. To do this ImageJ cell counter was 
employed and co-localising cells were counted using the cell counter one, and non-
colocalising cells were counted using the cell counter two. The percentage co-
localisation was then calculated and from the three values generated a mean was 
then calculated using Microsoft Excel. The standard deviation was further calculated 
and then standard error again using Microsoft Excel. The mean and standard error 
















Antibody Dilution Fix Block 1° 
and 2° 
diluent 
2° antibody Source 
Robo1 1:100 4% 
PFA 
3% BSA + 
0.05% 
Triton 
Anti-rabbit Abcam, Cambridge, 
UK 
Robo2 1:100 4% 
PFA 
3% BSA + 
0.05% 
Triton 
Anti-rabbit Santa Cruz, 
California, USA 
Slit2 1:100 4% 
PFA 
3% BSA + 
0.05% 
Triton 
Anti-rabbit Abcam, Cambridge, 
UK 
Slit3 1:100 4% 
PFA 





CD31 1:300 4% 
PFA 


















NeuN 1:300 4% 
PFA 







F480 1:300 4% 
PFA 








Table 2.6: Antibody information for immunofluorescence and 
immunocytochemistry studies. Table 2.5 shows all information associated with 
the primary antibodies used during immunofluorescent and immunocytochemistry 






2.16 General laboratory equipment and solutions 
 
Equipment Supplier 
Compact X4 automatic western blot 
processor   
Xograph Healthcare, Gloucestershire, 
UK 
Leica Ultracut E ultramicrotome  Leica Microsystems (UK) Ltd, Milton 
Keynes, UK 
MJ Research PTC-100 Peltier thermal 
cycler  
Bio-Rad Laboratories Ltd, Hertfordshire, 
UK 
Water bath  Bibby Scientific Ltd, Staffordshire, UK  
Embedding oven TAAB Laboratories Equipment Ltd, 
Berkshire, UK 
BioDoc-It™ Imaging system UVP, Cambridge, UK 
Nanodrop 2000 UV-Vis Spectrometer Thermo Scientific, Wilmington, USA 
















Solution Components  
10x phosphate buffered saline (PBS) 80g 1.36M Sodium Chloride  
2g 0.03M Potassium Chloride  
2g 0.014M Potassium phosphate 
monobasic  
11.5g 0.08M Sodium phosphate dibasic  
1L ddH2O 
10x Tris-buffered saline (TBS) 24g 0.15M TRIS hydrochloride 
5.6g 0.46M TRIS base  
88g 1.51M Sodium chloride 
1L ddH2O pH 7.6 
12% polyacrylamide running gel 6.5ml ddH2O  
3.8ml 1.5M TRIS hydrochloride pH 8.8 
0.0057M  
4.5ml 40% Acrylamide  
150ul 10% Sodium dodecyl sulphate  
150ul 10% Ammonium Persulfate 
20ul  Tetramethylethylenediamine 
4% polyacrylamide stacking gel 625µl 40% Acrylamide  
1.25ml 0.5% TRIS base pH 6.8  
50µl 10% Sodium dodecyl sulphate 
3.1ml ddH2O 
7.5µl Tetramethylethylenediamine 
37.5µl 10% Ammonium Persulfate 
10x western running buffer 30.3g 0.25M TRIS base                                          
144g 1.92M Glycine                                             
1l dH2O                                              
10x western transfer buffer 288g 3.84M Glycine 
6.04g 0.05M TRIS base 
2L dH2O 
1x western transfer buffer 100ml 10x western transfer buffer 
200ml Methanol 
700ml dH2O 
1x western stripping buffer 15g 0.2M Glycine 
1g 0.003M Sodium dodecyl sulphate  
10ml Tween20 
1L ddH2O pH 2.2 
4x reducing loading buffer 3.55mL Demonized water 
1.25mL 0.5M TRIS hydrochloride pH 
6.8 
2.5mL Glycerol  
2.0mL 10 % (w/v) Sodium dodecyl 
sulphate 
0.2 mL 0.5 % (w/v) Bromophenol blue  





50x tris-acetate-EDTA solution (TAE) 242g 2M TRIS base 
57.1ml Glacial Acetic Acid 
100mL 0.5M 
Ethylenediaminetetraacetic acid 
1ddH2O to 1L 
 
4% Paraformaldehyde  
8g Paraformaldehyde powder 
3 Sodium hydroxide pearls 
20ml 10x PBS 
150ml ddH2O 
Ajust pH to 7.4 with Hcl, final volume to 
200ml 
Lysis Buffer 80mg 25mM Sodium hydroxide 
0.67ug 0.2mM Disodium 
Ethylenediaminetetraacetic acid 
1L H2O pH12 
Neutralising Buffer 63.05g 0.4M TRIS hydrochloride  
1L H2O pH 5 
10x Salts 116.9g 2M Sodium chloride  
14.612g 0.043M 
Ethylenediaminetetraacetic acid  
15.8g 0.1M TRIS hydrochloride pH 7.5 
7.8g 0.07M Sodium dihydrogen 
phosphate 
7.1g 0.05M Sodium phosphate dibasic 
1ml Diethylpyrocarbonate 
1L ddH2O 
Hybridisation Buffer 50% Deionised Formamide 
0.1mg/ml yeast tRNA 
10% Dextran sulphate 
1x Denhardts 
5x Maleic acid buffer containing 
Tween®-20 
500ml dH2O 
29.025g 0.25M Maleic acid 
21.925g 0.38M Sodium Chloride  




4ml 5M Sodium Chloride  
10ml 1M Magnesium Chloride 
20ml 1M Tris pH 9.5 
0.2ml Tween-20 
166ml dH2O 
PVA staining solution 0.8ml of 5M Sodium Chloride  
2ml of 1M Magnesium Chloride  
4ml of 1M Tris pH 9.5 
13.2ml dH2O 
40 µl Tween®-20 
100µl of 5-bromo-4-chloro-3-indolyl-
phosphate/nitro blue tetrazolium 
(NBT/BCIP)  






20x Saline Sodium Citrate buffer 175.3g 3M Sodium Chloride 
88.2g 0.34M Sodium Citrate 
M-MLV RT 5X Reaction Buffer  39.4 Tris-HCl-pH 8.3  
28g 0.38M Potassium chloride 
1.43g 0.015M Magnesium chloride 





























Chapter 3 Expression of Robo/Slit in the adult sciatic nerve 
3.1 Introduction 
The expression of Slit/Robo during the development of the central nervous system 
has been well documented [Brose et al., 1999; Kidd et al., 1989; Kidd et al., 1999; 
Nguyen Ba-Charvet et al., 1999; Wang et al., 1999]. In comparison, the expression 
of the Slits and Robos in the adult peripheral nervous system has only been partly 
investigated [Tanno et al., 2005; Wang et al., 2013; Yi et al., 2006; Zhang et al., 
2010]. In these papers Slit/Robo expression in the PNS has been studied mainly 
using RT-PCR, revealing that Slit/Robos are expressed but not elucidating which 
cells each Robo and Slit are expressed in and how expression level varies between 
different cells within the peripheral nerve.  
The sciatic nerve is a peripheral nerve of the lower limb composed of axons of 
neurons and several different cells including SCs, fibroblasts and endothelial cells 
[Standring, 2016]. Unlike other studies, this study will entirely focus on the sciatic 
nerves from mice. Furthermore, the aim was to look at the expression of Slit/Robo in 
all cell types of the peripheral nerve in vivo to be able to compare how Slit/Robo 
expression varies between them. In comparison, previous work had focused on 
identifying the protein as either being expressed or not expressed in the nerve with 
no comparison of how the expression varies between cell types.  
This part of the study will focus on the expression of Slit2, Slit3, Robo1 and Robo2. 
The expression of Robo3 will not be investigated as evidence suggests that Robo3 is 
only expressed in commissural axons, functioning to negate the effects of Robo1 
and Robo2 as discussed in Chapter 1 [Sabatier et al., 2004].   Furthermore, we will 





to be specific to endothelial cells as discussed in Chapter 1, therefore it would be 
unlikely to herald any novel data [Huminiecki et al., 2002, Park et al., 2003; Okada et 
al., 2008]. In this part of the study, I was unable to identify any expression of Slit1 via 
immunohistochemistry in the uninjured adult sciatic nerve, which is why no results 
are shown for Slit1.  
It is important to fully clarify the expression of Slit/Robo to fully identify potential 
signalling pathways involved in maintaining the peripheral nerve structure, as 
understanding this could be implicit to develop therapies for degenerating diseases 
such as Charcot-Marie-Tooth disease. It is also important to carry out this work 
before carrying out any work in the peripheral nerve injury model, as we can confirm 



















3.2.1 Robo1 expression in the adult peripheral nerve 
It has been previously documented that Robo1 mRNA was present in the adult 
sciatic nerve of male Wistar rats [Tanno et al., 2005].  However, this study did not 
identify which cells expressed Robo1. Wang et al., (2013) showed that Robo1 mRNA 
and protein was expressed in SCs both in vitro and in vivo in mice through RT-PCR 
and immunohistochemistry.  
Our study will differ from Tanno et al., work by purely focussing on mouse specimens 
like Wang et al., [Tanno et al., 2005; Wang et al., 2013]. However, unlike Wang et 
al., we will go one step further in clarifying the full expression profile of Robo1 in the 
peripheral nerve, by identifying expression levels in other cells such as axons, 
fibroblasts and endothelial cells using immunohistochemistry.  
To investigate the expression level of Robo1 in different cell types of the peripheral 
nervous system, adult sciatic nerves were removed from two-month-old C57BL/6 or 
PLP-EGFP mice. The nerves were cryosectioned transversely into 15µm sections. 
Sciatic nerve sections from C57BL/6 mice were stained with Robo1 and NF; 
colocalisation was seen between Robo1 and neurofilament staining, indicating that 
Robo1 is expressed in the axons of the sciatic nerve [Figure 3.1]. Quantification of 
co-localisation revealed that Robo1 is expressed in 83% of axons [Figure 3.1]. 
Sciatic nerve sections from PLP-EGFP mice were stained with Robo1; the GFP 
signal was present in myelinating and non-myelinating SCs. Colocalisation between 
the GFP signal and Robo1 was observed apart from in very bright GFP-positive 
cells. Higher magnification images revealed that colocalisation of Robo1 and GFP 
was seen in myelinating SCs, which were less positive for GFP [Figure 3.2]. 





magnification of these regions revealed that these cells were non-myelinating SCs 
through their distinct morphology, indicating that Robo1 is not expressed in non-
myelinating SCs [Figure 3.2 I-L]. Robo1 appeared to be expressed at a similar level 
in axons and their associated myelinating SCs [Figure 3.2]. Quantification 
determined Robo1 expression in 85% of Schwann cells [Figure 3.2]. 
Robo1 was also present in other structures of the peripheral nerve. One of these 
structures was the vasa nervorum of the sciatic nerve. Staining using CD31, an 
endothelial cell marker, and Robo1 revealed colocalisation between the two proteins 
in cells within the sciatic nerve and around the periphery of the nerve. In blood 
vessels outside of the sciatic nerve, there was also Robo1 staining that was closely 
associated with the CD31-positive cells but did not colocalise [Figure 3.3].  This 
suggests that Robo1 is expressed in the endothelial cells of both internal and 
external blood vessels of the sciatic nerve, but may also be expressed in closely 
associated cells, such as smooth muscle cells in blood vessels that lie externally to 
the sciatic nerve [Tennant and McGeachie, 1990]. Robo1 expression in the blood 
vessels surrounding the sciatic nerve appeared particularly strong in comparison to 
Robo1-positive endothelial cells within the nerve. Robo1 expression has been 
previously documented in vascular endothelial cells, so it is not so surprising that it is 
expressed in the endothelial cells associated with the sciatic nerve [Enomoto et al., 
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Figure 3.1: Robo1 is expressed in axons of the sciatic nerve. Sciatic nerves 
from two-month-old C57BL/6 mice were stained with Robo1 (B, F) and 
neurofilament antibodies (NF) (C, G) and were counterstained with Hoechst (A, 
E).  A-D. Robo1 staining (B) appeared to be expressed in various cell types of the 
sciatic nerve some of which colocalised (D) with neurofilament staining (C). E-H. 
Higher magnification images of the nerve further confirm colocalisation (H, white 
arrows) between Robo1 (F) and neurofilament (G). This result indicates that 
Robo1 is expressed in the axons of the adult sciatic nerve. I. 83% of axons 
express Robo1.  (A-D scale bar=100µm, E-H scale bar=10µm) (n=3) 
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  Figure 3.2: Robo1 is expressed in myelinating Schwann cells of the sciatic 
nerve. Sciatic nerves from two-month-old PLP-EGFP mice were stained with 
Robo1 antibody (C, G, K) and counterstained with Hoechst (A, E, I). GFP was 
expressed in PLP-positive SCs (B, F, J) [Mallon et al., 2002]. A-D. Consistent with 
previous results, Robo1 (C) appeared in a variety of cells types within the adult 
sciatic nerve. Staining of Robo1 (C) did appear to colocalise (D) with some of the 
GFP signal (B). E-H. Higher magnification images revealed that Robo1 (G) 
colocalised (H) with the GFP signal (F) but this appeared confined to myelinating 
SCs. I-L. In non-myelinating SCs (J), identified by their morphology, Robo1 
staining (K) did not appear to colocalise (L) with the GFP signal and seemed 
confined to the small calibre axons that the non-myelinating SCs surround. M. 
Quantification of the number of Robo1 positive SCs (85%) in the adult sciatic 
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Figure 3.3: Robo1 is present in blood vessels associated with the sciatic 
nerve. Sciatic nerves from two-month-old C57BL/6 mice were stained with Robo1 
(B, F, J) and CD31 antibodies (C, G, K) and counterstained with Hoechst (A, E, I). 
A-D. Low magnification images reveal blood vessels stained with CD31 (C) inside 
and outside the nerve which colocalised (D, white arrows) with Robo1 staining 
(B). E-H. High magnification images of blood vessels outside the nerve confirm 
that Robo1 (F) colocalises (H) with CD31 staining (G) indicating Robo1 
expression in the blood vessels. Robo1 staining in blood vessels outside the 
nerve (F) could also been seen in cells surrounding the endothelial cells (H, white 
arrows). I-L. High magnification images of blood vessels inside the nerve show 
blood vessels stained with CD31 (K) and Robo1 staining (J) that colocalises (L, 
white arrows), indicating that Robo1 is expressed in blood vessels of the sciatic 






3.2.2 Robo2 expression in the adult peripheral nerve 
In comparison to Robo1, Robo2 expression in the peripheral nervous system has 
been previously documented in more detail. Robo2 mRNA was detected in cultured 
DRG neurons [Zhang et al., 2010], and in adult rat peripheral nerve tissue [Tanno et 
al., 2005]. Robo2 protein expression has also been detected in adult rat primary 
sensory axons [Yi et al., 2006; Zhang et al., 2010]. In addition to this Robo2 
expression has also been observed both in vitro and in vivo in mouse SCs of the 
sciatic nerve [Wang et al., 2013]. 
Unlike previous work, our work is purely done in mouse specimens. Furthermore, our 
work will aim to identify Robo2 expression in vivo, unlike Zhang et al. We will use 
immunohistochemistry to identify expression patterns in all cells of the peripheral 
nerve, unlike work by Yi et al., and Zhang et al., which focussed on primary sensory 
axons [Yi et al., 2006; Zhang et al., 2010]. 
To confirm these findings, we stained transverse sections of sciatic nerve from PLP-
EGFP [Figure 3.4 A-H], and C57BL/6 mice [Figure 3.4] with Robo2 antibodies. 
Robo2 staining did not colocalise with the GFP signal in sciatic nerve samples from 
the PLP-EGFP mice. This determined that Robo2 is not expressed in the majority of 
SCs of the sciatic nerve [Figure 3.4].  
In contrast, a Robo2 staining co-localised with neurofilament staining in 98% of 
cases, indicating that Robo2 expression is confined to the axons of the sciatic nerve 
[Figure 3.4]. However, the expression of Robo2 in axons of the sciatic nerve varied 
quite considerably, with some axons appearing to express Robo2 particularly 
strongly while others to a lesser extent. As axons with different calibres vary in 
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  Figure 3.4: Robo2 is expressed in axons of the sciatic nerve. Transverse 
sections of sciatic nerve from two-month-old PLP-EGFP mice (A-L) were stained 
with Robo2 antibody (C, G, J) and counterstained with Hoechst (A, E, I). SCs 
were GFP-positive (B, F) [Mallon et al., 2002]. A-D. Low magnification images 
suggested that Robo2 did not colocalise with the GFP signal indicating that 
Robo2 is not expressed in SCs. E-H. High magnification images further confirmed 
that Robo2 was not present in the SCs and appeared confined to the axons. I-L. 
Transverse sections of sciatic nerve from two-month-old C57BL/6 mice (I-L) 
stained with neurofilament (K) and Robo2 antibodies (J) and counter stained with 
Hoechst (I). This staining confirmed that Robo2 staining colocalises with 
neurofilament staining (L, white arrows) indicating that Robo2 is expressed in the 
axons. M. Quantification of the number of positive Robo2 axons (98%) and SCs  






3.2.3 Slit2 expression in the adult sciatic nerve 
The Slit ligands have been extensively studied in the development of the CNS for 
their important role in controlling axon pathfinding through chemorepulsion [Brose et 
al., 1999; Kidd et al., 1989; Kidd et al., 1999; Nguyen Ba-Charvet et al., 1999; Wang 
et al., 1999]. In comparison, their expression pattern and role in the adult PNS has 
been studied very little.  
Slit2 mRNA expression has been confirmed in motor neurons of the facial nerve of 
rats [Fujiwara et al., 2008], as well as in the sciatic nerves from rats [Tanno et al., 
2005]. Slit2 mRNA expression was also observed, using RT-PCR, in cultured SCs 
[Wang et al., 2013]. The same study also detected Slit2 protein expression in SCs 
both in vitro and in vivo in mice [Wang et al., 2013].  
Unlike Fujiwara et al., work we have focussed on all axons not primarily motor or 
sensory neurons and our work is based in mice unlike work from Tanno et al., 
[Fujiwara et al., 2008; Tanno et al., 2005]. Although our study is like Wang et al., as 
we will look at the protein expression of Slit2 in vivo using IHC, we furthered these 
findings by directly comparing expression in axons in comparison SCs.  
To investigate the expression of Slit2 in the sciatic nerve, transverse sections of 
sciatic nerve from C57BL/6 mice were stained with Slit2 antibody and neurofilament 
[Figure 3.5]. Staining revealed strong expression of Slit2 that colocalised with 
neurofilament, indicating that Slit2 is expressed in the axons of the sciatic nerve 
[Figure 3.5 A-H]. We quantified the number of axons that expressed Slit2 and 
determined that 75% of axons expressed Slit2 in the sciatic nerve [Figure 3.5].  
Slit2 IHC staining was performed on sciatic nerve sections from the PLP-EGFP mice. 
This staining showed weak Slit2 staining colocalising with the GFP signal [Figure 3.5 





where it is strongly expressed. We quantified that Slit2 was present in 78% of SCs 


























































F GFP E Ho 
M Percentage of Slit2 positive








































Figure 3.5: Slit2 is expressed in axons and Schwann cells of the sciatic 
nerve. Sciatic nerves, from two-month-old C57BL/6 mice, were stained with Slit2 
(B, F) and neurofilament antibodies (C, G) and counterstained with Hoechst (A, 
E). A-D. Low magnification images reveal Slit2 staining (B) within in the sciatic 
nerve, which is highly colocalised (D) with neurofilament (C). E-H. Higher 
magnification images again reveal strong Slit2 staining (F) in areas that colocalise 
(H, white arrows) with neurofilament (G). This suggests that Slit2 is strongly 
expressed in the axons of the sciatic nerve. Some Slit2 staining (F) is expressed 
in other cells of the sciatic nerve, although this staining is not as strong as in the 
axons. I-L. Transverse sciatic nerve sections from two-month-old PLP-EGFP 
mice were stained with Slit2 (G) and counterstained with Hoechst (I). The GFP 
signal was present in PLP-positive SCs (J) (Mallon et al., 2002). Staining revealed 
colocalisation between weak Slit2 staining and the GFP signal (L, white arrows) 
indicating that Slit2 is expressed weakly in SCs. M. Quantification of the number 
of Slit2 positive axons (75%) and SCs (78%) in the uncut nerve samples. (A-D 





3.2.4 Slit3 expression in the adult sciatic nerve 
Slit3 is another member of the Slit ligand family that binds to Robo receptors [Itoh et 
al., 1998]. Slit3 mRNA expression in the peripheral nervous system has been 
documented once using RT-PCR on cultured SCs, but its expression at the protein 
level was never measured [Wang et al., 2013].  
Our work will differ from previous work as we used in vivo mouse sciatic nerve 
samples as opposed to Wang et al., who concentrated on SC cultures. We focus on 
protein levels of Slit3 using immunohistochemistry to identify which cells express 
Slit3 in the mouse sciatic nerve in comparison to Wang et al., who identified the 
expression of Slit3 mRNA using RT-PCR [Wang et al., 2013]. Furthermore, we 
looked at both axons, cells in the epineurium and SCs to identify the expression 
profile of Slit3 within the adult sciatic nerve. 
Our work aimed at identifying protein expression in vivo, and to identify which cells 
expressed Slit3 within the sciatic nerve. This was achieved through performing IHC, 
using a repertoire of cell-type specific antibodies on sciatic nerve sections from 
C57BL/6 mice and PLP-EGFP mice. 
Our work identified that Slit3 was expressed in axons of the sciatic nerve, as Slit3 
staining colocalised with neurofilament staining [Figure 3.6]. This staining appeared 
relatively low in comparison to surrounding cells, but it did appear that all axons 
expressed Slit3 at similar levels throughout the nerve. We quantified the number of 
Slit3 positive axons and determined that approximately 88% of axons expressed 
Slit3 [Figure 3.6]. 
Using the PLP-EGFP sciatic nerve sections to identify SCs, we could determine that 
Slit3 is expressed in both myelinating and non-myelinating SCs. Staining suggested 





non-myelinating SCs appeared to express Slit3 at higher levels than myelinating SCs 
[Figure 3.7]. We quantified the number of Slit3 positive SCs in the adult sciatic nerve 
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Figure 3.6: Slit3 is expressed in the adult sciatic nerve. Sciatic nerves, taken 
from two-month-old C57BL/6 mice were stained with Slit3 (B, F) and 
neurofilament antibodies (C, G) and counterstained with Hoechst (A, E). A-D. Low 
magnification images reveals cells of different morphologies within the sciatic 
nerve that have a varying degree of Slit3 expression (B, white arrows). E-H. 
Higher magnification images reveal that Slit3 (F) is expressed in neurofilament-
positive cells at low levels (H, white arrows) in comparison to cells that surround 
the axons. This result indicates that Slit3 is expressed at low levels in axons of 
the adult sciatic nerve. I. Quantification of the number of Slit3 positive axons 
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Figure 3.7: Slit3 is expressed in myelinating and non-myelinating Schwann 
cells of the adult sciatic nerve. Sciatic nerves, taken from two-month-old PLP-
EGFP mice, were stained with Slit3 antibody (C, G, K) and counterstained with 
Hoechst (A, E, I). GFP was present in PLP-positive SCs of the sciatic nerve (B, F, 
J) [Mallon et al., 2002]. A-D. Low magnification images of the whole sciatic nerve 
reveal that highly positive Slit3 staining (C) colocalises (D, white arrows) with 
highly positive GFP cells of the sciatic nerve (B). E-H. High magnification images 
revealed that cells that did not express GFP (F) as brightly were myelinating SCs. 
These cells also expressed Slit3 (G, white arrows), indicating that Slit3 is 
expressed in the myelinating SCs of the adult sciatic nerve (H). I-L. High 
magnification images of the bright GFP-positive SCs (J) revealed they had the 
morphology of non-myelinating SCs. These cells were also highly positive for Slit3 
(K, L white arrows), suggesting that Slit3 is highly expressed in non-myelinating 






3.2.5 Expression of Slit3 and Robo1 in the epineurium  
The epineurium is the outermost layer of connective tissue surrounding the nerve; it 
binds together the nerve fascicles. Fibroblasts are present in the epineurium and are 
arranged along the fascicular axis [Stolinski., 1995]. Previous research has detected 
Robo1 mRNA and protein and Slit3 mRNA in the peripheral nerve but did not 
examine the presence of either in the fibroblasts that form the epineurium [Tanno et 
al., 2005; Wang et al., 2013]. Research into synovial fibroblasts has shown the 
presence of Robo1-3 and Slit1-3 mRNA in vitro [Denk et al., 2010]. However, the 
expression of the Slit/Robo in the fibroblasts of the epineurium remains 
undocumented. We therefore aimed at identifying the expression profile of Slit3 and 
Robo1 in the epineurium of sciatic nerves from mice. 
Using consecutive sections of a sciatic nerve from a two-month-old C57BL/6 mouse, 
we stained for fibronectin, Slit3 or Robo1 in conjunction with NF. Our results reveal 
fibronectin staining encircling the sciatic nerve revealing the structure of the 
epineurium [Figure 3.8]. Consecutive sections stained with Robo1 and Slit3 reveal a 
very similar staining pattern, suggesting that both are expressed in the epineurium 
[Figure 3.8]. 
Interestingly the same experiment was performed on 21-day old nerves, and Robo1 
and Slit3 were not present whereas fibronectin staining was present [Figure 3.9]. 
This suggests that at this time point Robo1 and Slit3 are not expressed in the 
epineurium and that their expression occurs at a later time point, to be present in 






Figure 3.8: Robo1 and Slit3 are expressed in the epineurium in adult sciatic 
nerves.  Sciatic nerves were taken from two-month-old C57BL/6 mice, and 
stained with neurofilament antibody (A, B, C) and all counter stained with 
Hoechst. Sections were also stained for fibronectin (A), Robo1 (B) and Slit3 (C). 
A. Fibronectin staining reveals strong expression in the epineurium as expected. 
B, C. Consecutive sections stained with Robo1 (B) and Slit3 (C) also show 
staining in the regions positive for fibronectin, however, the ring around the nerve 
appeared thinner than that seen in the fibronectin staining. This suggests that 
Robo1 and Slit3 are both expressed in a subset of cells in the epineurium of the 
adult sciatic nerve.  (A-C scale bar = 100µm) (n=3) 
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Figure 3.9: Robo1 and Slit3 are not expressed in the epineurium in 21 day 
old sciatic nerves. Sciatic nerves were taken from 21-day-old C57BL/6 mice, 
and stained with neurofilament antibody (A, B, C) and all counter stained with 
Hoechst. They were also stained with fibronectin (FN)(A), Robo1 (B) and Slit3 
(C). We have previously shown that Robo1 and Slit3 are both expressed in sciatic 
nerves from two-month-old C57BL/6 [Figure 3.9]. However, staining of 21 day old 
sciatic nerves reveals a lack of both Robo1 (B) and Slit3 (C) staining where 
fibronectin (A) is present (B, C white arrows). This indicates that Robo1 and Slit3 
are not expressed in the epineurium at 21 days and expression occurs after 21 
days. (A-C scale bar = 100µm) (n=3) 
A Ho FN NF B Ho Robo1 NF 





3.2.6 No primary negative controls on sciatic nerve sections 
Uninjured sciatic nerves were taken from 2-month-old C57BL/6 mutants and stained 
either with the primary antibody of interest in conjunction with secondary antibodies 
for the positive controls or no primary in conjunction with secondary antibodies for 
the negative control both following the same protocol detailed in Chapter 2 [Figure 
3.10].  
Positive controls for all Slit/Robos show strong staining within the sciatic nerve in 
comparison to the controls where minimal background staining can be observed 
[Figure 3.10]. This determines that secondary background binding is minimal, and 










































Figure 3.10: Validation of Slit 1-3, Robo1 and Robo2 antibodies. Staining with 
Slit1-3 and Robo1-2 antibodies is shown in green; staining with neurofilament heavy 
chain antibody is shown in in red. (A-B) Slit1 staining on transverse sections of sciatic 
nerve from Slit1 control (+/+, A) and Slit1 null (-/-, B) mice. (C-D) Slit3 staining on 
sciatic nerve samples from Slit3+/+ (C) and Slit3-/- (D) mice. (E-J) Slit2, Robo1 and 
Robo2 staining on sciatic nerve samples from C57BL/6 mice. Slit2, Robo1 and Robo2 
primary antibodies were used in E, G and I but were omitted in F, H and J. Staining 






Previous work had shown that Slit/Robo’s were expressed in the sciatic nerve [Table 
3.1]. However, it was not well documented what type of cells expressed the different 
Slit/Robo family members. Our study has revealed that Slit/Robo’s have a complex 
expression profile in the adult sciatic nerve.  
We have shown that Robo1 is expressed in both axons and myelinating SCs at a 
similar intensity [Figure 3.1 and 3.2]. Our evidence shows that Robo1 is expressed in 
83% of axons which was a novel and unexpected finding [Figure 3.1]. With previous 
work identifying the expression of Robo1 in SCs this was an expected finding, we 
furthered this knowledge by identifying that Robo1 expressed appeared in around 
85% of SCs in the uncut sciatic nerve [Figure 3.2] [Wang et al., 2013]. As we had 
previously determined Robo1 was not expressed in non-myelinating SCs [Figure 
3.2], the 15% of SCs that were not Robo1 positive could be non-myelinating. This 
may suggest that Robo1 may be important in signalling between axons and 
myelinating SCs but not in Remak bundles.   
We also determined that Robo1 was expressed in endothelial cells of the uncut 
sciatic nerve [Figure 3.3]. This has previously not been shown in the peripheral nerve 
so is a novel finding. However, the expression of Robo1 has been noted in 
endothelial cells previously [Wu et al., 20017; Zhao et al., 2014]. As Robo1 is 
expressed in endothelial cells of the uncut nerve it could suggest that it is involved in 
blood vessel stability rather than angiogenesis, previous work has determined a role 
of Robo1 in endothelial stability but not within peripheral nerves [Wu et al., 2017]. 
Our Robo2 staining identified the expression of Robo2 in a large percentage of 
axons (98%) of the peripheral nerve in comparison to no significant expression in 





documented the strong expression of Robo2 in SCs in vivo in mouse sciatic nerve 
[Wang et al. 2013]. Robo2 co-localised with GFP in a small number of SCs this could 
have been due to unspecific staining from the Robo2 primary antibody as it is highly 
unlikely Robo2 is expressed in such a small population of SCs.  
Furthermore, we also confirmed that Slit2 is expressed at high levels in axons of the 
sciatic nerve in comparison to myelinating SCs, where it is expressed at low levels 
[Figure 3.5]. This result was expected as previous papers had determined that Slit2 
was expressed in both SCs and axons. However, we have added novel knowledge 
by comparing the expression levels in these cells [Fujiwara et al., 2008; Tanno et al., 
2005].  We also identified that even though Slit2 was expressed in higher levels in 
axons, it was expressed in slightly fewer axons (75%) in comparison to the SCs 
(78%) [Figure 3.5].  
Additionally, we have confirmed that Slit3 is expressed at low levels in 88% of axons 
in comparison to myelinating SCs where it was expressed strongly [Figure 3.6]. 
However, expression of Slit3 in non-myelinating SCs was the highest observed 
expression level within the sciatic nerve [Figure 3.7]. This expression of Slit3 in SCs 
was expected as previous work had detected Slit3 mRNA in cultured SCs [Wang et 
al., 2013]. We have furthered this knowledge by identifying the expression of Slit3 
protein in vivo SCs in the mouse adult sciatic nerve. An unexpected result was the 
high expression of Slit3 observed in non-myelinating SCs and the expression of Slit3 
in axons as this has been previously not been explored. Furthermore, we identified 
that Slit3 is expressed in a high percentage of SCs (97%), as it also appears to be 
expressed strongly in these cells it may suggest an important role in the peripheral 





Moreover, we have shown that Robo1 and Slit3 are both expressed in the 
epineurium of the adult sciatic nerve, but Robo1 and Slit3 are not expressed in the 
epineurium of a P21 nerve [Figure 3.8 and 3.9]. This could suggest that Robo1 and 
Slit3 are expressed in fibroblasts that reside in the epineurium, and this expression 
occurs in response to a developmental stage of the peripheral nerve.  
Overall it may seem unusual to confirm the expression of both the ligand in the same 
cells. However, previous papers have identified expression of both Slits and Robo’s 
within the same cell as we have done here [Davidson et al., 2010; Small et al., 2010; 
Wang et al., 2013].  Furthermore, some studies have shown that the expression of 
Slit2 and Slit3 in Robo1 expressing cells may contribute to controlling the levels of 
Robo1 expressed by that cell. Therefore, this could be true for both axons and SCs 
[Davidson et al., 2010; Small et al., 2010]. As axons and SCs express both the 
ligand and the receptor it is plausible they are signalling to one another or even 
themselves in an autocrine manner. 
As the immunohistochemistry controls show low background [Figure 3.10], we can 
be sure that staining observed isn’t due to unspecific binding from the secondary 
antibodies. Primary antibodies target specific proteins and should in theory not 
produce any unspecific binding. However, some primary antibodies can bind to 
unspecific proteins.  
Further experiments I could do to confirm further my results would be to use 
antibodies from various companies all targeting the same proteins of interest to verify 
the results further. Western blotting could also be used to verify the expected levels 









 Previous knowledge Our data within the sciatic nerve 
Slit1 mRNA present in uncut sciatic nerve 
[Tanno et al., 2005]. 
Undetectable 
Slit2 mRNA present in uncut nerve [Tanno et 
al., 2005]. 
mRNA and protein expressed in SCs in 
vitro and in vivo [Wang et al. 2013]. 
Slit2 mRNA expression confirmed in 
motor neurons of the facial nerve of rats 
[Fujiwara et al., 2008] 
 
Protein expression observed: 
Axons ++  
Myelinating SCs +++ 
Non-myelinating SCs +++ 
Fibroblasts ++ 
Slit3 mRNA expressed in cultured SCs [Wang 
et al. 2013]. 
Protein expression observed: 
Axons ++ 
Myelinating SCs +++ 
Non-myelinating SCs+++ 
Fibroblasts ++ 
Robo1 mRNA expressed in nerve [Tanno et al., 
2005]. 
Robo1 protein expressed in SCs [Wang 
et al. 2013].  
 
Protein expression observed: 
Axons ++ 
Myelinating SCs ++ 
Non-myelinating SCs ++ 
Fibroblasts ++ 
Endothelial cells ++ 
Robo2 mRNA expressed in nerve [Tanno et al., 
2005]. 
Robo2 protein expressed in SCs [Wang 
et al. 2013]. 
 
Robo2 protein expression has also been 
detected in adult rat primary sensory 
axons [Yi et al., 2006; Zhang et al., 2010]. 
 
Protein expression observed: 
Axons ++ 
Key: 
+ low expression; 
++ medium expression; 
+++ high expression. 
Table 3.1: Summary of Slit/Robo expression in cells of the sciatic nerve and 










Chapter 4 Morphology of sciatic nerves in Slit/Robo mutant mice 
4.1 Introduction 
In Chapter 3 we identified that Slit2, Slit3 and Robo1 were all expressed in both 
axons and SCs. This could suggest that there may be signalling between these two 
types of cells potentially controlling the morphology of these cells. Therefore, we 
wanted to determine if disrupting the expression of the Slit/Robo genes would result 
in any defects in the morphology of the sciatic nerve. This work is important because 
it may indicate a potential role for Slit/Robo expression in the adult mouse sciatic 
nerve. 
No previous work has been documented on the morphology of the sciatic nerve in 
Slit/Robo mutants in comparison to their controls, and therefore this work is novel.  
To investigate this, sciatic nerves from Robo1Het (Robo1 heterozygous), Slit2Het (Slit2 
heterozygous), and Slit3KO (Slit3 homozygous) mutant mice and with their control 
counterparts, were prepared for low vacuum SEM. SEM images of the nerves allow 
for G-Ratios and axon diameters to be measured, and these measurements can be 
compared to the control animals to determine if the mutant mice have any 














4.2.1 Robo1 mutant mice have normal sciatic nerve structure 
Robo mutant mice were generated by Andrews et al., (2006) using Cre/loxp targeting 
to excise exon 5 of Robo1. They documented that the loss of Robo1 led to aberrant 
axon pathfinding in the corpus callosum and hippocampal commissure during 
development. However, in these mutants, the midline glia appeared to have 
developed normally [Andrews et al., 2006]. This disruption to axon pathfinding 
fascicles in the developing CNS may infer similar problems in the development of the 
PNS; our goal was to identify and map any structural changes in the sciatic nerve.  
Robo1 heterozygous mutants (Robo1Het) were used during this study as Robo1 
homozygous mutants die shortly after birth due to breathing difficulties [Andrews et 
al., 2006]. 
SEM images of Robo1 control (Robo1Cntrl) and Robo1Het sciatic nerves were 
produced and analysed for G-Ratio and axon diameter; no apparent abnormalities 
were evident from the images [Figure 4.1]. Comparison of the average G-ratio 
revealed no significant difference between Robo1Cntrl and Robo1Het mice; this verifies 
that the myelin sheaths in the Robo1Het mice are on average a similar thickness to 
those in the Robo1Cntrl mice [Figure 4.1]. A scatterplot shows the G-Ratios in 
Robo1Cntrl and Robo1Het mice plotted against the associated axon diameter. In both 
Robo1Cntrl and Robo1Het mice, linear regression lines have similar angles of slope 
suggesting that G-Ratio increases at a similar rate relating to axon diameter size 
[Figure 4.2].  
The average axon diameters of Robo1Het and Robo1Cntrl sciatic nerves were not 
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Figure 4.1: Robo1Het sciatic nerves show similar morphology to Robo1Cntrl 
sciatic nerves.  Low vacuum SEM images were taken of the sciatic nerves from 
two-month-old Robo1Cntrl (A, C) and Robo1Het (B, D) mice. A, B. Low 
magnification images show similar sized Robo1Cntrl (A) and Robo1Het (B) nerves. 
C, D. High magnification images of the nerves show more intricate detail, both 
images appear similar suggesting that the Robo1Het (D) and Robo1Cntrl (C) sciatic 
nerves have a similar range in axon density and myelin thickness.  E. G-Ratios 
were measured from SEM images of the sciatic nerve from two-month-old 
Robo1Het and Robo1Cntrl mice. The average G-Ratio was calculated for the 
Robo1Het nerve and Robo1Cntrl nerve, both being around the expected value of 
0.6, and there was no significant difference between the two sets of data. F. SEM 
images of sciatic nerves from Robo1Het and Robo1Cntrl mice were analysed, and 
the average axon diameter was calculated. Results revealed no significant 
difference between the average axon diameter of Robo1Het and Robo1Cntrl mice. 
Error bars are one standard error of the mean (p=<0.05) (n=3 for each genotype) 
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Figure 4.2: G-Ratio distribution in Robo1Het and Robo1Cntrl mice are similar. 
G-Ratio was plotted against axon diameter for both Robo1Het and Robo1Cntrl mice. 
The scatter plot reveals similar distributions of G-Ratios with linear regression 
lines of similar angles suggesting that the G-Ratios increase at a similar rate in 






4.2.2 Slit2Het mice display normal sciatic nerve structure 
Slit2 mutants were generated by Plump et al., (2002). They targeted part of the first 
exon and second exon of Slit2 and replaced it with an IRES-tauGFP-Neo cassette, 
resulting in the disruption of the signal sequence and part of the first LRR repeat of 
the protein. They determined that in the developing optic chiasm of Slit2Het mutants 
most axons extended along their normal path, but a small number did divert from the 
correct path [Plump et al., 2002]. 
Slit2 homozygous deficiency was determined to be lethal shortly after birth [Plump et 
al., 2002], this meant for these experiments we were limited to using Slit2 
heterozygous mutants (Slit2Het) instead.  
SEM images of Slit2 control (Slit2Cntrl) and Slit2Het revealed similar sized sciatic 
nerves and high magnification imaging and analysis revealed similar axon densities, 
G-Ratios and axon diameters suggesting that Slit2Het nerves did not have an altered 
structure compared to Slit2Cntrl nerves [Figure 4.3]. Analysis of the images 
determined that the average G-Ratio of the sciatic nerve from the Slit2Het and Slit2Cntrl 
were not significantly different. This establishes that the myelin sheaths in the Slit2Het 
mice are of a similar thickness to those in the Slit2Cntrl mice [Figure 4.3]. G-Ratio was 
plotted against axon diameter in a scatterplot for both Slit2Het and Slit2Cntrl results. 
Linear regression was plotted and revealed that G-Ratio increased at a similar rate in 
both the Slit2Het and Slit2Cntrl animals [Figure 4.4]. This suggests that G-Ratio is 
unchanged in the Slit2Het animals.  
The average axon diameter from the Slit2Het and Slit2Cntrl mouse were not 
significantly different, suggesting that sciatic nerves in Slit2Het mutants do not have 




































































Figure 4.3: Slit2Het and Slit2Cntrl sciatic nerves have similar characteristics. 
A-D. Low vacuum SEM images of sciatic nerves from two-month-old Slit2Het (B, 
D) and Slit2Cntrl (A, C) mice were taken at low magnification and high 
magnification.  The images are largely indistinguishable from one another with 
similar sized sciatic nerves with similar morphologies. E. SEM images of sciatic 
nerves from Slit2Het and Slit2Cntrl were analysed and the mean G-Ratio was 
calculated. T-test results confirmed there was no significant difference between 
the average G-Ratio of the sciatic nerve from Slit2Het and Slti2Cntrl mice. F. The 
average axon diameter of Slit2Cntrl and Slit2Het mice was calculated from SEM 
images of the sciatic nerve. Results reveal no significant difference between the 
two groups, with both groups having an average axon diameter around 2.3µm. 
Error bars are one standard error of the mean (p=<0.05) (n=3 for each genotype) 







Figure 4.4: Slit2Het and Slit2Cntrl G-Ratios are similarly distributed. Scatter plot 
of G-Ratio against axon diameter from Slit2Het and Slit2Cntrl sciatic nerve 
measurements. Results show a positive correlation between axon diameter and 
G-Ratio for both Slit2Het and Slit2Cntrl animals. Lines of regression have similar 
angle of slopes suggesting that the relationship between G-Ratio and axon 
diameter is the same in both Slit2Cntrl and Slit2Het animals. (n=3 for each 
genotype) (Slit2Cntrl r2=0.4784, Slit2Het r2=0.4659) 
G-Ratio according to axon diameter


























4.2.3 Slit3KO mice display normal sciatic nerve structure 
Slit3 mutant mice were generated by Yuan et al., (2003) by targeting a 1Kb section 
of Slit3 gene and replacing it with a β-Galactosidase gene. The deletion 
encompassed the 3` half of exon one which contains the signal peptide and initiation 
codon.  This group studied the effect upon the branching pattern and neuromuscular 
junction of the phrenic nerve during development, but they observed that the density 
and length of branches and sub-branches were unchanged as was the 
neuromuscular junction [Yuan et al., 2003]. Slit3 homozygous mutants (Slit3KO) are 
viable. Therefore, they could be used during this study in combination with Slit3 
control mice (Slit3Cntrl). 
Sciatic nerves from Slit3KO and Slit3Cntrl animals were imaged using low vacuum 
SEM. G-Ratios and axon diameters were calculated from these images. The nerves 
appeared similar in appearance from the Slit3KO and Slit3Cntrl animal [Figure 4.5]. 
Analysis of the G-Ratio using a t-test revealed that the average G-Ratio in the Slit3KO 
and Slit3Cntrl mice were not significantly different (p=<0.05). This indicates that the 
myelin thickness is unchanged in Slit3KO mutants. G-Ratios were plotted against 
axon diameter in a scatterplot, and the linear regression line was calculated for both 
Slit3KO and Slit3Cntrl. Both linear regression lines have similar angles of slope. 
Determining that in Slit3KO and Slit3Cntrl mice G-Ratio increases at a similar rate as 
axon diameter increases, and further confirms that G-Ratio is unchanged in the 
Slit3KO mutant mice [Figure 4.6]. 
The average axon diameter was calculated and results from Slit3KO and Slit3Cntrl 
animals were compared using a t-test. Results showed that the average axon 
diameter was not significantly different between Slit3KO and Slit3Cntrl animals 
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Figure 4.5: Slit3Cntrl and Slit3KO sciatic nerves display similar morphologies. 
Low vacuum SEM images were taken of sciatic nerves from two-month-old 
Slit3Cntrl (A,C) and Slit3KO (B,D) mice. A, B. Low magnification images display 
similar sized nerves with apparent similar disruptions of axons with similar myelin 
thickness. C, D. High mag images also appear very similar in terms of range of 
axon diameters, axon density and myelin thickness E. SEM images of the sciatic 
nerves from Slit3Cntrl and Slit3KO mice were analysed to calculate G-Ratios. 
Analysis revealed the average G-Ratio in the sciatic nerves from Slit3Cntrl and 
Slit3KO mice were not significantly different and both around the expected value of 
0.6. F. SEM images from Slit3KO and Slit3Cntrl were analysed to determine average 
axon diameter. The average axon diameter of the sciatic nerve was not 
significantly different between Slit3KO and Slit3Cntrl mice. Error bars are one 
standard error of the mean (p=<0.05) (n=3) (A, B scale bar=100µm, C, D scale 


















Figure 4.6: Slit3KO and Slit3Cntrl G-Ratio are similarly distributed. Scatterplot 
of G-Ratios against axon diameter using data attained from Slit3KO and Slit3Cntrl 
sciatic nerves. Both Slit3KO and Slit3Cntrl animals show a positive association 
between axon diameter and G-Ratio. Linear regression lines have similar angles 
and overlap suggesting that in both animals G-Ratio increases at a similar rate 
when axon diameter is the constant. (n=3 for each genotype) (Slit3Cntrl r²=0.3253, 
Slit3KO r2=0.3220) 
G-Ratio according to axon diameter


























4.2.4 Gene dosage effects in Robo1 and Slit mutants 
Sciatic nerves from Robo1Cntrl and Robo1Het mutants and Slit3Cntrl, Slit3Het and Slit3KO 
mutants were removed from healthy uninjured 2-month-old mice and prepared for 
western blotting. The Robo1Cntrl and Robo1Het western blot membrane was probed 
for Robo1 protein [Figure 4.7]. Results show that protein loading was even with the 
same amount of tubulin represented in each sample. The amount of Robo1 protein 
can be seen to be reduced in the Robo1Het mutant, determining there is a gene 
dosage affect in the Robo1Het mutant. 
In the Slit3 experiment the membrane was probed for Slit3 protein [Figure 4.7]. In the 
Slit3Cntrl samples Slit3 protein is present, in comparison in the Slit3Het protein levels 
are decreased and in the Slit3KO samples Slit3 protein is absent. This confirms that 
there is a gene dosage affect in the Slit3 mutants in comparison to the control. Both 


















































Figure 4.7 Gene dosage in Slit3 and Robo1 mutants. A. Western blotting results 
on sciatic nerves from Robo1Cntrl and Robo1Het mice. Downregulation of the Robo1 
protein can be observed in the Robo1Het mutant. B. Western blotting results on 
sciatic nerves from Slit3Cntrl, Slit3Het and Slit3KO mutants shows the step-wise 
downregulation of the protein in the Slit3Het and Slit3KO mutants. Credit for this work 







We have shown in previous work that Slit2, Slit3 and Robo1 are all expressed in SCs 
and axons of the adult mouse sciatic nerve (Chapter 3). As strong expression of 
Robo1, Slit2 and Slit3 can be seen in the sciatic nerve; we might expect there to be 
disruptions in the structure of the sciatic nerve in Slit2Het, Slit3KO and Robo1Het 
mutant mice.  
Low vacuum SEM and analysis of sciatic nerves from Slit2Het, Slit3KO and Robo1Het 
mutant mice revealed no major changes to either axon diameters or G-Ratio in 
comparison to their control counterparts. This novel data indicates that axons of the 
sciatic nerve develop normally, as do their associated SCs information which was 
not available before. 
This was unexpected data as there is such strong expression of Slit2, Slit3 and 
Robo1 in the adult peripheral nerve it is unusual that disrupting this pathway had no 
effects on peripheral nerve morphology. This may be due to the nature of the 
mutants, as only Robo1Het mutants can be achieved and Slit2 and Slit3 may 
compensate for one another in single Slit2Het and Slit3KO animals.  
Using SEM images from sciatic nerves to measure G-Ratio is a well-documented 
and reliable and reproducible way to measure myelin thickness and axon diameter in 
the peripheral nervous system [Bond and Parkinson., 2018; Chomiak and Hu., 
2009]. Another method we could have used to analyse myelin thickness is by using 
staining for myelin basic protein on sciatic nerve sections to look at myelin 
morphology and thickness. We could have also used IHC using neurofilament 
primary antibody to look axon diameter. However, IHC results would have been 





Further experiments could have included producing variable double mutants 
including Slit2Het Slit3KO or Slit3KORobo1Het or potentially a Robo1HetSlit2HetSlit3KO 
triple mutant to fully elucidate if the Slit/Robo signalling pathway was involved in 


























Chapter 5 Expression of Slit/Robo in the dorsal root ganglia 
5.1 Introduction 
The dorsal root ganglia (DRG) are aggregations of neuronal somata that are 
enveloped by satellite glial cells [Standring, 2016]. DRG neurons are 
pseudounipolar; they extend a shorter branch to the spinal cord and a longer branch 
to the periphery; these neurons are responsible for conveying peripheral sensory 
information into the CNS [Lieberman, 1976]. L4-L5 DRG peripheral branches extend 
to form part of the sciatic nerve [Standring, 2016]. The cell bodies are ensheathed by 
satellite glial cells; these cells are thought to partially control the microenvironment 
and signal transmission of the sensory neuron [Hanani, 2005].  
As we have previously identified the expression of Slit2, Slit3, Robo1 and Robo2 in 
axons of the sciatic nerve [Chapter 3] we wanted to determine the expression of 
these proteins in their corresponding cell bodies.  It is important to clarify the 
expression within the cell bodies as they control protein expression within the axons 
of the sciatic nerve. It is therefore important to confirm proteins expressed in axons 
reflect the expression seen in cell bodies. Otherwise, there is a potential that SCs 
could be trafficking mRNA to axons, enabling local protein synthesis within the axons 
[Court et al., 2008].  
Previous studies have documented the expression of Slit/Robo in cell bodies of the 
rat adult DRG, yet these results varied between studies and in some cases only the 
mRNA expression was studied [Bloechlinger et al., 2004; Yi et al., 2006; Zhang et 
al., 2012; Zheng et al., 2012]. Therefore, we wanted to document the expression of 





protein level. No data for the expression of Robo1, Robo2, Slit1-3 is currently 










































5.2.1 Robo1 expression in the L4-L5 adult dorsal root ganglia 
Robo1 has been previously documented to be expressed in the adult DRG in rats. 
Zheng et al., (2012) showed that Robo1 mRNA was detectable in DRG from rats by 
RT-PCR. They also confirmed the presence of Robo1 protein in DRG from rats, 
using immunostaining and IHC. The staining appeared to be similar in large, medium 
and small calibre cell bodies of the DRG [Zheng et al., 2012].  
We also confirmed that Robo1 mRNA was present in cell bodies of the L4-L5 DRG 
from C57BL/6 mice by RT-PCR [Figure 5.1] and in situ hybridisation [Figure 5.2]. Our 
in situ hybridisation results showed varying levels of Robo1 mRNA, with some DRG 
cell bodies appearing to have stronger staining than others do, this pattern did not 
appear to be specified by the size of the soma.  
We also identified the expression of Robo1 in DRG using IHC on L4-L5 DRG from 
C57BL/6 mice. Our IHC results revealed that Robo1 colocalised with NeuN, this 
confirmed that Robo1 is expressed in the cell bodies of the DRG. Similar patterns of 
staining seen in the in situ hybridisation results were observed in the IHC results, 
with a variety of staining intensities among the DRG cell bodies, again this pattern 
did not appear to be specified by size [Figure 5.3].  Our results confirm the presence 
of Robo1 in the cell bodies of sensory axons of the sciatic nerve.  
5.2.2 Robo2 expression in the L4-L5 adult dorsal root ganglia 
Robo2 mRNA expression has been previously documented in L5-L6 DRG from rats 
using RT-PCR [Yi et al., 2006; Zhang et al., 2012]. Bloechlinger et al., (2004) also 
identified Robo2 mRNA using in situ hybridisation. Their results displayed very 





Robo2 has been shown to be expressed in cultured rat DRG [Zhang et al., 2010], as 
well as in L6 DRG tissue from rats [Yi et al., 2004; Zheng et al., 2012]. 
We have also shown, through RT-PCR, that Robo2 mRNA is expressed in L4-L5 
DRG in adult C57BL/6 mice [Figure 5.1]. In situ hybridisation further confirmed that 
Robo2 mRNA is strongly expressed in the cell bodies of L4-L5 DRG from C57BL/6 
mice. Staining appeared strong in all cell bodies, suggesting that high levels of 
Robo2 mRNA are present [Figure 5.2]. We identified the expression of Robo2 
through IHC [Figure 5.4]. Sections of L4-L5 DRG were taken from C57BL/6 animals 
and stained with Robo2 and NeuN. Images taken reveal colocalisation between 
Robo2 and NeuN, indicating that Robo2 is expressed in the sensory cell bodies of 











Figure 5.2: In situ hybridisation of adult L4-L5 dorsal root ganglia reveals 
the presence Robo/Slit mRNA. In situ hybridisation was carried out on adult L4-
L5 DRG from two-month-old C57BL/6 mice for detection of Robo1 and 2 and 
Slit1-3 mRNA. The expression profile suggested that all Robo/Slits mRNA’s that 
were tested for could be detected within the cell bodies of the L4-L5 DRG. (n=3) 
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Figure 5.1: Slit/Robo mRNA is expressed in the 
adult L4-L5 dorsal root ganglia. RT-PCR 
performed on cDNA prepared from L4-L5 DRG from 
two-month-old C57BL/6 mice reveals that Robo1, 2 









Figure 5.3: Robo1 is expressed in the cell bodies of the L4-L5 dorsal root 
ganglia. L4-L5 DRG were taken from two-month-old C57BL/6 mice and stained 
for Robo1 (B, F) and NeuN antibodies (C, D) and counterstained with Hoechst (A, 
E). A-D. Low magnification images revealed colocalisation (D, white arrows) of 
NeuN (C) and Robo1 (B), indicating that Robo1 is variably expressed in the 
sensory cell bodies of neurons projecting axons into the sciatic nerve. E-H. Higher 
magnification images of the DRG cell bodies reveal similar results, further 
confirming that Robo1 (F, white arrows) is expressed in the cell bodies of the 
DRG marked with NeuN (G). (Scale bars A-D=100µm, E-H=10µm) (n=3) 
B Robo1 
D Ho Robo1 NeuN 
E  


















D Ho Robo2 NeuN 
Figure 5.4: Robo2 is expressed at high levels in the cell bodies of adult L4-
L5 dorsal root ganglia. L4-L5 DRG were dissected from two-month-old C57BL/6 
mice and stained with Robo2 (B, F) and NeuN antibodies (C, G) and 
counterstained with Hoechst (A, E). A-D. Staining revealed colocalisation (D, 
white arrows) of Robo2 (B) and NeuN (C) staining at low magnification. This 
indicates that Robo2 is present in sensory cell bodies of neurons projecting into 
the sciatic nerve.  E-H. Higher magnification images again revealed colocalisation 






5.2.3 Slit1 expression in the L4-L5 adult dorsal root ganglia. 
Slit1 mRNA has previously been documented as being present in L6 rat DRG [Yi et 
al., 2006; Zhang et al., 2010]. In situ hybridisation has also been used to confirmed 
that Slit1 mRNA was present in the rat DRG, the staining appeared very strong and 
localised to the cell bodies of the DRG [Bloechlinger et al., 2004]. Slit1 was also 
expressed in cultured rat DRG neurons [Zhang et al., 2010], and in rat tissue Slit1 
was expressed in L5-L6 cell bodies of sensory neurons [Yi et al., 2006].   
Through RT-PCR we also confirmed that Slit1 mRNA was present in mouse L4-L5 
DRG [Figure 5.1]. Our in situ hybridisation revealed that Slit1 mRNA was expressed 
in sensory cell bodies with a variety of staining intensities, suggesting varying levels 
of Slit1 mRNA [Figure 5.2].  We identified that Slit1 was strongly expressed in the L4-
L5 DRG by using IHC on tissue sections from C57BL/6 mice [Figure 5.5]. Slit1 
staining colocalised with NeuN staining, confirming that Slit1 is expressed in the cell 
bodies of sensory axons of the sciatic nerve [Figure 5.5].  
5.2.4 Slit2 expression in the L4-L5 adult dorsal root ganglia. 
Slit2 has not been previously described as being expressed in the adult rodent DRG. 
However, our work did identify the expression of both Slit2 mRNA and Slit2 protein in 
L4-L5 mouse DRG. RT-PCR confirmed that Slit2 mRNA is present in the DRG 
[Figure 5.1]. Furthermore, we identified that Slit2 was expressed in the cell bodies of 
the DRG through in situ hybridisation. Staining appeared relatively even among the 
majority of cells, apart from a few cell bodies which appeared to express Slit2 at high 
levels [Figure 5.2]. We identified that Slit2 colocalised with NeuN staining, in L4-L5 
DRG from C57BL/6 animals, confirming that Slit2 is expressed in the cell bodies of 





5.2.5 Slit3 expression in the L4-L5 adult dorsal root ganglia. 
Bloechlinger et al., (2004) determined the presence of Slit3 mRNA in L6 rat DRG at 
low levels. Slit3 mRNA appeared to be present in some, but not all the cell bodies of 
the DRG [Bloechliger et al., 2004]. However, due to the disparity in our model to 
theirs, we wanted to determine the presence of the Slit3 in mouse L4-L5 DRG. Using 
L4-L5 DRG samples from C57BL/6 mice, we confirmed the presence of Slit3 mRNA 
through RT-PCR [Figure 5.1], and in situ hybridisation [Figure 5.2]. The in situ 
hybridisation study showed that Slit3 mRNA appeared in most cell bodies of the 
DRG [Figure 5.2]. We also confirmed the expression of Slit3 protein in DRG through 
IHC on L4-L5 DRG from C57BL/6 mice. Our staining results revealed colocalisation 
between NeuN and Slit3, confirming that Slit3 is expressed in the cell bodies of 
sensory axons of the sciatic nerve [Figure 5.7]. 
5.2.6 Control experiments 
DRG cDNA samples from 2-month-old C57BL/6 mice were used as controls for RT-
PCR experiments. Robo, Robo2, Slit1, Slit2 and Slit3 primers were used during this 
experiment [Figure 5.8]. The PCR was ran with a ladder with corresponding water 
controls. Water controls show no unspecific bands suggesting primer specificity 
[Figure 5.8]. In the positive control experiments Slit/Robo bands are observed at the 
correct molecular mass. 
Uninjured DRG samples from 2-month-old C57BL/6 mice were used for positive 
controls using the Robo1 antibody and no primary negative controls [Figure 5.9]. 
Results show strong Robo1 staining of the cell bodies as expected. In comparison 
minimal background staining in negative controls is observed suggesting primary 









Figure 5.5: Slit1 is expressed in the sensory cell bodies of the L4-L5 dorsal 
root ganglia. L4-L5 DRG from two-month-old C57BL/6 mice were stained with 
Slit1 (B, F) and NeuN antibodies (C, G) and counterstained with Hoechst (A, E). 
A-D. Low magnification images show that Slit1 (B) is expressed in the sensory 
cell bodies of the DRG and this staining colocalises (D, white arrows) with NeuN 
staining (C). E-H. High magnification images further confirm that Slit1 (F) does 
colocalise (H, white arrows) with NeuN (G). These results show that Slit1 is 
expressed in the sensory cell bodies of neurons projecting into the sciatic nerve. 
(Scale bars A-D=100µm, E-H=10µm) (n=3) 
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G NeuN H Ho Slit1 NeuN 
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Figure 5.6: Slit2 is expressed in the cell bodies of the L4-L5 dorsal root 
ganglia. L4-L5 DR were dissected from two-month-old C57BL/6 mice and stained 
for Slit2 (B, F) and NeuN antibodies (C, G) and counterstained with Hoechst (A, 
E). A-D. Low magnification images indicated that Slit2 was expressed in the cell 
bodies of the DRG as Slit2 staining (B) colocalised (D, white arrows) with NeuN 
(C). E-H. High magnification images provides further evidence that Slit2 (F) is 
expressed in NeuN-positive cells (G, white arrows). This indicates that Slit2 is 
expressed in the sensory cell bodies of axons of the sciatic nerve. (Scale bars A-
D=100µm, E-H=10µm) (n=3) 
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Figure 5.7: Slit3 is expressed in the sensory cell bodies of dorsal root 
ganglia neurons projecting into the sciatic nerve. L4-L5 DRG from two-month-
old C57BL/6 mice were stained with Slit3 (B, F) and NeuN antibodies (C, G) and 
counterstained with Hoechst (A, E). A-H. Staining at both low magnification and 
high magnification show Slit3-positive cells (B, C) which colocalise (D, H, white 
arrows) with NeuN (C, G). As NeuN stains sensory cell bodies of the DRG this 
result indicates that Slit3 is present in the sensory cell bodies of axons projecting 
into the sciatic nerve. (Scale bars A-D=100µm, E-H=10µm) (n=3) 
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Figure 5.8 RT-PCR control samples.  Gel A shows RT-PCR carried out on adult 
DRG from mixed-sex 2-month-old C57BL/6 mice primers included Robo1 (R1), 
Robo2 (R2), Slit1 (S1), Slit2 (S2) and Slit3 (S3). Bands are shown at their 








































A Robo1 C Robo1, Ho 
D Rabbit 488 F Rabbit 488, Ho 
H Ho 
K Ho 
G Robo1 I Robo1, Ho 
J Rabbit 568 L Rabbit 568, Ho 
Figure 5.9: No primary controls for secondary antibodies 488 and 568 on 
DRG. L4-L5 DRG from two-month-old C57BL/6 mice were stained with Robo1 (A, 
and G), or no primary with either secondary Rabbit 488 (D) or Rabbit 568 (J) and 
counterstained with Hoechst (B, E, H and K). A-C. Positive control showing 
Robo1 positive DRG with Rabbit 468 secondary. D-F. No primary control for 
Rabbit 468 secondary, shows low level’s of background staining. G-I. Positive 
control showing Robo1 positive DRG cells with Rabbit 568 secondary. J-L. No 







We have documented the expression of Robo1, Robo2, Slit1, Slit2 and Slit3 in the 
mouse L4-L5 DRG at both the mRNA and protein level. Previous work had 
documented the expression of the Slit/Robo family presence in the DRG [Bloechliger 
et al., 2004; Yi et al., 2006; Zhang et al., 2010; Zheng et al., 2012] [Table 5.1]. 
However, this work was in rats and studied the expression profile to different 
degrees.  
Here we agglomerate expression data from all Slits, Robo1 and Robo2 in the L4-L5 
mouse DRG. Our results conclude that Robo1 is expressed in the DRG cell bodies 
at the mRNA and protein level [Figure 5.1, 5.2 and 5.3]. Robo2 is expressed strongly 
in the cell bodies of the DRG at both the protein and mRNA level [Figure 5.1, 5.2 and 
5.4]. We also determined Slit1 mRNA and protein are both expressed in the cell 
body of the DRG [Figure 5.1, 5.2 and 5.5].  Slit2 and Slit3 mRNA and protein were all 
confirmed in the cell bodies of the DRG [Figure 5.1, 5.2, 5.6 and 5.7]. 
As these results had been previously confirmed in rats, apart from Slit2, they were 
not unexpected. Furthermore, we had observed the expression of most of these 
proteins in axons of the sciatic nerve [Chapter 3], suggesting that there would be 
strong expression of proteins in the cell bodies of these neurons, these proteins 
could then be potentially be trafficked down the axon. However, my work did not 
identify the expression of Slit1 in axons of the peripheral nerve. This could suggest 
that Slit1 is not trafficked down the axons and remains within the cell bodies or our 
approach did not identify the Slit1 protein that was present within the sensory axons. 
RT-PCR is a useful tool to determine if mRNA is expressed if used correctly. 
However, it is not a reliable tool to use in a quantifiable manner as the band intensity 





much mRNA is present in comparison to other mRNAs. qPCR in comparison can 
accurately measure how much mRNA is present in each sample; this could have 
been a further experiment we could have performed to produce a quantifiable result.  
As our study did not focus in vitro, we used in situ hybridisation on mouse sciatic 
nerve to determine which cells expressed different mRNAs, in situ hybridisation 
probes should bind specifically giving reliable results. Our control also supports there 
was no unspecific binding from the anti-biotin or digoxigenin (DIG) probes. One 
major disadvantage of in situ hybridisation is the degradation of mRNAs by RNase’s. 
If RNase’s remain active within the sample the staining is not completely 
representative of the mRNA present.  
Immunohistochemistry was used to determine protein expression in DRG cells. 
Controls show little background staining suggesting that there is no unspecific 
staining from the secondaries used [Figure 5.9]. To further confirm these results 
antibodies from various companies could be used to identify if the staining patterns 
was similar. Another approach to identifying protein expression in the DRG cell 
would be to carry out western blotting on DRG samples and then probing the 
membrane with the same antibodies. This would further confirm if the protein was 















 Previous knowledge Our data for L4-L5 DRG 
Slit1 mRNA and protein expression observed in 
rat DRG[Yi et al., 2006; Zhang et al., 2010; 
Bloechlinger et al., 2004]. 
mRNA present 
Protein expression: +++ 
Slit2 N/D mRNA present 
Protein expression: ++ 
Slit3 Weak mRNA expression observed in rat 
DRG [Bloechlinger et al., 2004]. 
mRNA present 
Protein expression: ++ 
Robo1 Robo1 mRNA and protein confirm in rat 
DRG [Zheng et al., 2012]. 
mRNA present 
Protein expression: ++ 
Robo2 mRNA expressed in rat DRG [Yi et al., 2006; 
Zhang et al., 2010; Bloechlinger et al., 
2004]. 
mRNA present 
Protein expression: +++ 
Key: 
+ low expression; 
++ medium expression; 
+++ high expression. 
N/D – No Data 





















Chapter 6: Slit/Robo expression in the L4-L5 region of the spinal cord 
6.1 Introduction 
During development of the CNS Slit/Robo signalling plays a central part in axon 
pathfinding [Brose et al., 1999; Kidd et al., 1989; Kidd et al., 1999; Nguyen Ba-
Charvet et al., 1999; Wang et al., 1999]. However, in the adult CNS, only a few 
studies have been performed to look at the expression pattern of Slit and Robo 
[Jacobi et al., 2014; Li et al., 2017; Liu et al., 2011, Wehrle et al., 2005].  
We have previously identified that Robo1, Robo2, Slit2 and Slit3 were present in 
axons of the sciatic nerve [Chapter 3]. We then identified that Robo1, Robo2 and 
Slit1-3 were present in cell bodies of the DRG that gave rise to sensory axons of the 
sciatic nerve [Chapter 5]. However, the sciatic nerve is a mixed nerve of both 
sensory and motor axons, so we had not characterised the expression in cell bodies 
of motor axons. The cell bodies of motor neurons, that reside in the L4-L5 spinal 
cord region, give rise to axons that contribute to the sciatic nerve [Ebraheim et al., 
2004]. Therefore, we aimed to clarify the expression of Slit/Robo in cells of the L4-L5 
region adult mouse spinal cord. 
To do this, we studied the lumbar region (L4-L5) of the spinal cord. This enabled us 
to first characterise Slit/Robo expression in motor neuron cell bodies of the adult 
spinal cord, and later determine if any changes occur in Slit/Robo expression in 
these cells after sciatic nerve injury. We also looked at other cells within the spinal 
cord, including astrocytes and oligodendrocytes, to determine if Slit/Robo was 





Previous work has looked at the expression of Slit/Robo in rats. However, these 
studies have only looked at the mRNA expression [Jacobi et al., 2014; Liu et al., 
2011; Wehrle et al., 2005]. Our work will look at both mRNA and protein expression 
of Slit/Robos. Furthermore, these studies were focused on the cervical and thoracic 
regions of the spinal cord [Jacobi et al., 2014; Liu et al., 2011; Wehrle et al., 2005].  
In comparison, we will look at the lumbar region that gives rise to motor axons of the 
sciatic nerve. One study looked at Slit/Robo protein levels in the thoracic regions of 
rats, in comparison, our study will focus on the lumbar region of mice [Li et al., 2017]. 
Our study will provide novel results on mRNA and protein expression of Slit/Robo’s 






















6.2.1 Robo1 expression in the L4-L5 spinal cord 
The expression of Robo1 mRNA and protein has been previously documented in the 
thoracic region of the adult spinal cord of rats [Liu et al., 2011]. The same study 
showed, through IHC, that Robo1 was expressed in cell bodies of the grey matter. 
However, Robo1 did not colocalise with neurofilament staining in the thoracic region 
of the spinal cord [Liu et al., 2011]. Jacobi et al., (2014) documented that Robo1 was 
expressed in all laminae layers of the grey matter, in the cervical spinal cord of mice. 
Another study confirmed that Robo1 was expressed in motor neuron cell bodies, in 
the dorsal region of the thoracic spinal cord in rats [Li et al., 2017].  Petit et al., 
(2007) reported that Robo1 mRNA was present in adult spinal cord progenitor cells.  
Our results also confirmed, through RT-PCR, the presence of Robo1 mRNA in the 
mouse lumbar spinal cord [Figure 6.1]. We further confirmed the presence of Robo1 
mRNA, in the lumbar region of the mouse spinal cord, by carrying out in situ 
hybridisation on cryosections of this area [Figure 6.2]. Robo1 expression appeared 
confined to cell bodies in the grey matter with a distribution in both the dorsal and 
ventral regions. 
We also confirmed that Robo1 protein is present, in the lumbar region of the mouse 
spinal cord. IHC, carried out on L4-L5 spinal cord sections, revealed strong Robo1 
expression throughout the grey matter of the spinal cord [Figure 6.3]. This 
expression colocalised with NeuN expression, determining that Robo1 is expressed 
in neuronal cell bodies of this region, in line with other groups results [Figure 6.3] [Liu 
et al., 2011].  However, we also observed staining around the cell bodies that did not 





like axon projections, so we used IHC to co-stain for neurofilament and Robo1 
[Figure 6.4]. By previously published results [Liu et al., 2011], Robo1 did not 
colocalise with neurofilament, indicating that Robo1 is not expressed in the axons 
[Figure 6.4].  
As Robo1 was not present in axon projections, we pursued the possibility of Robo1 
expression in other cells of the grey matter, such as oligodendrocytes and 
astrocytes. Published work has shown the expression of Robo1 protein in 
oligodendrocyte precursor cells (OPCs) in the adult mouse spinal cord [Liu et al., 
2012]. We used the L4-L5 spinal cord from PLP-EGFP mice, as PLP is expressed in 
oligodendrocytes so the GFP marker would also be present, making 
oligodendrocytes easy to identify [Mallon et al., 2002]. Our results show that Robo1 
does not colocalise with the GFP in these mice, suggesting that Robo1 is not 
expressed in adult oligodendrocytes [Figure 6.5].  
Previous work by Park et al., (2016) determined that unreactive astrocytes of the rat 
hippocampus, did not express Robo1 but reactive astrocytes did. However, due to 
the disparities in model and anatomical area, we considered the possibility of Robo1 
expression in astrocytes of the spinal cord in the mouse model. Glial fibrillary acid 
protein (GFAP) is present in astrocytes of the CNS [Sofroniew et al., 2010]. 
Therefore, we used L4-L5 sections from a GFAP-GFP mouse, in which astrocytes 
would also express GFP [Zhuo et al., 1997]. When these sections were stained, 
Robo1 was observed to colocalise with the GFP, determining that Robo1 is 
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Figure 6.1 RT-PCR shows that Slit/Robo mRNA is present in the L4-L5 
region of spinal cord. RT-PCR was carried out on the L4-L5 spinal cord region 
of two-month-old C57BL/6 mouse spinal cords, to look for Slit/Robo mRNA 
expression. The results show that Robo1,2 and 4 mRNA was present and Slit1-3 















































































Figure 6.2: In situ hybridisation for Slit/Robos in the L4-L5 spinal cord 
shows a variation of staining patterns. In situ hybridisation was carried out on 
L4-L5 sections of spinal cord from two-month-old C57BL/6 mice using various 
Slit/Robo probes. B. Robo1 mRNA expression was present in cells of the grey 
matter region, these cells appeared evenly distributed between the dorsal and 
ventral horns. Robo1 staining looked strongest in large cell bodies of the ventral 
horn of the grey matter (black arrows). C. Robo2 mRNA expression was also 
present in cells of the grey matter, most of these cells were contained within the 
ventral horn of the grey matter (black arrows) with little staining in the dorsal 
region. D. Slit1 mRNA expression appeared to be very weak in the spinal cord, 
appearing in a subset of only certain cell bodies (black arrows). E. Slit2 mRNA 
expression appeared in smaller cell bodies of the grey matter, that were largely 
confined to the ventral horn (black arrows). F Slit3 appeared mainly in the larger 
cell bodies of the ventral horn (black arrows). These results demonstrate that 
Robo and Slit mRNA are present in the cell bodies of the adult L4-L5 murine 
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Figure 6.3: Robo1 is expressed in the cell bodies of the L4-L5 region of the 
spinal cord. Transverse sections from the L4-L5 region of the spinal cord of 
C57BL/6 two-month-old mice were stained with Robo1 (B, F) and NeuN 
antibodies (C, G) and counterstained with Hoechst (A, E). A-D. Robo1 staining is 
concentrated in the grey matter and shows colocalisation with NeuN staining (D, 
white arrows). This indicates that Robo1 is expressed in all the motor cell bodies, 
residing in the L4-L5 region of the spinal cord. However, all the NeuN-positive 
cells are Robo1-positive while not all the Robo1 stain colocalises with NeuN 
staining (D, white arrows). This suggests that Robo1 may also be expressed in 
other cell types of the spinal cord. E-H. High magnification images confirms that 
Robo1 staining (F) does colocalise (H, white arrows) with the NeuN staining (G). 
Although, Robo1 staining does appear in different cells of the spinal cord that are 


























Figure 6.4: Robo1 staining does not colocalise with neurofilament staining 
at the L4-L5 level of the spinal cord. The L4-L5 spinal cord region was 
dissected from two-month-old C57BL/6 mice and transverse sections were 
stained with Robo1 (B, F) and neurofilament antibodies (C, H) and counterstained 
with Hoechst (A, E). A-D. Staining reveals high levels of Robo1 in the grey matter 
of the spinal cord (D). E-H. High magnification images show Robo1 staining in 
large cells of the grey matter (F, white arrows), and Robo1 staining can also be 
seen around this area (F, orange arrows). However, Robo1 staining does not 
colocalise with the neurofilament stain (H, orange arrows). This result suggests 
that Robo1 is not expressed in axons projecting through the L4-L5 region of the 
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Figure 6.5: Robo1 staining shows no colocalisation with GFP-positive cells 
in the L4-L5 spinal cord, from PLP-EGFP mice. Transverse sections of the L4-
L5 region of the spinal cord from two-month-old PLP-EGFP mice were stained 
with Robo1 (C, G) and counterstained with Hoechst (A, E). GFP was present in 
PLP-positive oligodendrocytes (B, F) [Mallon et al., 2002]. A-D. Images do not 
show colocalisation (D) between the GFP-positive oligodendrocytes (B) and the 
Robo1-positive cells (C). E-H. High magnification images confirm that Robo1 (G, 
white arrows) and GFP (F, orange arrows) do not colocalise with each other (H), 
showing that Robo1 is not expressed in oligodendrocytes in the L4-L5 region of 




















  Figure 6.6: Robo1 colocalises with GFP-positive cells in the L4-L5 spine 
from GFAP-GFP mice. Transverse sections of the L4-L5 spinal cords were taken 
from two-month-old GFAP-GFP mice and stained with Robo1 antibody (C, G) and 
counterstained with Hoechst (A, E). GFP was present in GFAP-positive 
astrocytes (B, F) [Zhuo et al., 1997]. A-D. In lower magnification images of the 
spinal cord it is difficult to tell whether staining is colocalising (D). Although, the 
presence of some yellow regions suggests that Robo1 (C) and GFP (B) may be 
colocalising (D, white arrows). E-H. High magnification images confirm that 
Robo1 staining (G) and the GFP reporter (F) colocalise (H, white arrows). This 
result shows that Robo1 is expressed in the astrocytes in the L4-L5 region of the 











6.2.2 Robo2 expression in the L4-L5 spinal cord 
Jacobi et al., (2014) documented that Robo2 mRNA was expressed in all laminae 
layers, apart from laminae I, of the grey matter of the cervical spinal cord in mice. 
Our results reveal that Robo2 mRNA is expressed in the L4-L5 area of the mouse 
spinal cord [Figure 6.1]. We further confirmed this finding by carrying out in situ 
hybridisation on L4-L5 spinal cord sections using a Robo2 probe. Our results confirm 
that Robo2 mRNA is present in this area and appears confined to the cell bodies of 
the grey matter. Robo2 mRNA expression appears very strongly in cells in the 
ventral horn and to a lesser extent in the cells of the dorsal horn.  
Using IHC, we also observed Robo2 protein expression in the L4-L5 mouse spinal 
cord, which appeared confined to the grey matter [Figure 6.7] when Robo2 was 
stained with NeuN the staining colocalised, indicating that Robo2 is expressed in the 
cell bodies of the spinal cord [Figure 6.7]. We also stained neurofilament with Robo2, 
no colocalisation was seen, and again the staining appeared confined to the cell 
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  Figure 6.7: Robo2 staining colocalises with NeuN in the L4-L5 region of the 
spinal cord from C57BL/6 mice. The spinal cords of two-month-old C57BL/6 
mice were dissected and the L4-L5 region was isolated. Transverse cryosections 
of this region were stained with Robo2 (B, F) and NeuN antibodies (C, G) and 
counterstained with Hoechst (A, E). A-D. Staining reveals that all Robo2-positive 
cells (B) colocalise (D, white arrows) with NeuN staining (C). E-H. High 
magnification images show colocalisation (H, white arrows) of Robo2 (F) and 
NeuN (G) in cell bodies of the dorsal horn of the spinal cord. This confirms that 
Robo2 is expressed in the cell bodies of the L4-L5 region of the spinal cord. 























Figure 6.8: Robo2 staining in the L4-L5 spinal cord region does not 
colocalise with neurofilament staining. Transverse cryosections of the L4-L5 
spinal cord region from two-month-old C57BL/6 mice were stained with Robo2 (B, 
F) and neurofilament antibodies (C, G) and counterstained with Hoechst (A, E). 
A-D. Low magnification images did not appear to show Robo2 staining (B) 
colocalising (D) with neurofilament (C). E-H. High magnification images confirmed 
that Robo2 (F, white arrows) was present in cells of the spinal cord, but this 
staining did not colocalise (D, white arrows) with neurofilament staining (G). This 
result determined that Robo2 is not expressed in axon tracts of the L4-L5 spinal 











6.2.3 Slit1 expression in the L4-L5 spinal cord 
Slit1 mRNA expression data in the mouse thoracic spinal cord has been previously 
published. This data revealed Slit1 positive cells in the dorsal region of the spinal 
cord, which appeared to be neuronal cell bodies [Wehrle et al., 2005]. The 
expression of Slit1 mRNA in the cervical mouse spinal cord has also been 
documented using in situ hybridisation. The group reported staining in all laminae 
layers of the grey matter [Jacobi et al., 2014]. 
Through RT-PCR we have shown that Slit1 mRNA is present in the L4-L5 region of 
the spinal cord [Figure 6.1]. Furthermore, in situ hybridisation shows that Slit1 was 
present in cell bodies within the grey matter of the L4-L5 mouse spinal cord [Figure 
6.2]. However, this staining appeared weak and only present in a small subset of 
cells. IHC was used to look at Slit1 protein expression in the L4-L5 spinal cord. Slit1 
and NeuN staining on L4-L5 spinal cord cryosections revealed that Slit1 was present 
in a subset of NeuN-positive cells [Figure 6.9]. This shows that Slit1 is expressed in 
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Figure 6.9: Slit1 is present in a sub-population of cell bodies in the L4-L5 
spinal cord. Transverse cryosections of the L4-L5 spinal cord region from two-
month-old C57BL/6 mice, were stained with Slit1 (B, F) and NeuN antibodies (C, 
G) and counterstained with Hoechst (A, E). A-D. Low magnification images show 
a small subpopulation of cells that appear Slit1-positive (B). These cells appeared 
to colocalise (D, white arrows) with NeuN (C), indicating that they are cell bodies 
of the spinal cord. E-H. Higher magnification images of this subpopulation reveal 
Slit1-positive cells (F) colocalising (H, white arrows) with NeuN staining (G). 





6.2.4 Slit2 expression in the L4-L5 spinal cord 
Slit2 mRNA expression has previously been documented in the mouse thoracic grey 
matter using in situ hybridisation. The Slit2 expression appeared strongest in large 
cells of the ventral region of the spinal cord and was confined to the grey matter. 
This expression appeared to be in the neurons of the spinal cord rather than the glial 
cells [Wehrle et al., 2005]. Slit2 mRNA was also detected in rat thoracic spinal cords 
using qPCR [Liu et al., 2011]. Jacobi et al., (2014) demonstrated that Slit2 mRNA 
was expressed in all laminae layers of the grey matter of the cervical spinal cord in 
mice. Another study confirmed that Slit2 was expressed in motor neuron cell bodies 
in the dorsal region of the thoracic spinal cord in rats [Li et al., 2017].  
We also verified the presence of Slit2 mRNA in the L4-L5 spinal cord. Using RT-
PCR, we first determined that Slit2 mRNA was expressed in the spinal cord [Figure 
6.1]. In situ hybridisation further confirmed the presence of Slit2 mRNA in the spinal 
cord. The expression appeared confined to the grey matter; positive cell bodies were 
seen throughout with some highly positive cells in the ventral horn [Figure 6.2].  
IHC staining confirmed that Slit2 protein was present in the L4-L5 spinal cord of mice 
[Figure 6.10 and 6.11].  L4-L5 spinal cord sections from C57BL/6 mice were stained 
for Slit2 and NeuN. Staining showed colocalisation between Slit2 and NeuN, 
demonstrating that Slit2 is expressed in the neuronal cell bodies of the grey matter 
[Figure 6.10].  
Published work has shown that Slit2 also influences migration of OPCs during 
development [Liu et al., 2012]. We wanted to determine if Slit2 was expressed in 
oligodendrocytes, so we used the L4-L5 region of the spinal cord from PLP-EGFP 
mice. Oligodendrocytes are labelled with the GFP marker in this model so can easily 





found that Slit2 and the GFP marker did not colocalise, demonstrating that Slit2 is 
not expressed in the oligodendrocytes of the L4-L5 spinal cord in mice [Figure 6.11].  
Slit2 expression in reactive astrocytes has previously been documented. However, 
the same study determined that unreactive astrocytes did not express Slit2 [Park et 
al., 2016]. Slit2 staining was carried out on L4-L5 spinal cord sections from GFAP-
GFP mice. GFAP is present in astrocytes, therefore, in the GFAP-GFP mice, GFP 
will also be present in astrocytes [Zhuo et al., 1997]. Slit2 staining was again present 
throughout the grey matter of the spinal cord. However, GFP and Slit2 staining did 
not colocalise [Figure 6.12]. This confirms that Slit2 is not expressed in astrocytes of 
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Figure 6.10: Slit2-positive cells are present in the grey matter of the spinal 
cord. The L4-L5 region of the spinal cord from two-month-old C57BL/6 mice were 
stained with NeuN (B, F) and Slit2 antibody (C, G) and counterstained with 
Hoechst (A, E). A-D. Slit2 staining (C) was confined to the grey matter and 
colocalised (D, white arrows) with NeuN staining (B). This indicates that Slit2 is 
expressed in the cell bodies of the spinal cord. E-H. High magnification images 
further confirm that Slit2 (G) colocalises (H, white arrows) with NeuN (F). (Scale 



























Figure 6.11: Slit2 staining shows no colocalisation with GFP-positive cells 
in the L4-L5 spinal cord, from PLP-EGFP mice. Transverse sections of the L4-
L5 region of the spinal cord from two-month-old PLP-EGFP mice were stained 
with Slit2 antibody (C, G) and counterstained with Hoechst (A, E). GFP was 
present in PLP-positive oligodendrocytes (B, F) [Mallon et al., 2002]. A-D. Images 
do not show colocalisation (D) between the GFP-positive oligodendrocytes (B) 
and the Slit2-positive cells (C). E-H. High magnification images confirm that Slit2 
(G, white arrows) and GFP (F, orange arrows) do not colocalise with each other 
(H), showing that Slit2 is not expressed in oligodendrocytes in the L4-L5 region of 




















Figure 6.12: Slit2 staining does not colocalise with GFP-positive cells from 
GFAP-GFP mice. The L4-L5 region of the spinal cord was removed from two-
month-old GFAP-GFP mice. Transverse cryosections of this region were stained 
with Slit2 antibody (C, G) and counterstained with Hoechst (A, E). GFP was 
present in GFAP-expressing astrocytes (B, F) [Zhuo et al., 1997]. A-D. Low 
magnification images did not clarify if Slit2 (C) was expressed in GFP-positive 
cells (B) due to low expression levels of GFP. E-H. However, higher magnification 
images revealed that although Slit2-positive cells (G, white arrows) were present 
in the spinal cord, they did not colocalise (H) with GFP (F, orange arrows). This 
result shows that Slit2 is not expressed in the astrocytes of the L4-L5 region of 







6.2.5 Slit3 expression in the L4-L5 spinal cord 
Slit3 mRNA expression has been shown to be present in the cell bodies of the 
thoracic region in the mouse spinal cord. This expression appeared strongest in the 
ventral horn of the spinal cord [Wehrle et al., 2005]. Slit3 mRNA has also been 
detected in the cervical spinal cord of mice; weak Slit3 expression appeared in all 
laminae levels of the grey matter [Jacobi et al., 2014].  
To determine if Slit3 mRNA was expressed in the spinal cord we carried out RT-PCR 
on L4-L5 spinal cord samples from C57BL/6 mice. This experiment confirmed that 
Slit3 mRNA was present [Figure 6.1]. To further verify this finding in situ hybridisation 
was performed, on L4-L5 spinal cord samples from C57BL/6 mice. The results 
revealed strong Slit3 expression in the cell bodies of the ventral horn of the spinal 
cord. Slit3-positive cell bodies were also present throughout the grey matter. 
However, this staining was weaker than that seen in the ventral horn [Figure 6.2].  
Slit3 protein expression in the L4-L5 spinal cord was investigated using IHC on 
mouse samples [Figure 6.13 and 6.14]. Slit3 staining was present throughout the 
grey matter of the L4-L5 spinal cord section from C57BL/6 mice [Figure 6.13]. This 
staining colocalised with NeuN staining, determining that Slit3 is expressed in 
neuronal cell bodies of the spinal cord. To verify if Slit3 was expressed in axons 
within the spinal cord, we stained spinal cord sections from C57BL/6 mice with 
neurofilament and Slit3 antibodies [Figure 6.14]. We found that Slit3 and 
neurofilament staining did not colocalise, determining that Slit3 is not expressed in 







6.2.6 No primary negative controls on spinal cord sections 
Spinal cord sections from 2-month-old C57BL/6 mice were used to perform no 
primary negative controls and Robo1 primary positive controls. Spinal cord sections 
were either stained with Robo1 primary antibody solution or the same solution 
without the primary antibody. Secondary antibody solutions were applied in the same 
manner to both experiments.  
Results show strong Robo1 staining within the grey matter, the location of interest 
due to it containing the cell bodies of motor neurons [Figure 6.15 and 6.16]. In 
comparison the negative controls show minimal background staining with no 
background staining within the grey matter [Figure 6.15 and 6.16]. This suggests our 


























Figure 6.13: Slit3 is present in the cell bodies of the L4-L5 region of the 
spinal cord. Spinal cords of two-month-old C57BL/6 were dissected and the L4-
L5 region was isolated. Transverse sections were stained with Slit3 (B, F) and 
NeuN antibodies (C, G) and counterstained with Hoechst (A, E). Low 
magnification (A-D) and high magnification images (E-H) reveal Slit3-positive cells 
(B, F) in the L4-L5 region of the spinal cord. Expression of Slit3 appears confined 
to the grey matter of the spinal cord. Slit3 (B, F) and NeuN staining (C, G) 
colocalises (D, H, white arrows). This colocalisation establishes that the cell 
bodies of the L4-L5 region of the spinal cord express Slit3. (Scale bar A-D= 



























Figure 6.14: Slit3 is not expressed in axons present within the L4-L5 region 
of the spinal cord.  The L4-L5 region of the spinal cord from two-month-old 
C57BL/6 mice was stained with Slit3 (B, F) and neurofilament antibodies (C, G) 
and counterstained with Hoechst (A, E). A-D. Low magnification images reveal 
Slit3-positive cells (B) within the grey matter and many axons within the spinal 
cord (D), although colocalisation was not apparent in these images (D). E-H. High 
magnification images show Slit3 cells (F, white arrows) in the grey matter that do 
not colocalise (H) with neurofilament (G, orange arrows). These results indicate 
that Slit3 is not expressed in the axonal tracts of the spinal cord. (Scale bar A-D= 










Figure 6.15: No primary controls for secondary antibodies 488 and 569 on 
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Figure 6.15: No primary controls for secondary antibody 488 on spinal cord 
samples. Spinal cords of two-month-old C57BL/6 were dissected and the L4-L5 
region was isolated. Transverse sections were stained with Robo1 (A) or no 
primary with Rabbit 488 secondary (D) and counterstained with Hoechst (B, E). 
A-C. Positive control, Robo1 cells can be observed in the grey matter as shown in 
previous results. D-F. Negative control, secondary Rabbit 488 with no primary 
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Figure 6.16: No primary controls for secondary antibody 568 on spinal cord 
samples. Spinal cords of two-month-old C57BL/6 were dissected and the L4-L5 
region was isolated. Transverse sections were stained with Robo1 (A) or no 
primary with Rabbit 568 secondary (D) and counterstained with Hoechst (B, E). 
A-C. Positive control, Robo1 positive cells can be observed in the grey matter has 
previously observed. D-F. Negative control, no primary control with secondary 
Rabbit 568 shows very little background within the grey matter suggesting 






Previous work has documented the expression of Slit and Robo in the spinal cord 
[Jacobi et al., 2014; Li et al., 2017; Liu et al., 2011; Wehrle et al., 2005] [Table 6.1]. 
However, this work has been among various models and areas of the spinal cord as 
well as only either the mRNA or protein level. We had previously identified the 
expression of Robo1, Robo2, Slit2 and Slit3 in axons of the sciatic nerve [Chapter 3]. 
We, therefore, wanted to explore if these Slit/Robo’s were expressed in the cell 
bodies of these axons. We previously identified that these proteins were expressed 
in sensory cell bodies [Chapter 4] and wanted to determine the expression in motor 
cells bodies. Therefore, our work is a systematic study of Slit/Robo expression in the 
mouse lumbar spinal cord at both the mRNA and protein level.  
Having previously documented the expression of Robo1 in axons of the sciatic nerve 
it was an expected result to determine that Robo1 mRNA was detected in the lumbar 
spinal cord of mice using RT-PCR [Figure 6.1]. Other groups had previously 
documented Robo1 mRNA expression in the cervical and thoracic regions [Jacobi et 
al., 2014; Liu et al., 2011]. Having determined that Robo1 mRNA was present it was 
unsurprising that in situ hybridisation results revealed disperse Robo1 staining in the 
grey matter appearing to be expressed in cell body structures [Figure 6.2]. IHC 
staining for Robo1 confirmed a similar pattern of disperse Robo1 staining throughout 
the grey matter of the spinal cord that mostly co-localised with NeuN [Figure 6.3]. 
These results, therefore, confirmed the expression of Robo1 in motor cell bodies 





However, an unexpected result was observed in the expression of Robo1 in a non-
NeuN positive cells. We, therefore, looked at other cell types within the spinal cord to 
determine which cells also expressed Robo1. We determined that Robo1 was not 
expressed in either axons or oligodendrocytes of the spinal cord [Figure 6.4 and 6.5]. 
We then looked at astrocytes and determined that Robo1 is expressed in astrocytes 
of the same region [Figure 6.6].  
Having confirmed Robo1 expression, we looked at Robo2 expression in cell bodies 
of the spinal cord. Robo2 mRNA was detected by RT-PCR, and this expression was 
further confirmed by using in situ hybridisation to detect Robo2 mRNA in spinal cord 
sections [Figure 6.1 and 6.2]. Robo2 in situ staining was focused within the ventral 
horn of the spinal cord with a few positive cells seen in the dorsal horn, suggesting 
that Robo2 is present is in cell bodies that give rise to axons of the sciatic nerve. 
As we had previously detected the expression of Robo2 mRNA, it was an expected 
result to observe strong Robo2 protein expression in the ventral horn of the spinal 
cord that co-localised with NeuN [Figure 6.7]. As Robo2 can also be detected in 
axons that these cell bodies give rise to it is likely that this protein is trafficked down 
the axons. We further determined that Robo2 was not expressed in axons of the L4-





Slit1 mRNA expression was confirmed in the spinal cord using RT-PCR, it was 
therefore unsurprising that we could detect Slit1 mRNA very weakly in a subset of 
cell bodies in the spinal cord using in situ hybridisation [Figure 6.1 and 6.2]. We then 
used IHC to look at Slit1 protein expression and determined is was also expressed 
very weakly in a subset of cell bodies [Figure 6.9]. These cells did not appear in the 
ventral horn of the spinal cord but rather in the central region of grey matter. This 
would suggest that Slit1 is not expressed in cell bodies of motor axons of the sciatic 
nerves as staining would be present in the ventral horn and could be an explanation 
as to why my work does not identify Slit1 in axons of the sciatic nerve.  
Slit2 mRNA presence was detected in the L4-L5 spinal cord using RT-PCR and in 
situ hybridisation [Figure 6.1 and 6.2]. In situ hybridisation results revealed small 
positive Slit2 cells present throughout the grey matter with the darkest staining in 
cells of the ventral horn. Slit2 IHC staining showed positive Slit2 cell bodies in the 
dorsal horn and the ventral horn which co-localised with NeuN [Figure 6.10]. This 
disparity could suggest that there are relatively high translation rates of Slit2 in the 
ventral horn in comparison to transcription rates, resulting is high protein levels in 
comparison to mRNA levels, it has been documented that protein and mRNA 
expression are not always correlated [Gygi et al., 1999; Liu et al., 2016]. Slit2 was 
not expressed in astrocytes or oligodendrocytes of the L4-L5 region of the mouse 
spinal cord, this was expected as all Slit2 staining co-localised with NeuN [Figure 





Slit3 mRNA was confirmed to be present in the mouse lumbar spinal cord using both 
RT-PCR and in situ hybridisation [Figure 6.1 and 6.2]. Unsurprisingly Slit3 in situ 
staining was concentrated in the ventral horn where cell bodies would be located that 
give rise to motor axons of the sciatic nerve. However, when we looked at Slit3 
protein expression using IHC staining was not only seen in the ventral horn but also 
throughout the grey matter [Figure 6.13]. These two conflicting results suggest a 
disparity; this could be explained by mRNA instability compared to relative protein 
stability. Further theories could include relatively low transcription rates in 
comparison to relatively high translation rates as mRNA and protein levels are not 
always similar [Gygi et al., 1999; Liu et al., 2016]. There could also be a high 
turnover of mRNA in these cells resulting in mRNA breakdown making it 
undetectable. Furthermore, Slit3 was not expressed in axons of the spinal cord; this 
was an expected result as all Slit3 staining co-localised with NeuN [Figure 6.14]. 
RT-PCR is a useful technique to determine if mRNA is present, however, this result 
is not quantifiable. Therefore, qPCR could be employed in the future to determine 
exactly how much mRNA is present in the spinal cord sample for the different 
Slit/Robo’s.  
Furthermore, where Robo’s or Slits were confirmed as present or not present within 
oligodendrocytes and astrocytes further in vitro work could be performed. These 
cells could be cultured and qPCR, western blotting and IHC could be used to further 





As we have shown low background from our secondary antibodies based on no 
primary controls, we would expect our primary antibodies to be binding specifically 
[Figure 6.15 and 6.16]. However, unspecific binding of primaries can sometimes 
occur. To further confirm these results different antibodies could be employed 
targeting the same proteins to confirm protein expression patterns. In addition to the 
IHC work, western blotting could also be employed to determine protein expression 























 Previous knowledge Our data in the L4-L5 spinal cord of mice 
Slit1 Slit1 mRNA expression was strong in 
the dorsal horn in thoracic spinal cord 




Central cell bodies: + 
 
Protein expression: 
Central cell bodies: + 
Slit2 Slit2 mRNA expression was strong in 
the ventral horn in thoracic spinal cord 
[Wherle et al., 2005].   
Slit2 mRNA was also detected in rat 
thoracic spinal cords using QPCR [Liu 
et al., 2011]. Slit2 mRNA was 
expressed in the cervical spinal cord in 
mice [Jacobi et al., 2014].  
Slit2 was expressed in the thoracic 




Dorsal horn: + 
Ventral horn: ++ 
 
Protein expression: 
Dorsal neurons: ++ 
Ventral neurons: ++ 
Slit3 Slit3 mRNA expression was strong in 
the ventral horn in thoracic spinal cord 
[Wherle et al., 2005].   
Slit3 mRNA detected in the cervical 





Dorsal horn:  
Ventral horn: +++ 
 
Protein expression: 
Dorsal neurons: ++ 
Ventral neurons: ++ 
Robo1 Robo1 mRNA and protein has been 
detected in the thoracic region of the 
adult spinal cord of rats [Liu et al., 
2011].   
Robo1 expressed in the cervical spinal 
cord of mice [Jacobi et al., 2014].  
Robo1 is expressed in motor neuron 
cell bodies, in the dorsal region of the 
thoracic spinal cord in rats [Li et al., 




Dorsal horn:  ++ 
Ventral horn: ++ 
 
Protein expression: 
Dorsal neurons: ++ 
Ventral neurons: ++ 
Astrocyte: +++ 
Robo2 Robo2 mRNA in the grey matter of the 
cervical spinal cord in mice [Jacobi et 




Dorsal horn: + 
Ventral horn: +++ 
 
Protein expression: 
Dorsal neurons: ++ 
Ventral neurons: ++ 
 
Key: 
+ low expression; 
++ medium expression; 
+++ high expression 


































Chapter 7 Slit/Robo expression after peripheral nerve injury 
7.1 Introduction 
The peripheral nervous system possesses the ability to regenerate following injury. 
However, successful recovery correlates strongly with the type of injury that occurs 
[Menorca et al., 2013]. If the nerve is transected recovery will be very poor, this is 
because axons must leave the proximal nerve stump and transverse the newly-
formed nerve bridge to reach the distal nerve stump [Zochodne, 2012]. The 
mechanisms of this process are poorly understood.  
Although, there is some evidence of Slit/Robo signalling being involved in peripheral 
nerve regeneration. [Tanno et al., 2005; Wang et al., 2013; Yi et al., 2006; Zhang et 
al., 2010]. The precise roles of Slit/Robo signalling in peripheral nerve regeneration 
have not yet been elucidated.  
As we have previously documented the expression of Slit/Robo in cells of the uncut 
sciatic nerve [Chapter 3], as well as in the cell bodies of the axons of the sciatic 
[Chapter 5 and 6], we wanted to look at if this expression pattern was affected during 
peripheral nerve regeneration. Furthermore, as Slit/Robo signalling influences axon 
pathfinding during CNS development we postulated that it could have a similar 
potential function in axon guidance following a sciatic nerve cut [Seeger et al., 1993; 
Kidd et al., 1998a; Kidd et al., 1998b]. 
Patients with a large peripheral nerve injury have a poor outcome regarding 
regaining function to the affected area [Houschyar et al., 2016]. Therefore, it is 
important to understand the full orchestra of signalling pathways that influence 
peripheral nerve regeneration following a cut injury. This may lead to a potential 





In our work, we first aimed to fully map the expression of Slit/Robo signalling during 
peripheral nerve regeneration. Our work will differ from previous work as it will aim to 
identify the expression of Slit/Robo proteins across the nerve bridge. We will do this 
by comparing expression of the same proteins in the same cells across the nerve at 
different points along the injury site. This will tell us the protein dynamics in specific 
cells across the nerve bridge something that has not previously been done. 
Furthermore, our experiments will include completely novel data which will include 
the expression of Robo1 in endothelial cells throughout the nerve bridge and the 
expression of Slit3 in the regenerating nerve. From this data, we hoped to uncover a 




















7.2.1 Robo1 expression in endothelial cells after sciatic nerve transection 
Following sciatic nerve transection, the nerve bridge is depleted of endothelial cells. 
Three days post-sciatic nerve transection the number of endothelial cells within the 
nerve bridge increases and these blood vessels are functional [Cattin et al., 2015]. In 
comparison the process in mice is slower, endothelial cells begin to migrate into the 
nerve bridge later, and by day five functional blood vessels can be observed with 
vascularisation of the bridge complete at six days [Cattin et al., 2015; Dun and 
Parkinson, 2015]. However, in both rats and mice, blood vessels form in a polarised 
manner, extending from the proximal stump and distal stump to cross the nerve 
bridge. This enables SCs to migrate along endothelial cells, using them as a scaffold 
[Cattin et al., 2015]. This time difference is an important consideration when 
comparing the models as events during peripheral nerve regeneration that have 
been shown to occur in the rat may happen later in mice. 
In our previous work, we have shown that Robo1 is expressed in endothelial cells of 
the uncut sciatic nerve [Figure 3.3]. In other models, Robo1 has also been shown to 
be expressed in endothelial cells, where it promotes vascularisation by enabling 
endothelial migration and blood vessel tube formation [Rama et al., 2015; Wang et 
al., 2003]. This suggests that Robo1 could play a role in revascularisation of the 
nerve bridge after sciatic nerve transection, however, no previous work has been 
documented on the expression of Robo1 during peripheral nerve regeneration in 
newly forming blood vessels across the nerve bridge. Therefore, this novel work-
aimed at determining the expression profile in endothelial cells in different areas of 





To address this question, C57BL/6 mice underwent sciatic nerve transection and 
seven days post-injury the nerve was removed encompassing the proximal stump, 
nerve bridge and distal stump and was sectioned longitudinally. The sections were 
stained with Robo1 and the endothelial marker CD31 [Figure 7.1]. Confocal imaging 
of the stained sections revealed that a network of blood vessels had formed across 
the nerve bridge. Robo1 expression can be observed in both the proximal stump and 
distal stump. However, higher levels of Robo1 expression can be observed in the 
areas adjacent to the nerve bridge (proximal and distal nerve tips) as well as the 
nerve bridge. Robo1 can be seen colocalising with the blood vessel marker CD31 in 
the proximal stump [Figure 7.1].   
Higher magnification images were taken to fully establish the expression pattern of 
Robo1 in endothelial cells across the nerve bridge [Figure 7.2]. As previously seen, 
Robo1 expression appeared relatively high and colocalised with CD31-positive 
endothelial cells in the proximal stump [Figure 7.2 P1-P4]. In comparison, Robo1 
appeared to be expressed in endothelial cells at much lower levels in the proximal 
tip, nerve bridge, distal tip, and distal stump of the injured nerve [Figure 7.2 PT1-D4].  
We have previously established that Robo1 is expressed in the vasculature of the 
intact sciatic nerve [Figure 3.3]. We confirm that in the proximal stump, seven days 
post-sciatic nerve transection, Robo1 continues to be expressed in endothelial cells. 
As in previous studies, we confirm that seven days post-sciatic nerve transection a 
network of endothelial cells forms across the nerve bridge. However, Robo1 
expression is much lower in the newly formed vasculature of the nerve bridge, 
suggesting that Robo1 does not play an important part in the re-vascularisation of 
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  Figure 7.1: Robo1 expression is low in newly formed vasculature of the 
nerve bridge. Two-month-old C57BL/6 mice underwent sciatic nerve 
transection surgery. Seven days post-sciatic nerve transection the nerves were 
removed and sectioned. A. Hoechst, Robo1 and CD31 staining with demarcated 
regions of the nerve injury. Sections were stained for Robo1 (B), CD31(C) and 
Robo1/CD31 (D).  B. Robo1 staining appeared strongest in the proximal tip (PT) 
and nerve bridge (NB). C. Newly formed blood vessels, stained with CD31, can 
be seen forming in the proximal tip and distal tip (DT) as well as the nerve 
bridge. D. Colocalisation of Robo1 and CD31 can be observed in the proximal 
stump of the injured nerve (white arrows). However, this image does not show 
convincing evidence for expression of Robo1 in newly formed blood vessels in 
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Figure 7.2: Robo1 expression is low in newly formed blood vessels during 
peripheral nerve regeneration. High magnification images were taken of the 
nerve in Figure 7.1 to establish if Robo1 was expressed in CD31-positive cells. 
P1-P4. Robo1 (P2) and CD31(P3) can be seen to colocalise in the proximal 
stump (P4, white arrows). PT1-B4. In comparison, there seems to be very little 
colocalisation (PT4, B4, white arrows) of Robo1 in the proximal tip (PT2) and 
nerve bridge (B2) where CD31-positive cells (PT3, B3) are located. DT1-D4. 
Some very low expression of Robo1 can be seen in the distal tip and distal stump 
(DT2, D2) with some staining appearing to colocalise (DT4, D4) with CD31 (DT3, 






7.2.2 Robo1 expression in axons during peripheral nerve regeneration 
Four days post-sciatic nerve transection axons will begin to elongate towards the 
nerve bridge [Dun and Parkinson, 2015]. To cross the nerve bridge axons must have 
directional cues to elongate in the correct direction. During the development of spinal 
motor axons in mice, growth cones of these axons express Robo1 and respond to 
the Slit ligand in a chemorepellent manner [Brose et al., 1999; Kidd et al., 1998]. 
We have previously shown that Robo1 is expressed in axons of the sciatic nerve 
[Figure 3.1], and another group has noted the upregulation of Robo1 in large calibre 
axons after axotomy. However, this study used rats [Yi et al., 2006]. As rats and 
mice appear to have a variable peripheral nerve regeneration pattern regarding time 
[Cattin et al., 2015], we wanted to investigate whether Robo1 was expressed in 
elongating axons after sciatic nerve transection in the mouse model.  
To determine whether Robo1 was expressed in elongating axons after a peripheral 
nerve injury, a sciatic nerve transection was performed on C57BL/6 mice. Seven 
days post-sciatic nerve transection injured nerves were removed from the proximal 
stump site to the distal stump site, spanning the injury site, processed and 
longitudinally sectioned. Sections were stained with Robo1 and neurofilament. 
Results confirmed that Robo1 was expressed in axons of the proximal stump and 
proximal tip [Figure 7.3]. In the nerve bridge many Robo1 positive cells were present. 
However, low magnification images were not sufficient to determine if Robo1 was 
expressed in the tips of elongating axons within the nerve bridge. Neurofilament 
staining in the distal stump did not appear to correspond to Robo1 staining, 
indicating that Robo1 is not expressed in fragmenting axons.  
To further establish the expression profile of Robo1 in the regenerating nerve we 





axons express Robo1 in the regenerating nerve, showing that a large percentage 
express Robo1 [Figure 7.3].  
Higher magnification images further confirmed the expression of Robo1 in the 
proximal stump and proximal tip axons [Figure 7.4]. Higher magnification images 
revealed that Robo1 is expressed in the tips of extending axons within the nerve 
bridge. In comparison, higher magnification images show that Robo1 is still present 
at very low levels in fragmenting axons within the distal stump.  
We have determined that Robo1 is expressed in the proximal stump, proximal tip, 
and nerve bridge axons. As Robo1 is expressed in the tips of extending axons, it 
may be plausible that Robo1 is involved in axon pathfinding after sciatic nerve 
transection. Conversely, Robo1 is expressed in axons of the uninjured sciatic nerve, 
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Figure 7.3: Robo1 is expressed in axons during peripheral nerve 
regeneration. Injured sciatic nerves were removed from two-month-old C57BL/6 
mice seven days post-sciatic nerve transection. Samples were longitudinally 
sectioned and stained with Robo1 (B) and neurofilament antibodies (C) and 
counterstained with Hoechst (A). A. Hoechst, Robo1 and neurofilament staining 
with injury areas marked B. Robo1 staining appeared very strongly in the 
proximal tip (PT) and nerve bridge (NB). C. As expected, axons stained with 
neurofilament were seen in the proximal stump (PS) and proximal tip, as they 
began sprouting and elongating after injury. Some axons had extended into the 
nerve bridge. D. In the proximal stump and proximal tip strong colocalisation 
could be observed between Robo1 and neurofilament. This indicates that Robo1 
is expressed in most sprouting axons, seven days post-sciatic nerve transection. 
From these images, it was not clear as to whether Robo1 was expressed in 
axons that had elongated into the nerve bridge, or in fragmenting axons of the 
distal stump (DS). E. Quantification of Robo1 positive axons (80%) of the 
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Figure 7.4: Robo1 is expressed in elongating axons of the nerve 
bridge. High magnification images were taken of the nerve in Figure 7.3 to 
establish if Robo1 was expressed in elongating axons after sciatic nerve 
transection. P1-P4. Robo1 (P2) and neurofilament (P3) colocalised in the 
proximal stump (P4, white arrows). PT1-PT4. In the proximal tip, neurofilament 
(PT2) also colocalised (PT4) with Robo1 (PT2). B1-B4. In the nerve bridge, only a 
few axons could be observed (B3), however, these axons did appear to be also 
strongly positive for Robo1 (B2). D1-D4. In comparison, Robo1 staining (D2) in 
the distal stump appeared to weakly colocalise (D4) with neurofilament staining 
(D3). These results show that Robo1 is expressed in axons of the proximal 
stump, proximal tip and in tips of axons that had reached the nerve bridge at this 











7.2.3 Robo1 expression in Schwann cells of the regenerating peripheral nerve 
After sciatic nerve transection SCs undergo adaptive cellular reprogramming. This 
reprogramming leads to the transformation of SCs, they begin to remove their myelin 
through autophagy followed by phagocytosis by macrophage and SCs, proliferate, 
and begin to migrate [Harringsingh et al., 2004; Jessen and Mirsky, 2008; Jessen, 
Mirsky and Arthur-Farraj, 2005; Jessen and Mirsky, 2016; Gomez-Sanchez et al., 
2015; Son and Thompson, 1995]. SCs migrate away from the proximal stump and 
distal stump into the nerve bridge. The SCs form cords across the nerve bridge 
[Refer to introduction for a details description]. Regenerating axons, of the proximal 
stump, use the SC cords for directional guidance to cross the nerve bridge [Chen et 
al., 2005; Parrinello et al., 2010; Son and Thompson, 1995].  
We have previously shown that Robo1 is expressed in SCs of the sciatic nerve 
[Figure 3.2], as have other groups [Wang et al., 2013]. Wang et al., also showed that 
Robo1 signalling is involved in SC migration in vitro. Therefore, we wanted to 
investigate what happens to Robo1 expression in SCs after sciatic nerve transection. 
PLP-EGFP transgenic mice underwent sciatic nerve transection, PLP-EGFP 
transgenic mice SCs express GFP so we can use this system to track SC migration 
patterns over the nerve bridge during peripheral nerve regeneration. Seven days 
post-sciatic nerve transection we removed the nerve longitudinally from the proximal 
stump to the distal stump, processed it and cut longitudinal sections. Sections were 
stained with Robo1 and imaged using a confocal microscope. Low magnification 
images show GFP-positive SCs migrating from the proximal stump and distal stump, 
into the nerve bridge as expected [Figure 7.5B]. Many Robo1-positive cells can be 
seen in the proximal tip and the nerve bridge [Figure 7.5C]. In the proximal stump 





positive SCs also appear to be Robo1-positive.  However, in the distal stump Robo1 
is expressed at very low levels in GFP-positive SCs in comparison to the other areas 
of the nerve injury. Robo1-positive cells are also present around the GFP-positive 
SCs, indicating that Robo1 is expressed in other cell types during peripheral nerve 
regeneration. To further establish the expression pattern of Robo1 in SCs we 
quantified the number of PLP positive cells that co-localised with Robo1. We 
determined that 98% of SCs expressed Robo1, showing that the majority of SCs do 
express Robo1 [Figure 7.5].  
High magnification images confirm that Robo1 was expressed in SCs in the proximal 
stump [Figure 7.6]. Robo1 is also strongly expressed in SCs of the proximal tip 
[Figure 7.6] and can also be observed in SC processes that are extending into the 
nerve bridge [Figure 7.6]. In SCs of the distal tip and distal stump, Robo1 is 
expressed at lower levels than that seen in the proximal stump, proximal tip, and 
nerve bridge [Figure 7.6].  
We have previously shown the Robo1 is expressed in SCs of the sciatic nerve 
[Figure 3.2], and Robo1 has been implicated in guiding migration of SCs [Wang et 
al., 2013]. We have confirmed that Robo1 is expressed in SCs of the proximal 
stump, proximal tip, nerve bridge and distal tip. In these cells, Robo1 could be 
involved in guiding SCs across the nerve bridge, as it is expressed in SC processes 
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A Figure 7.5: Migrating Schwann cells during peripheral nerve regeneration 
are Robo1-positive. Two-month-old PLP-EGFP mice underwent sciatic nerve 
transection surgery. Injured sciatic nerves were removed seven days post-sciatic 
nerve transection and stained with Robo1 antibody (C) and counterstained with 
Hoechst (A). A. Hoechst, GFP and Robo1 staining with outlined areas of the 
nerve injury. B. Cells expressing Robo1 at high levels are present in the nerve 
bridge (NB) and the proximal tip (PT). C. GFP-positive SCs are observed 
migrating from the proximal stump (PS) and distal stump (DS), towards the nerve 
bridge D. Migrating SCs in the proximal tip, distal tip (DT) and nerve bridge 
appear positive for Robo1. However, many Robo1-positive cells are present in the 
nerve bridge that are not GFP-positive, indicating that Robo1 is expressed in 
other cells of the nerve bridge. SCs of the proximal stump also appear positive for 
Robo1. However, Robo1 expression levels in SCs of the distal stump remains 
unclear at this magnification. E. Quantification of the number of Robo1 positive 


















Figure 7.6: Robo1 expression levels vary in Schwann cells during peripheral 
nerve regeneration. High magnification images of the nerve in Figure 7.5 were 
taken to analyse Robo1 expression level in SCs. P1-P4. Robo1 is further 
confirmed to be expressed in the proximal stump at relatively high levels. PT1-
PT4. In the proximal tip Robo1 (PT3) is highly expressed in GFP-positive SCs 
(PT2). B1-B4. In the nerve bridge, GFP-positive SCs are observed migrating 
across the nerve bridge (B2). Robo1 expression (B3) is seen in the SC process 
(B2). DT1-DT4. In the distal tip, Robo1 (DT3) expression is weaker than in 
previous areas, but does still colocalise with GFP. D1-D4. In the distal stump, 
GFP-positive SCs express Robo1 at very low levels. Relatively, the expression of 
Robo1 in proximal stump and proximal tip is higher than in the nerve bridge and 





7.2.4 Robo1 expression in fibroblasts during peripheral nerve regeneration 
After sciatic nerve transection, fibroblasts migrate into the nerve bridge forming a 
distinct population of cells. Fibroblasts induce SC sorting via ephrin B2-EphB2 
signalling, which causes the relocation of N-cadherin in SCs. This enables the SCs 
to form chains through the nerve bridge, due to the relocalisation of cell-cell 
adherens [Parrinello et al., 2010].  
We have previously observed that Robo1 and fibronectin are expressed in the same 
regions of the mouse sciatic nerve [Figure 3.8]. Therefore, we wanted to determine if 
Robo1 was expressed in similar regions, to fibronectin, in the regenerating nerve 
after sciatic nerve transection.  
To address this question, we performed a sciatic nerve transection on C57BL/6 
mice. Seven days post-sciatic nerve transection the nerve was removed and 
longitudinally sectioned. We stained a section with Robo1, and the sequential 
section with fibronectin, to determine if Robo1 was expressed in fibroblasts [Figure 
7.7]. This was due to our primary antibodies originating from the same host. Our 
results reveal two sections with very similar staining patterns. Fibronectin-positive 
cells fill the nerve bridge seven days post-injury. Comparably, Robo1-positive cells 
also fill the nerve bridge at this time point.  
Our result strongly suggests that fibroblasts that fill the nerve bridge, seven days 
post-sciatic nerve transection, are Robo1-positive. However, due to the antibodies 
being derived from the same host we were unable to show colocalisation between 
these two markers and therefore also unable to quantify the number of Robo1 
positive fibroblasts.  
Recent work by Dr Xin-peng Dun has shown the co-localisation of Robo1 and 





transection. Vimentin is expressed in both fibroblasts and SCs, confirming that 
Robo1 is expressed in both cell types that fill the nerve bridge during peripheral 











Figure 7.7: Robo1 staining shows a similar staining pattern to fibronectin 
during peripheral nerve regeneration. Sciatic nerve transection surgery was 
performed on two-month-old C57BL/6 mice, seven days post-sciatic nerve 
transection nerves were removed, longitudinally sectioned, and stained. 
Sequential sections were stained with either Robo1 (A) or fibronectin antibodies 
(C) and counterstained with Hoechst (B,D). Robo1 staining (B) and fibronectin (C) 
staining revealed similar staining patterns, with upregulated expression in the 
proximal tip, nerve bridge, and distal tip. Staining along the outside of the 
proximal stump and distal stump can also be seen, which is alike in both the 
fibronectin and Robo1 stained nerves. This suggests that Robo1 could be 
upregulated in fibroblasts within the nerve bridge at seven days post-sciatic nerve 
transection. (n=3) (A-D scale bars=500µm) 
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7.2.5 Robo2 expression after peripheral nerve injury 
So far, we have documented the expression of Robo1 during peripheral nerve 
regeneration. However, Robo2 upregulation after nerve axotomy has also been 
demonstrated by Yi et al., (2006). They determined that after axotomy large diameter 
sensory neurons appeared to upregulate Robo2, and smaller calibre sensory axons 
continued to express Robo2 [Yi et al., 2006]. Zhang et al., (2010) also reported that 
Slit1-Robo2 signalling promoted neurite outgrowth in DRG explants. Moreover, 
Tanno et al., (2005) confirmed that seven days post-axotomy there was an increase 
in Robo2 mRNA in the distal stump.  
We have previously shown that Robo2 is expressed in axons of the mouse sciatic 
nerve [Figure 3.4]. As others have noted the expression of Robo2 in the intact 
peripheral nerve and during peripheral nerve regeneration, we wanted to determine 
the expression pattern of Robo2 after sciatic nerve transection. 
To investigate this, we carried out a sciatic nerve transection on C57BL/6 mice. 
Seven days post-sciatic nerve transection the nerve was removed, processed and 
longitudinally sectioned. Sections were stained with Robo2 and neurofilament. Our 
results reveal that Robo2 colocalises with neurofilament in the proximal stump seven 
days post-sciatic nerve transection [Figure 7.8]. This study determined that Robo2 is 
expressed in elongating axons. Robo2 expression increases in the proximal tip 
compared to the proximal stump, and this expression colocalised with neurofilament. 
This indicates that Robo2 may be upregulated in the newly formed regions of axons, 
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Figure 7.8: Robo2 is expressed in axons during peripheral nerve 
regeneration. Two-month-old C57BL/6 mice underwent sciatic nerve transection 
surgery. Seven days post-sciatic nerve transection the nerve was removed and 
sectioned longitudinally. The sectioned nerve was stained with neurofilament (B) 
and Robo2 antibodies (C) and counterstained with Hoechst (A). A. Hoechst 
staining with areas of the nerve injury defined. B. Neurofilament staining marks 
elongating axons of the proximal stump (PS) and proximal tip (PT), and 
fragmenting axons of the distal stump (DS). C. The proximal stump is Robo2-
positive, moreover, the proximal tip displays high levels of Robo2 staining D. 
Robo2 and neurofilament colocalise in the proximal stump and proximal tip, 
showing that Robo2 is expressed in elongating axons of the proximal stump and 






7.2.6 Slit1 expression during peripheral nerve injury 
Having mapped the expression of Robo1 and Robo2 receptors during peripheral 
nerve regeneration, we next wanted to determine the expression pattern of their 
associated ligands Slit1-3. Yi et al., (2006) previously documented the expression of 
Slit1 in the sciatic nerve before and after sciatic nerve transection. The group later 
observed strong Slit1 staining in the proximal stump which colocalised with S100 
staining, demonstrating that Slit1 was expressed in the SCs [Zhang et al., 2010]. 
However, other groups have previously confirmed that Slit1 mRNA is not present in 
cultured SCs [Wang et al., 2013]. Slit1 has also been shown to promote neurite 
formation and elongation of cultured adult rat neurons and that Slit1 continued to be 
expressed in the distal stump [Zhang et al., 2010]. In comparison, another study 
observed no changes to the expression of Slit1 mRNA levels in the distal stump, 
after either a crush or cut injury, compared to the uninjured nerve [Tanno et al., 
2005].  
Currently, results appear conflicting on the expression profile of Slit1 after sciatic 
nerve transection. Our work aimed to clarify the expression pattern of Slit1 after 
sciatic nerve transection, and determine the specific cells types that express Slit1. 
To address this question, we performed a sciatic nerve transection on two-month-old 
C57BL/6 mice. Seven days post-sciatic nerve transection the nerve was removed 
and sectioned longitudinally. We stained the section with neurofilament, Slit1 and 
counterstained with Hoechst [Figure 7.9]. Our results revealed high levels of 
expression of Slit1 in the proximal stump and proximal tip of the regenerating nerve. 
In comparison, minimal Slit1 staining could be observed in the distal stump, this 





unlike other groups, we observed that Slit1 staining colocalised with neurofilament in 
the proximal stump and proximal tip. This staining indicates that Slit1 is expressed in 
the elongating axons of the proximal stump. However, at the tips of the axons, Slit1 
did not colocalise with neurofilament. As neurofilament is not expressed at the very 
tips of elongating axons, it could suggest that Slit1 is present in the tips of 
regenerating axons. In the fragmenting axons of the distal stump, Slit1 is not 
expressed.  We also performed a western blot on sciatic nerve, proximal stump, 
nerve bridge, and distal stump samples to determine the expression of Slit1. Our 
results reveal Slit1 expression in both the uninjured sciatic nerve and proximal 
stump. However, in comparison, we see no expression of Slit1 in the nerve bridge or 
distal stump [Figure 7.9E]. This result agrees with the expression profile of Slit1 seen 
with IHC. 
From our results, we can conclude that Slit1 is expressed in elongating axons of the 
proximal stump and proximal tip seven days post-sciatic nerve transection.  Slit1 is 
expressed in the tips of the axons, where neurofilament is not present. However, 
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  Figure 7.9: Slit1 is expressed in axons of the regenerating sciatic 
nerve. Sciatic nerve transection surgery was performed on two-month-old 
C57BL/6 mice. Seven days post-sciatic nerve transection nerves were removed 
and sectioned longitudinally. Nerves were then stained with Slit1 (C) and 
neurofilament antibodies (B) and counterstained with Hoechst (A). A. Hoechst 
staining with areas of the nerve injury outlined. B. Neurofilament staining shows 
axons elongating into the nerve bridge (NB) from the proximal stump (PS). C. 
Slit1 staining is confined to the proximal stump. D. Staining reveals colocalisation 
of Slit1 and neurofilament in the proximal stump and proximal tip (PT). In 
comparison, Slit1 staining was not present in the distal stump. This confirms that 
Slit1 is present in proximal axons that are elongating, but not in fragmenting 
axons of the distal stump (DS). E. Western blot data for Slit1 expression in the 
uninjured sciatic nerve (SN), proximal stump (PS), nerve bridge (NB) and distal 
stump (DS). Out result shows Slit1 expression in the uninjured sciatic nerve and 
slightly upregulated Slit1 expression in the proximal stump. In comparison, no 
expression of Slit1 can be seen in the nerve bridge or the distal stump. (n=3) (A-D 





7.2.7 Slit2 expression during peripheral nerve injury 
Tanno et al., (2005) observed a twenty-fold increase in Slit2 mRNA expression in the 
distal stump seven days post-sciatic nerve transection. They also carried out IHC on 
the distal stump and observed Slit2 staining colocalising with S100, a SC marker. 
Their result presents evidence that seven days post-sciatic nerve transection, SCs in 
the distal stump up-regulate Slit2. Another in vitro study observed that Slit2 can repel 
cultured SCs [Wang et al., 2013], suggesting a possible role in the migration of SCs 
after sciatic nerve transection. 
As there is little evidence of Slit2 expression pattern after sciatic nerve transection, 
we wanted to clarify the expression profile and determine the cells that express Slit2 
during peripheral nerve regeneration.  
To establish the expression pattern of Slit2 we performed a sciatic nerve transection 
on two-month-old C57BL/6 mice. Seven days post-sciatic nerve transection we 
removed the nerves and longitudinally sectioned them. We then stained the nerve 
sections with neurofilament, Slit2 and counterstained with Hoechst. We observed 
Slit2 staining in the proximal stump and proximal tip, with no staining occurring in the 
nerve bridge and very little in the distal stump [Figure 7.10]. When this staining was 
compared to the neurofilament staining, colocalisation in the proximal stump, 
proximal tip, and distal stump could be observed, showing that Slit2 is expressed in 
elongating axons of the proximal stump and proximal tip; Slit2 is also present in 
fragmenting axons of the distal stump.  
Higher magnification images further confirm that Slit2 colocalises with neurofilament 
in the proximal stump, proximal tip, and distal stump [Figure 7.11]. However, weak 
Slit2 staining that did not colocalise with neurofilament was also present in the 





other cells of the sciatic nerve, such as SCs which has been previously observed 
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Figure 7.10: Slit2 is expressed in axons of the regenerating sciatic 
nerve. Sciatic nerve transection surgery was performed on two-month-
old C57BL/6 mice. Transected nerves were removed seven days post-sciatic 
nerve transection and stained with Slit2 (B) and neurofilament antibodies (C) 
and counterstained with Hoechst (A). A. Hoechst staining with regions of the 
nerve injury marked. B. Slit2-positive staining is present in the proximal stump 
(PS), proximal tip (PT), and distal stump (DS). However, no Slit2 staining is 
present in the nerve bridge (NB). C. Axons of the proximal stump, stained with 
neurofilament, begin to elongate across the nerve bridge. Axons in the distal 
stump are fragmented. D. Staining in the proximal stump and proximal tip 
reveals that Slit2 and neurofilament staining colocalise, indicating that Slit2 is 
expressed in elongating axons. The nerve bridge appears to lack any Slit2 
or neurofilament staining and in the distal stump fragmented axons remain 
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Figure 7.11: Slit2 is expressed in cells surrounding axons during peripheral 
nerve regeneration. High magnification images of the nerve from Figure 7.2 
reveal similar patterns of expression as previously described. P1-P4. Slit2 is 
highly expressed in axons in the proximal stump (white arrows), and to a lesser 
extent in cells surrounding these axons (orange arrows). PT1-PT4. Slit2 is also 
expressed in elongating axons in the proximal tip (white arrows) and again to a 
lesser extend in cells surrounding these axons. B1-B4. Slit2 expression cannot be 
seen in the nerve bridge. D1-D4. Slit2 expression remains in fragmented axons of 
the distal nerve stump (white arrows) and is still expressed in cells surrounding 






7.2.8 Slit3 expression during peripheral nerve regeneration 
Previous work has not yet established a role or an expression profile for Slit3 during 
peripheral nerve regeneration. Our recent work established that Slit3 was expressed 
in SCs, fibroblasts, and axons of the mouse sciatic nerve [Figure 3.6, 3.7 and 3.8]. 
However, the changes that occur to Slit3 expression during peripheral nerve 
regeneration remain unknown.  
There is some evidence that Slit3 is expressed in cells involved in the processes of 
peripheral nerve regeneration. Slit3 mRNA has been shown to be present in cultured 
SCs in vitro [Wang et al., 2013]. This suggests that Slit3 could be expressed in SCs 
during peripheral nerve regeneration.  
Slit3 expression has also been observed, in vitro, in LPS stimulated macrophages 
[Tanno et al., 2007].   Macrophages, haematogenous and resident, assist SCs in the 
clearance of myelin through phagocytosis and myelinophagy [Brück, 1997; Gomez-
Sanchez et al., 2015; Martini, Fischer, López-Vales, and David, 2008]. Not only do 
macrophages contribute to the phagocytosis of myelin debris, they have also been 
shown to secrete VEGF-A. The expression of VEGF-A results in migration of 
endothelial cells that form a network of blood vessels across the nerve bridge [Cattin 
et al., 2015]. It was observed that Slit3 was weakly expressed in macrophages 
before LPS treatment, but with the onset of LPS treatment Slit3 expression 
increased in a time-dependent manner. The group showed that Slit3 was localised to 
the plasma membrane and mitochondria and was involved in cell migration and 
spreading through activation of Cdc42/Rac GTPases [Tanno et al., 2007].  
To determine the expression pattern of Slit3 during peripheral nerve regeneration, 
C57BL/6 mice underwent sciatic nerve transection, and the nerves were removed 
seven days post-injury. The nerves were then sectioned longitudinally and stained 
 
  
   
  





with Slit3 and F4/80, which is a marker for macrophages. Our results reveal highly 
positive Slit3 cells surrounding the nerve bridge. This staining colocalised with F4/80, 
indicating that these cells were macrophages [Figure 7.12]. Colocalisation of Slit3 
and F4/80 can also be observed in the distal stump. However, Slit3-positive 
macrophages inside the nerve bridge did not express Slit3 to the same degree as 
those surrounding the nerve bridge. We quantified the percentage of Slit3 and F480 
nuclei in the regenerating nerve and determined a mean of 90.1% [Figure 7.12]. This 
shows that Slit3 is expressed in most macrophages within the regenerating nerve.  
To determine the exact expression levels of Slit3 in macrophages throughout the 
nerve, high magnification images were taken in the proximal stump, proximal tip, 
nerve bridge, distal tip, distal stump and outside the nerve bridge [Figure 7.13]. In the 
proximal stump, nerve bridge and distal tip, Slit3 was seen to be expressed at very 
low levels in macrophages. However, in the proximal tip and distal stump, Slit3 
expression is relatively higher than that seen in the nerve bridge. In comparison, the 
macrophages outside the nerve bridge express Slit3 at very high levels compared to 
the macrophages inside the nerve bridge.  
From longitudinal sections, it was unclear if Slit3-positive macrophages surrounded 
the whole of the nerve bridge. To confirm this, we performed a sciatic nerve 
transection on C57BL/6 mice and removed the nerve seven days post-sciatic nerve 
transection. We then sectioned the nerve transversely, and stained sections from the 
nerve bridge. We tested two antibodies to confirm the expression pattern of Slit3. 
Both our antibodies revealed Slit3-positive cells surrounding the nerve bridge. These 
cells colocalised with F4/80, indicating that these cells were macrophages [Figure 





Slit3-positive macrophages appear to form a natural perimeter around the nerve 
bridge, surrounding the area in which sprouting axons migrate through. To determine 
if this was true, we stained transverse sections from the proximal tip with 
neurofilament and F4/80 [Figure 7.15]. Our findings confirmed our theory; we 
observed F4/80-positive cells surrounding neurofilament staining. Indicating that 
macrophages surround the area into which sprouting axons elongate into.  
As we had confirmed that macrophages surround sprouting axons in the proximal tip, 
we wanted to confirm further that these cells surround the region axons elongate into 
across the entire nerve bridge. To determine this, we longitudinally sectioned seven-
day post-sciatic nerve transection from C57BL/6 mice and stained the sections with 
Slit3 and neurofilament [Figure 7.16]. Our staining revealed highly positive Slit3 cells 
surrounding the entire length of the nerve bridge, with axons, stained with 
neurofilament, elongating into the area between the Slit3-positive macrophages.  
SCs migrate out of the proximal stump and distal stump to guide axon regeneration 
across the nerve bridge. Therefore, we wanted to determine if Slit3-positive cells 
also surround migrating SCs. To address this, we performed a sciatic nerve 
transection on PLP-EGFP mice, seven days post-sciatic nerve transection we 
removed the nerve and sectioned it longitudinally. We stained the sections with Slit3 
[Figure 7.17]. As expected, we observed GFP-positive SCs migrating out of the 
proximal stump and distal stump. Slit3-positive cells can be seen surrounding the 
area that the GFP-positive cells are migrating into. This confirms that Slit3-positive 
macrophages surround the nerve bridge and the area in which SCs migrate into 
forming a natural perimeter. 
Slit3 expression was also present within the nerve bridge. Slit3 staining in the nerve 





7.13]. However, in the proximal stump further staining was present that was not 
specific to macrophages.  We determined that Slit3 staining co-localised with 
approximately 38% of neurofilament staining, indicating expression in axons [Figure 
7.16]. Staining of Slit3 on PLP-EGFP mice saw some co-localisation indicating that 
Slit3 is expressed in some SCs [Figure 7.17]. Quantification of this staining 
determined that Slit3 was expressed in approximately 31% of SCs of the 
regenerating nerve [Figure 7.17].   
To confirm that our antibody staining was specific, we stained Slit3KO sciatic nerve 
cut sections seven days post-sciatic nerve transection with Slit3 and F4/80. Our 
result showed no Slit3 staining, but the presence of F4/80-positive macrophages 
[Figure 7.18], demonstrating that our antibody is specific, and our results are 
validated.  
Slit3-positive macrophages surround the nerve bridge seven days post-sciatic nerve 
transection. These cells surround the area that sprouting axons elongate through 
and SCs migrate into. Slit3-positive macrophages appear to form a natural perimeter 
for migrating SCs and fibroblasts and regenerating axons. Slit3-positive 
macrophages can also be observed inside the proximal tip and the distal stump. 
These macrophages could be expressing Slit3 at this time point to stop migrating 
cells turning around and migrating in the incorrect direction. We also identified the 
expression of Slit3 in the SCs and axons of the proximal stump. Slit3 could be 
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Figure 7.12: Slit3-positive macrophages surround the nerve bridge during 
peripheral nerve regeneration. Two-month-old C57BL/6 mice underwent sciatic 
nerve transection surgery, seven days post-sciatic nerve transection nerves were 
removed and stained with Slit3 (B) and F4/80 antibodies (C) and counterstained 
with Hoechst (A). A. Hoechst, Slit3 and F4/80 staining, with specific areas of the 
regenerating nerve demarcated. B. Highly positive Slit3 cells can be seen 
surrounding the nerve bridge (NB). Highly positive Slit3 cells outside the nerve 
bridge also appear to stretch out across the nerve bridge to surround the proximal 
tip and stump (PT and PS) and the distal tip and stump (DT and DS) C. F4/80-
positive cells also form a ring like structure around with nerve bridge, with some 
cells infiltrating into the nerve bridge. The F4/80 positive cells also appear not 
only to surround the nerve bridge, but also the proximal tip and stump as well as 
the distal tip and stump. D. Slit3 staining and F4/80 staining colocalise in cells 
surrounding the nerve bridge, indicating that Slit3 is highly expressed in 
macrophages surrounding the injured nerve outside the nerve bridge. Slit3-
positive cells can also be observed in all other areas of the nerve bridge, some of 
these cells are also F4/80-positive. E. Quantification of the number of Slit3 
positive macrophages (91%) within the injury model 7 days post-cut. (n=3) (A-D 
scale bar =500µm) 
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  Figure 7.13: High magnification images confirm that Slit3 is expressed, at 
varying levels, in macrophages throughout the nerve bridge. High 
magnification images of the nerve from Figure 7.12 confirm that Slit3 is expressed 
is F4/80-positive cells to varying degrees. P1-P4. In the proximal stump, Slit3 
expression levels appear very low in comparison to cells outside the nerve bridge, 
proximal tip or distal stump. PT1-PT4. In the proximal tip Slit3 is also expressed in 
F4/80-positive cells (white arrows). Slit3 expression in macrophages of the 
proximal tip is lower than macrophages outside the nerve bridge, but comparable 
to Slit3 expression levels seen in the distal stump (D1-D4). B1-B4 and DT1-DT4. 
Slit3 levels in F4/80-positive cells of the nerve bridge and distal tip are similar to 
those seen in proximal stump. OB1-OB4. Slit3 is expressed at its highest levels in 
F4/80-positive cells surrounding the nerve bridge. (P1-OB4 scale bar=10µm) 
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Figure 7.14: Slit3-positive macrophages surround the nerve bridge during 
peripheral nerve regeneration. Two-month-old C57BL/6 mice underwent sciatic 
nerve transection surgery, and seven days post-sciatic nerve transection nerves 
were removed and transversely sectioned. Sections from the nerve bridge were 
stained with F4/80 antibody (C and G) and either Sigma Slit3 antibody (B) or R&D 
Slit3 antibody (F), then counterstained with Hoechst (A and E).  B, F. Both 
antibodies revealed comparable results, with Slit3-positive cells appearing to 
surround the nerve bridge. C, G. F4/80-positive macrophages appeared to mainly 
surround the nerve bridge, however a subset of macrophages appeared within 
the nerve bridge. D, H. Slit3-positive cells, using either antibody, colocalised with 
F4/80, indicating that Slit3-positive macrophages surround the nerve bridge at 














Figure 7.15: Macrophages surround sprouting axons in the proximal tip. 
Two-month-old C57BL/6 underwent sciatic nerve transection surgery, seven days 
post-sciatic nerve transection nerves were removed and sectioned transversely. 
Sections were taken of the proximal tip and stained with neurofilament (B) and 
F4/80 antibodies (C), and counterstained with Hoechst (A). F4/80-positive 
macrophages again formed a ring like structure around the proximal tip (C), that 
elongating axons (B) appeared to migrate through (D). (n=3) (A-D scale bar= 
500µm) 
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Figure 7.16: Slit3-positive cells surround the nerve bridge and elongating 
axons during peripheral nerve regeneration. Two-month-old C57BL/6 mice 
underwent sciatic nerve transection surgery. Seven days post-sciatic nerve 
transection nerves were removed and sectioned longitudinally. Sections were 
stained with Slit3 (B) and neurofilament antibodies (C) and counterstained with 
Hoechst (A). A. Hoechst, Slit3 and neurofilament staining with demarcated areas 
of interest. B. Strong Slit3-positive cells can be observed outside the nerve bridge 
(NB), surrounding the region that the sprouting axons elongate into. Weaker Slit3 
staining can also be observed within the proximal stump (PS) and proximal tip 
(PT). C. As expected, neurofilament staining reveals axons sprouting and 
extending into the proximal tip with some reaching the nerve bridge. D. Slit3 
staining colocalised with some neurofilament staining, indicating that Slit3 is 
expressed in some regenerating axons of the sciatic nerve. However, Slit3 did not 
appear to co-localise with neurofilament staining in the distal tip (DT) or distal 
stump (DS) showing that Slit3 is not expressed in fragmenting axons of the 
injured sciatic nerve. E. Quantification of the number of Slit3 positive axons (38%) 
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Figure 7.17: Slit3-positive cells surround migrating Schwann cells during 
peripheral nerve regeneration. Two-month-old mice PLP-EGFP mice 
underwent sciatic nerve transection surgery, and seven days post-sciatic nerve 
transection their nerves were removed and sectioned longitudinally. Sections 
were stained with Slit3 antibody (C) and counterstained with Hoechst (A). GFP 
was present in SCs (B). A. Hoechst and Slit3 staining with GFP; areas of the 
nerve injury are shown. B. GFP-positive SCs migrate out of the proximal stump 
(PS) and distal stump (DS) towards the nerve bridge (NB) C. Highly positive Slit3 
cells surround the nerve bridge. D. Slit3-positive cells surround the area that the 
GFP-positive SCs are migrating into. In the proximal stump, proximal tip (PT), and 
distal tip (DT) weak Slit3 staining does colocalise with some GFP positive cells. 
This shows that Slit3 is also weakly expressed in SCs of the proximal stump and 
migrating SCs of the proximal tip. E. Quantification of the number of Slit3 positive 
SCs (31%) of the regenerating nerve.  (n=3) (A-D scale bar= 500µm)  











































Figure 7.18: Slit3KO mice do not have Slit3 positive macrophages. Two-
month-old Slit3KO mice underwent sciatic nerve transection surgery, and nerves 
were removed seven days post-sciatic nerve transection. Nerves were sectioned 
longitudinally and stained using the Slit3 R&D antibody (F) and F4/80 antibody 
(G) and counterstained with Hoechst (E). The lack of staining by the Slit3 
antibody suggests that this stain is specific and further confirms our result that 
Slit3 is expressed in macrophages surrounding the nerve bridge.  (n=3) (A-D 









7.2.9 No primary negative controls on seven day post-injury nerve sections 
C57BL/6 2-month-old mice underwent sciatic nerve transection. Seven days post-
injury the nerves were removed and prepared for IHC. The nerves were sectioned 
longitudinally. Nerves were then either stained with Robo1 primary or no primary 
antibody buffer solution, both then followed the same protocol.  
The Robo1 primary control for both the 488 and 568 secondaries shows strong 
staining in the proximal and distal nerve tips as expected [Figure 7.19 and 7.20]. In 
comparison the negative controls show very minimal staining [Figure 7.19 and 7.20]. 
This determines that the secondary antibodies used during these experiments have 
very little background staining on cut nerve sections and indicates that the staining 






























Figure 7.19: No primary control on cut nerve for Rabbit 488. Two-month-old 
C57BL/6 mice underwent sciatic nerve transection surgery, and nerves were 
removed seven days post-sciatic nerve transection. Nerves were sectioned 
longitudinally and stained using either Robo1 (B, positive control) or no primary 
(D, negative control) and counterstained with Hoechst (A and C). The lack of 
staining in the negative control suggests the secondaries are not binding to 
unspecific targets. This secondary antibody was used in conjunction with Robo1, 
















































Figure 7.20: No primary control on a cut nerve for Rabbit 568. Two-month-old 
C57BL/6 mice underwent sciatic nerve transection surgery, and nerves were 
removed seven days post-sciatic nerve transection. Nerves were sectioned 
longitudinally and stained using either Robo1 (B, positive control) or no primary 
(D, negative control) and counterstained with Hoechst (A and C). The lack of 
staining in the negative control suggests the secondaries are not binding to 
unspecific targets. This secondary antibody was used in conjunction with Robo1, 








Our results reveal a dynamic expression profile of Slit1-3 and Robo1-2 signalling 
during peripheral nerve regeneration. Previous work by other groups had indicated 
that Slit/Robos were expressed during regeneration, we have further advanced this 
work [Table 7.1] 
As we had previously identified Robo1 expression in endothelial cells of the uncut 
nerve [Figure 3.3], it was unsurprising Robo1 remained high in the endothelial cells 
of blood vessels in the proximal nerve stump [Figure 7.1]. However, it was an 
unexpected finding to observe Robo1 being downregulated in endothelial cells within 
the nerve bridge [Figure 7.2]. This was a surprising finding as there is evidence to 
show the Robo1 promotes angiogenesis [Li et al., 2015; Sheldon et al., 2009; Zhang 
et al., 2009]. However, there is also evidence that Robo1 inhibits angiogenesis 
[Wang et al., 2003; Wang et al., 2007] This variable expression may suggest that 
Robo1 is involved in inhibiting angiogenesis in the uncut nerve and proximal nerve 
stump and is therefore downregulated in endothelial cells forming new blood vessels 
in the nerve bridge.  
In the uncut nerve, we had previously identified the expression of Robo1 in both SCs 
and axons [Figure 3.1 and 3.2]. It was therefore unsurprisingly to see the expression 
of Robo1 in axons crossing the nerve bridge and surrounding SCs [Figure 7.3, 7.4, 
7.5 and 7.6].  We determined that 80% of elongating axons express Robo1 [Figure 
7.3], as a large proportion of axons express Robo1 it could suggest a ligand could 
act on most of these axons to guide them across the nerve bridge. Importantly, we 
observed Robo1 expressed in the tips of elongating axons suggesting that Robo1 





Furthermore, strong staining of Robo1 was observed in SCs of the nerve bridge and 
potentially surrounding fibroblasts [Figure 7.5, 7.6 and 7.7]. We were also able to 
determine that 98% of SCs express Robo1 [Figure 7.5], this would suggest that the 
majority of migrating SCs express Robo1 and are therefore able to respond to a 
ligand that could be involved in directional migration of these cells into the nerve 
bridge from the proximal and distal stumps. Additionally, Robo1 has been shown to 
influence SC migration in vitro making this a plausible theory [Wang et al., 2013]. 
We confirmed that Robo2 was expressed in elongating axons of the proximal nerve 
stump and fragmenting axons of the distal stump [Figure 7.8]. This was an 
unsurprising result as we had previously determined that Robo2 expression was 
exclusive to axons of the peripheral nerve [Figure 3.4]. This expression could 
suggest that Robo2 is expressed in elongating axons to guide them across the nerve 
bridge. 
As I had been unable to detect Slit1 in the uncut nerve using IHC, it was therefore 
surprising to observe Slit1 in elongating axons of the proximal stump [Figure 7.9]. 
However, we had previously determined that Slit1 was expressed in L4-L5 DRG, 
suggesting that sensory neurones do produce Slit1 [Figure 5.5]. We also used 
western blotting to determine that Slit1 protein was present in the uncut nerve and 
proximal nerve stump but not present in the bridge and distal nerve stump supporting 
this result [Figure 7.9]. Therefore, it is possible that these axons are sensory axons 





We confirmed the expression of Slit2 in axons of the proximal stump and 
degenerating axons of the distal nerve stump [Figure 7.10 and 7.11]. This was an 
expected result as we had previously identified the expression of Slit2 in axons of the 
uninjured sciatic nerve [Figure 3.5]. We also noted expression of Slit2 in cells 
surrounding axons, we had previously identified that Slit2 is expressed in SCs of the 
uncut nerve, so it is plausible that this expression continues [Figure 3.5].  
No previous work had explored the expression of Slit3 during peripheral nerve 
regeneration. However, our previous work in the injured sciatic nerve had identified 
the strong expression of Slit3 in SCs and axons [Figure 3.6 and 3.7]. Our staining of 
Slit3 revealed very strong positive cells surrounding the nerve bridge that we 
identified as macrophages [Figure 7.12 and 7.13]. This was a very surprising result. 
However, Slit3 had been shown to be expressed in LPS stimulated macrophages 
previously [Tanno et al., 2007].  We quantified that 91% of macrophages express 
Slit3 [Figure 7.12], this high percentage and high expression would suggest a 
potentially strong role for Slit3 in peripheral nerve regeneration.  
We further verified these results by taking transverse sections of the nerves and 
confirmed that Slit3 positive macrophages surrounded the nerve bridge using 
different antibodies for assurance [Figure 7.14] and determined that axons migrate 
through the perimeter formed by Slit3 positive macrophages [Figure 7.15 and 7.16]. 
This was an interesting result as we had previously identified that elongating axons 
of the proximal nerve stump express both Robo1 and Robo2 which could respond to 






We further confirmed that SCs migrate through the macrophage’s perimeter [Figure 
7.17], this was an interesting finding as we have previously shown that SCs in the 
nerve bridge express Robo1 [Figure 7.3 and 7.4]. These SCs could, therefore, 
respond to directional cues provided by the Slit3 positive macrophages to migrate in 
the correct direction.  
A proportion of axons and SCs remained Slit3 positive [Figure 7.16 and 7.17]. This is 
unsurprising as Slit3 is expressed in both these cell types in the adult uninjured 
sciatic nerve [Figure 3.7 and 3.8]. This expression could be residual expression from 
Slit3s role in the uninjured nerve.   
We confirmed the specificity of the primary antibody we used by testing the Slit3 
staining protocol on Slit3KO sciatic nerve cut samples [Figure 7.18]. Images show 
little background suggesting that our antibody is specific.  
During these experiments, IHC was used to determine the expression pattern of the 
Slit/Robos over the nerve bridge with other markers to detect axons, SCs, 
endothelial cells, fibroblasts and macrophages. As our no primary controls for both 
Rabbit 468 and 588 are relatively clear of any background staining in comparison to 
the positive Robo1 control, we can assume there was no unspecific binding by the 
secondary antibodies [Figure 7.19 and 7.20]. Furthermore, we have shown that in 
Slit3KO mice there is minimal background when using the Slit3 primary suggesting 
that Slit3 primary is specific [Figure 7.17]. There is a chance with IHC that the 
primary antibodies can target unspecific sites, we tried to minimise this through 
extensive blocking.  
We further confirmed our work in Slit3 by using different antibodies to verify that the 
expression profile was correct [Figure 7.14]. Further experiments could involve using 





experiment we used a western blot to confirm the expression pattern [Figure 7.9]. 
Further experiments could include doing this for all Slit/Robo expression profiles to 






 Previous knowledge Our data within the sciatic nerve 
Slit1 Slit1 is expressed before, and following a sciatic 
nerve transection [Yi et al., 2006] Slit1 is expressed in 
the SCs in the proximal nerve stump [Zhang et al., 
2010].  
Slit1 mRNA is not present in cultured SCs [Wang et 
al., 2013].  
Slit1 promotes neurite formation and elongation of 
cultured adult rat neurons and continues to be 
expressed in the distal stump [Zhang et al., 2010].  
Slit1 mRNA levels remained unchanged in the distal 
stump, after either a crush or cut injury [Tanno et al., 
2005]. 
Western blot data:  
Slit1 protein is only present in uncut 
nerve and proximal nerve stump. 
IHC results: 
Proximal stump axons ++ 
Slit2 Slit2 mRNA expression increased in the distal stump 
seven days post-sciatic nerve transection [Tanno et 
al., 2005]. Slit2 was expressed in SCs in the distal 
nerve stump seven days post-injury [Tanno et al., 
2005].  
Slit2 can repel cultured SCs in vitro [Wang et al., 
2013]. 
IHC results: 
Proximal stump axons ++ 
Fragmenting distal stump axons + 
Unknown cells within the nerve bridge 
+ 
Slit3 No data for any injury model IHC results: 
Macrophages surrounding nerve 
bridge +++ 
Proximal stump axons + 
Schwann cells + 
Robo1  Robo1 mRNA was upregulated 7 and 14 days post-
injury in the distal nerve stump [Tanno et al., 2005]. 
mRNA expression in nerve unchanged following a 
nerve crush [Tanno et al., 2005]. 
Robo1 is upregulated in large calibre axons after 
axotomy in rats [Yi et al., 2006]. 
Robo1 is expressed in SCs of the sciatic nerve and 
can control SC migration in vitro [Wang et al., 2013].  
IHC results  
Proximal stump axons +++ 
Schwann cells proximal stump and tip 
+++ 
Bridge and distal tip ++ 
Distal stump + 
Proximal stump endothelial cells ++ 
Bridge endothelial cells + 
Fibroblasts ++ 
Robo2 Robo2 mRNA expression in nerve unchanged 
following nerve crush [Tanno et al., 2005]. 
Robo2 mRNA upregulation following sciatic nerve 7 
and 14 days post-injury in the distal nerve stump 
[Tanno et al., 2005]. 
Large diameter sensory neurons upregulated Robo2 
following axotomy and smaller calibre sensory axons 
continued to express Robo2 [Yi et al., 2006].  
Slit1-Robo2 signalling promoted neurite outgrowth in 
DRG explants [Zhang et al., 2010].  
Seven days post-axotomy Robo2 mRNA was 
upregulated in the distal stump. [Tanno et al., 2005]. 
 
IHC results: 
Proximal stump axons +++ 
Key: 
+ low expression; 
++ medium expression; 
+++ high expression. 
Table 7.1: Summary table of previous knowledge and new knowledge provided by this 



































Chapter 8 Slit/Robo expression in sciatic nerve cell bodies following sciatic 
nerve transection 
8.1 Introduction 
For peripheral nerve regeneration to be successful, the cell bodies of the neurons 
must respond accordingly. Sensory neuron cell bodies of the sciatic nerve reside in 
the L4-S3 DRG. In comparison, the cell bodies of motor neurons reside in the L4-S3 
grey matter of the ventral spinal cord. 
Upon injury, the cell bodies must undergo profound transcriptional changes to cope 
with the demands of regeneration after sciatic nerve transection cell bodies begin 
upregulating regeneration-associated genes (RAGs) such as ATF3, GAP-43 and c-
Jun to promote axonal regeneration [Herdegen et al., 1997; Seijffers et al., 2007; 
Woolf et al., 1990]. 
We have previously demonstrated the presence of Slit/Robo expression in the motor 
and sensory cell bodies of the uninjured sciatic nerve [Chapter 5 and 6]. We have 
also determined that Slit/Robo proteins have a dynamic expression pattern during 
peripheral nerve regeneration with Slit3 positive cells forming a perimeter around 
migrating SCs and elongating axons [Chapter 7]. We observed strong staining of 
Robo1 and Robo2 in elongating axons of injured of the nerve. Therefore, we wanted 
to determine if there were any changes to Slit/Robo expression in the cell bodies of 
these axons following injury.   
Looking at the upregulation or downregulation of mRNA and proteins is important to 
understand the cellular events following injury. This insight into the cellular changes 
could potentially lead to a therapeutic target to help improve nerve injury patient 
functional recovery outcomes. 
Previously work undertaken in this field to address the regulation of Slit/Robo has 





Due to peripheral regeneration happening slightly slower in mice in comparison to 
rats it is important we establish the expression pattern in mice [Cattin et al., 2015; 
Dun and Parkinson, 2015]. Furthermore, previous studies have only looked at 
Slit/Robo expression changes following injury in the DRG and not the motor cell 
bodies within the spinal cord in comparison; our study will, therefore, elucidate any 
changes in protein or mRNA expression following axotomy of the sciatic nerve in 
both types of cell bodies.   
8.2 Results 
8.2.1 Robo1 and Robo2 expression in the sensory DRG cell bodies of the 
sciatic nerve following sciatic nerve transection 
Robo1 mRNA changes have been previously documented in the DRG after sciatic 
nerve transection. Previous work has determined that Robo1 and Robo2 mRNA 
levels increase in rat L4-L6 DRG seven and fourteen days post-sciatic nerve 
transection [Zheng et al., 2010; Zheng et al., 2012]. An increase in both Robo1 and 
Robo2 protein expression in rat DRG seven days following nerve injury has also 
been observed [Yi et al., 2006; Zheng et al., 2010; Zheng et al., 2012]. Robo2 
expression appeared confined to a subset of cell bodies [Zheng et al., 2012]. Robo2 
activation in cultured DRG neurons resulted in the inhibition of neurite formation and 
elongation, suggesting a potential role in peripheral nerve regeneration [Zheng et al., 
2012].  
Previous studies have documented changes in both Robo1 and Robo2 expression 
after sciatic nerve transection [Yi et al., 2006; Zheng et al., 2010; Zheng et al., 2012]. 
However, due to the differences in animal model and DRG being used, we wanted to 





Our study of Robo1 and Robo2 mRNA expression in the L4-L5 DRG determined, 
using RT-PCR, that there were no changes in expression level at 4, 7, 10 or 14 days 
after sciatic nerve transection [Figure 8.1]. We also determined, using IHC, that there 
were no changes in staining intensity or staining location of either Robo1 or Robo2 in 
the DRG sensory cell bodies seven days post-sciatic nerve transection, in 
comparison to the uncut control sample [Figure 8.2].  
8.2.2 Slit1, Slit2 and Slit3 expression in sensory cell bodies of the sciatic nerve 
following sciatic nerve transection 
RT-PCR and IHC have previously been used to show that Slit1 mRNA and protein 
levels increase in L5-L6 rat DRG, 7 to 28-days post-sciatic nerve transection [Yi et 
al., 2006; Zheng et al., 2010]. The expression of Slit2 in DRG has not been 
previously studied, whereas Slit3 mRNA expression has only been confirmed in rat 
L6 DRG of uninjured neurons [Bloechlinger et al., 2004].  
Slit1 and Slit2 have both been shown to be positive regulators of dendritic extension 
in cultured DRG neurons [Wang et al., 1999; Zheng et al., 2010; Zhao et al., 2015]. 
The effect of Slit2 on the elongation and branching of DRG neurons was dependent 
upon the presence of an extracellular matrix, specifically on the presence of 
fibronectin [Nguyen-Ba-Charvet et al., 2001]. Moreover, a different study looked at 
the effects of Slit2 on the growth cone in more detail. They established that Slit2 
causes the elongation of DRG neuron filopodia, however, Slit2 inhibited the growth 
of lamellipodia [McConnell et al., 2016]. 
We have previously confirmed the expression of Slit1, Slit2 and Slit3 in L4-L5 DRG 
[Chapter 5]. Here, we wanted to establish the expression pattern of the Slit ligands in 





Our study of Slit1, Slit2 and Slit3 mRNA expression in the L4-L5 DRG determined, 
using RT-PCR, that there were no changes in expression level at 4, 7, 10 and 14 
days after injury [Figure 8.1]. We further confirmed, using in situ hybridisation, that 
there were no changes to Slit1, Slit2 or Slit3 mRNA expression four days after injury. 
Our result revealed similar expression intensities and expression patterns of Slit1, 
Slit2 and Slit3 between the uncut DRG and the four-day post-cut DRG sample 
[Figure 8.1]. Both results indicated that Slit1, Slit2 and Slit3 mRNA levels in the L4-
L5 DRG are unaffected by sciatic nerve transection.  
We also determined, using IHC, that there were no changes in staining intensity or 
staining location of Slit1, Slit2 or Slit3 in the DRG sensory cell bodies seven days 
post-injury in comparison to the uncut sample [Figure 8.3]. These results indicate 
that Slit2 levels in the sensory cell bodies of neurons of the sciatic nerve are 
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Figure 8.1 Slit/Robo mRNA expression remains unchanged, in L4-L5 
dorsal root ganglia at various time point post-sciatic nerve transection. 
Two-month-old C57BL/6 mice underwent a sciatic nerve transection. The 
DRG from the injured and uninjured sides were collected at 4, 7, 10 and 14 
days for RT-PCR and 4 days post-sciatic nerve transection for in situ 
hybridisation. A, B. In situ hybridisation control probe staining revealed no 
staining determining probe specificity. C, D. Robo2 expression in both 
uninjured (C) and injured DRG (D) revealed similar intensities of staining in 
the DRG cell bodies, indicating no changes in mRNA expression. E, F. Slit1 
uninjured (E) and Slit1 injured (F) DRG also had similar levels and patterns of 
expression. G-J. Slit2 injured (H) and uninjured DRG (G), and Slit3 injured (J) 
and uninjured DRG (I) expression appeared unchanged in pattern and 
intensity four days after sciatic nerve transection. K. RT-PCR supported the 
in situ hybridisation findings. No changes in band intensity between uninjured 
and injured DRG appeared for Robo1, 2 and 4 at 4, 7, 10 or 14 days post-
sciatic nerve transection. There was also no band intensity change for Slit1, 2 
or 3 at any time point. These results show that after sciatic nerve transection 
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Figure 8.2 Robo1 and Robo2 protein levels appear unchanged in L4-L5 
dorsal root ganglia seven days post-sciatic nerve transection. L4-L5 DRG 
from both the uninjured and injured sides were removed from two-month-old 
C57BL/6 mice, seven days following sciatic nerve transection. All sections were 
stained with NeuN (R1C, R1G; R2C, R2G) and counterstained with Hoechst 
(R1A, R1E; R2A, R2E). R1A-H. Robo1 primary antibody was used to stain cut 
and uncut DRG, the staining intensity appeared unchanged after seven days 
post-injury compared to the uninjured DRG. The staining pattern of Robo1 also 
appeared unchanged, colocalising with NeuN before and after sciatic nerve 
transection. R2A-H. Robo2 primary was used to stain uncut and cut DRG, the 
staining in the uninjured sample and seven days post-sciatic nerve transection did 
not change in intensity or staining pattern. Robo2 staining continued to colocalise 
with NeuN staining. These results indicate that protein level and location of Robo1 
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Figure 8.3 Slit protein levels remain unchanged in L4-L5 dorsal root ganglia, 
seven days post-sciatic nerve transection. Injured and uninjured L4-L5 DRG 
were removed from two-month-old C57BL/6 mice seven days post-sciatic nerve 
transection. DRG sections were stained with NeuN (S1C, S1G; S2C, S2G; S3C, 
S3G), either Slit1 (S1B, S1F), Slit2 (S2B, S2F) or Slit3 (S3B, S3F) and 
counterstained with Hoechst (S1A, S1E; S2A, S2E; S3A, S3E). Injured and 
uninjured DRG were stained and imaged under the same conditions. S1A-H. Slit1 
staining intensity appeared unchanged seven days post-sciatic nerve transection. 
The staining pattern was also unchanged, and continued to colocalise (S1D and 
S1H) with NeuN (S1C and S1G).  S2A-H. Staining intensity levels of Slit2 were 
indistinguishable between the uninjured and the injured DRG. Similar patterns of 
Slit2 staining could be observed in both tissues, with Slit2 colocalising with NeuN. 
S3A-H. Similar results can be seen for Slit3, with the staining intensity and pattern 
appearing unchanged in the injured DRG in comparison to the uninjured DRG. 
Slit3 staining continued to colocalise with NeuN staining. These results indicate 
that Slit1, Slit2 and Slit3 protein expression remain unchanged in the L4-L5 DRG, 





8.2.3 Robo1 and Robo2 expression in the motor cell bodies of the sciatic nerve 
following sciatic nerve transection 
Robo1 expression has been documented in the cell bodies of the thoracic spinal 
cord in rats [Liu et al., 2011; Li et al., 2017]. Robo2 expression has been previously 
observed in motor cell bodies of the mouse spinal cord [Jacobi et al., 2014]. Our 
group has also confirmed that Robo1 and Robo2 are present in motor cell bodies of 
the L4-L5 spinal cord of C57BL/6 mice [Chapter 6]. However, changes in the levels 
of Robo1 and Robo2 in motor cell bodies of the spinal cord after sciatic nerve 
transection has not been investigated.  
To determine if changes in Robo1 expression were present in the L4-L5 motor cell 
bodies after sciatic nerve transection, we performed a sciatic nerve transection on 
C57BL/6 mice. We removed the L4-L5 spinal cord at 4, 7, 10 and 14 days post-
sciatic nerve transection and performed RT-PCR on spinal cord samples from both 
the injured and uninjured side. Our results revealed no changes in Robo1 or Robo2 
expression at any time point after sciatic nerve transection, showing that Robo1 and 
Robo2 mRNA levels stay constant in the L4-L5 spinal cord after sciatic nerve 
transection [Figure 8.4]. We also performed in situ hybridisation on L4-L5 spinal cord 
sections seven days following sciatic nerve transection. Our result determined no 
changes in Robo1 mRNA expression level or expression pattern in the spinal cord of 
the injured side in comparison to the uninjured side [Figure 8.4].  
Having demonstrated that Robo1 and Robo2 mRNA levels do not change after 
sciatic nerve transection, we then wanted to determine if Robo1 and Robo2 protein 
levels were also unchanged. We performed IHC on L4-L5 spinal cord seven days 
post-sciatic nerve transection. Robo1 and Robo2 staining appeared at similar 





expression is unchanged in the motor cell bodies of the sciatic nerve following sciatic 
nerve transection [Figure 8.5].  
8.2.4 Slit1, Slit2 and Slit3 expression in motor cell bodies of the sciatic nerve 
following sciatic nerve transection 
Previous work identified the expression of Slit1, Slit2 and Slit3 in the cervical region 
of the mouse spinal cord [Jacobi et al., 2014]. Slit2 and Slit3 mRNA expression has 
also been confirmed in the thoracic mouse spinal cord [Wherle et al., 2005]. We also 
confirmed the expression of Slit1, Slit2 and Slit3 positive cell bodies in the L4-L5 
region of mouse spinal cord [Chapter 6].  
Fujiwara et al., (2008) mapped changes in the Slit ligands in the motor nuclei of the 
rat facial nuclei following axon transection. Slit1 mRNA levels were upregulated 
seven days post-transection, in comparison Slit2 mRNA levels decreased seven 
days post-injury and Slit3 mRNA levels remained unchanged. In comparison to this 
study, the upregulation of Slit2 in the spinal cord of rats has been detected seven 
days post-spinal cord injury [Liu et al., 2012].  As there seems to be disparities in 
results depending on the location and type of injury, we wanted to determine any 
changes in Slit ligand expression pattern in the L4-L5 spinal cord following sciatic 
nerve transection.  
To address this question, we performed RT-PCR on L4-L5 spinal samples from both 
injured and uninjured sides at 4, 7, 10 and 14 days post-sciatic nerve transection. 
Our results revealed no changes in Slit1 or Slit2 mRNA levels in the L4-L5 spinal 
cord at any time point after sciatic nerve transection [Figure 8.4], showing that Slit1 
and Slit2 mRNA expression in the L4-L5 spinal cord is unaffected by a sciatic nerve 
transection. To further confirm this finding, we performed in situ hybridisation on 





hybridisation result revealed a similar intensity and location of Slit2 and Slit3 
expression of the spinal cord from both the injured and uninjured side. This 
reinforces previous findings that Slit2 mRNA levels, in the L4-L5 spinal cord, are 
unaffected by sciatic nerve transection and determines that Slit3 mRNA levels are 
also unchanged [Figure 8.4].  
To determine if Slit2 or Slit3 protein levels are altered in the L4-L5 spinal cord by 
sciatic nerve transection, we performed IHC on seven-day post-sciatic nerve 
transection spinal cord sections from C57BL/6 mice. Our results determined that 
Slit2 and Slit3 staining is a similar intensity and location on both the uncut and the 
injured side of the spinal cord [Figure 8.5], determining that Slit2 and Slit3 levels 
remain unchanged seven days post-sciatic nerve transection in the motor cell bodies 
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Figure 8.4 Slit/Robo mRNA levels in the L4-L5 spinal cord appear constant 
after sciatic nerve transection. The L4-L5 spinal cord region was removed from 
two-month-old C57BL/6 mice at 7 days post-sciatic nerve transection for in situ 
hybridisation (A-E), and 4, 7, 10 and 14 days post-sciatic nerve transection for 
RT-PCR (F). A. The control sense probe sample for in situ hybridisation remained 
unstained, indicating specificity of the probes. B-D. The uninjured and injured side 
of the spinal cord for Robo1 (B), Slit2 (C) and Slit3 (D) in situ hybridisation 
revealed similar patterns and intensities of expression. E. RT-PCR for Robo1, 
Robo2, Robo4, Slit1 and Slit2 showed unchanging band intensities at all four time 
points post-sciatic nerve transection between the uninjured and injured side of the 
spinal cord. These results indicate that mRNA levels of the Slit/Robo members 
were unchanged following sciatic nerve transection, in the L4-L5 region of the 







Figure 8.5 Slit/Robo expression appears similar in uninjured and injured 
sides of the L4-L5 spinal cord. Two-month-old C57BL/6 mice underwent sciatic 
nerve transection, and seven days post-sciatic nerve transection the L4-L5 region 
of the spinal cord was removed and stained. Spinal cords were stained with 
Robo1 (A), Robo2 (B), Slit2 (C) and Slit3 (D). Staining revealed no apparent 
changes between the injured (I) and non-injured (UI) side for any Slit/Robo. 
Indicating that protein levels of Robo1 and Robo2 and Slit2 and Slit3 remained 
unchanged seven days after sciatic nerve transection, in the L4-L5 spinal cord 
region. (n=3) (A-D scale bar=500µm) 
A Robo1 B Robo2 












Previous work on Slit/Robo expression in the cell bodies of the sciatic nerve after a 
peripheral nerve injury has not been systematically studied. Here we provide a 
systematic approach to map changes in the expression patterns of Slit/Robo in 
sciatic nerve cell bodies after sciatic nerve transection.  
We used RT-PCR and in situ hybridisation to map Slit/Robo mRNA changes in both 
the L4-L5 DRG and spinal cord after sciatic nerve transection. We report no changes 
to Robo1, Robo2 or Slit1-3 mRNA levels at any time point after sciatic nerve 
transection, in either the L4-L5 DRG or spinal cord [Figure 8.1 and 8.4].  
We also wanted to determine if Slit/Robo protein levels change in the L4-L5 DRG 
and spinal cord in response to sciatic nerve transection. We used IHC on seven days 
post-sciatic nerve transection L4-L5 DRG and spinal cord sections to address this 
question. Our results in the DRG determined no changes in Robo1, Robo2 or Slit1-3 
protein levels or localisation after sciatic nerve transection [Figure 8.2 and 8.3]. We 
also have shown no changes to Robo1, Robo2, Slit2 or Slit3 protein levels or 
localisation in the L4-L5 spinal cord after sciatic nerve transection [Figure 8.5]. 
With other groups reporting changes to the Slit/Robo mRNA levels following injury 
and strong staining observed in elongating axons of the proximal nerve stump for 
Robo1 and Robo2 [Figure 7.3 and 7.8], these results were unexpected and 
disappointing [Yi et al., 2006; Zhang et al., 2010; Zheng et al., 2012]. However, as 
previous studies were in rats and we looked at mice and only looked at some of the 
time points following injury the discrepancy could lie in the time difference in 
regeneration patterns between mice and rats. Furthermore, we had previously 





[Figure 3.1 and 3.4]. Therefore, this strong expression could have continued 
following axotomy and may be enough to mount a response to the injury. In addition 
to this, cell bodies were previously producing enough protein to supply the whole 
nerve, however, following axotomy the protein level would only need to supply up to 
the proximal stump within the first week of injury. Therefore, although an increase in 
expression may not be seen at the cell body, there could be a potential increase at 
the axonal tip. 
RT-PCR is a useful method to determine is mRNA is expressed or not in the sample. 
However, it is difficult to correctly quantify the expression profile and compare the 
uninjured and injured side. However, our in situ hybridisation result suggest similar 
results supporting our findings using RT-PCR. The best current method to produce 
quantifiable and reliable data would be to use QPCR on the two data sets to 
establish if there were any mRNA changes between the uncut and cut samples.  
Our results to determine protein expression were all based on using IHC. We have 
previously discussed that unspecific staining by the secondary antibody can be a 
problem. We have addressed this by providing no primary controls for the 
secondaries we used in both DRG and spinal cords [Figure 5.9, 6.15 and 6.16]. To 
further support the IHC finding’s western blot data would have been informative on 
protein changes within the cell bodies. Another method we could have used was 










 Previous knowledge of Slit/ Robo 
in spinal cord following injury. 
Our data within the spinal cord in response 
to injury 
Slit1 No data RT PCR: mRNA present no changes 
observed. 
 
Slit2 No data RT PCR: mRNA present no changes 
observed. 
In-situ: Staining similar on both the uncut and 
cut side of both spinal cord. 
IHC: Similar intensities and staining patterns 
on both the uncut and cut side of spinal cord. 
Slit3 No data In-situ: Staining similar on both the uncut and 
cut side of both spinal cord. 
 IHC: Similar intensities and staining patterns 
on both the uncut and cut side of the spinal 
cord.  
Robo1  No data 
 
RT PCR: mRNA present no changes 
observed. 
In-situ: Staining similar on both the uncut and 
cut side of both spinal cord.  
IHC: Similar intensities and staining patterns 
on both the uncut and cut side of the spinal 
cord.  
Robo2 No data RT PCR: mRNA present no changes 
observed.:  
IHC: Similar intensities and staining patterns 
on both the uncut and cut side of the spinal 
cord.  
Table 8.1: Table of currently known knowledge around changes to Slit/Robo expression 
in the spinal cord following sciatic nerve transection and the knowledge this study has 
















 Previous knowledge of Slit/Robo 
in the DRG following sciatic nerve 
injury. 
Our data within the DRG before and after 
injury. 
Slit1 Slit1 mRNA upregulation 14 days 
post cut in DRG in rats [Yi et al., 
2006]. 
Slit1 mRNA expression upregulated 
following transection in rats [Zhang 
et al., 2010]. 
 
RT PCR: mRNA present no changes 
observed. 
In-situ: Staining in DRG from cut and uncut 
side similar. 
 IHC: Similar intensities and staining patterns 
on both the uncut and cut side of the spinal 
cord. 
Slit2 No data RT PCR: mRNA present no changes 
observed. 
In-situ: Staining in DRG from cut and uncut 
side similar. 
IHC: Similar intensities and staining patterns 
on both the uncut and cut side of the spinal 
cord. 
Slit3 No data RT PCR: mRNA present no changes 
observed. 
In-situ: Staining in DRG from cut and uncut 
side similar. 
IHC: Similar pattern and intensity of staining 
seen in DRG in uncut and cut side. 
Robo1 Robo1 mRNA levels increase in rat 
L4-L6 DRG seven and fourteen 
days post-sciatic nerve transection 
[Zheng et al., 2012].  
Robo1 protein expression increase 
in rat DRG seven days following 
nerve injury has also been observed 
[Zheng et al., 2012]. 
 
RT PCR: mRNA present no changes 
observed. 
IHC: Similar pattern and intensity of staining 
seen in DRG in uncut and cut side. 
Robo2 Robo2 mRNA expression 
upregulated following transection in 
rats [Zhang et al., 2010]. 
Robo2 mRNA upregulation in 
sensory cell bodies seven days post 
cut in rats [Yi et al., 2006] 
Protein upregulation observed in 
large cell bodies and their axons in 
rats following axotomy [Yi et al., 
2006]. 
RT PCR: mRNA present no changes 
observed. 
In-situ: Staining in DRG from cut and uncut 
side similar. 
IHC: Similar pattern and intensity of staining 
seen in DRG in uncut and cut side. 
Table 8.2. Table of currently known knowledge around changes to Slit/Robo expression 
in DRG following sciatic nerve transection and the knowledge this study has contributed 






Chapter 9 Peripheral nerve regeneration in Slit/Robo mutant mice 
9.1 Introduction 
Previous work has established that Slit/Robo mutants have disrupted axonal 
pathfinding during CNS development. In Slit1 and Slit2 double knockout mice, the 
development of the optic chiasm is severely disrupted. Axons of the optic nerve in 
these mutants projected aberrantly into the incorrect optic nerve tract [Plump et al., 
2002].   
Slit1, Slit2 and Slit3 triple knockout mice also have severely disrupted commissural 
axon development. In these triple knockouts, axons appeared to project into 
incorrect areas of the floorplate, with some appearing to re-cross the floorplate. The 
same study identified disrupted axon pathfinding in the floor plate in Robo1 deficient 
mutants, with many axons also appearing to have stalled growth [Long et al., 2004]. 
Bagri et al., (2002) also identified that in the internal capsule of the telencephalon 
severely abnormal axon trajectories were present in Slit2 homozygous mutants. 
These mice also exhibit abnormal development of the corpus callosum, due to 
corticocortical projections becoming misguided and therefore not reaching the 
corpus callosum [Bagri et al., 2002]. 
The above evidence shows us that Slit/Robo mutants have disrupted axon 
pathfinding during CNS development. Axon pathfinding during peripheral nerve 
regeneration, following nerve transection, is imperative for reinnervation and the 
regain of function.  
However, no evidence is available that determines if axonal pathfinding during 
peripheral nerve regeneration is affected in Slit/Robo mutants. We previously 
determined that elongating axons and SCs expressed Robo1 strongly, and Slit3 





cells [Chapter 7]. Therefore, we wanted to try and establish the role of the Slit/Robo 
signalling we had previously observed [Chapter 7]. To do this, we used Slit/Robo 
mutants to try and establish any effects on peripheral nerve regeneration due to loss 
of function of these proteins.  
During these experiments, heterozygous mutants were used due to the embryonic 
lethality of some of the mutants previously discussed in Chapter Two. In some 
cases, heterozygous mutants were used due to breeding limitations and time 
restraints.  
It is important we study the effects on peripheral nerve regeneration in Slit/Robo 
mutants to try and decipher their role in peripheral nerve regeneration. With 
previously results we have shown expression but not function. Therefore, these 
experiments were aimed at trying to elucidate this. This work is an important factor in 
understanding the role of Slit/Robo during peripheral nerve regeneration and 
therefore how we may be able to harness this pathway in potential therapies of the 















9.2.1 Axonal pathfinding in Slit/Robo mutants during peripheral nerve 
regeneration 
To observe axon pathfinding, we used a whole mount staining technique 14 days 
post-sciatic nerve transection; neurofilament antibody was used to identify axons. 
This allows visualisation of the organisation of axons across the nerve bridge. Axons 
should leave the proximal stump, pass across the nerve bridge and enter the distal 
stump with few axons diverging from this path. Axon pathfinding that does not 
adhere to this pattern can be identified as disrupted [Dun, X-P & Parkinson, D. 
2015].  
In control animals, regenerating axons leave the proximal stump, cross the nerve 
bridge and enter the distal stump in an organised manner [Figure 9.1]. Slit1KO, 
Slit2Het, and Robo2Het mutants have similar phenotypes to that seen in the control 
mice. In Slit1KO, Slit2Het and Robo2Het mutant’s axons elongate from the proximal 
stump into the nerve bridge, and enter the distal stump, with little disturbance to 
axonal pathfinding compared to control mice [Figure 9.1B, C and D]. Dr Xin-Peng 
quantified how many axons could be observed leaving the nerve bridge in these 
mutants but found no statistical difference between these mutants and the controls 
[Figure 9.1K]. 
In comparison, Robo1Het mice have a disrupted phenotype. In Robo1Het mice, axons 
leave the proximal stump and enter the nerve bridge. However, once the axons 
reach the nerve bridge, many appear to leave the nerve bridge and do no enter the 
distal stump [Figure 9.1]. Dr Xin-Peng’s work established that on average 100 axons 
leave the nerve in Robo1Het mutants, this is statistically significant in comparison to 





A similar phenotype to that seen in the Robo1Het mutant can be observed in the 
Slit3Het mutant. Again, axons do elongate out of the proximal stump, but upon 
entering the nerve bridge, they appear to become misguided. Many axons leave the 
nerve bridge and are subsequently not able to enter the distal stump [Figure 9.1]. Dr 
Xin-Peng’s work further established that on average 60 axons leave the nerve in 
Slit3Het mutants and that on average 110 axons leave the nerve bridge in Slit3KO 
mutants. These results were both statistically significant in comparison to the 
C57BL/6 controls where only ten axons leave the nerve bridge on average [Figure 
9.1K]. 
The double Robo1HetSlit3Het mutants have an even more severe phenotype than that 
observed in the single mutants. Axons entering the nerve bridge appear to become 
misguided, with many more axons leaving the nerve bridge than in the single 
mutants [Figure 9.1]. Dr Xin-Peng calculated that on average a total of 200 axons 
could be observed leaving the nerve bridge. This was a statistically significant result 
in comparison to controls. Furthermore, Dr Xin-Peng’s work also revealed that 
statistically less axons could be observed entering the tibial nerve in the 



































Figure 9.1: Slit3 and Robo1 have defects in axonal pathfinding, 14 days post-
sciatic nerve transection. Two-month-old Slit/Robo mutant and control mice 
underwent sciatic nerve transection surgery and the nerves were removed 14 days 
later. Nerves were stained with neurofilament antibody, using a whole mount 
technique. This figure is a combined effort between Dr Xin-Peng Dun and myself. 
In all images the nerve bridge is indicated between two dotted lines. A. The sciatic 
nerve 14 days post injury taken from a control mouse shows axons leaving the 
proximal stump, crossing the nerve bridge (white arrows), and entering the distal 
stump in a coordinated manner. B-D. Slit1KO, Slit2Het and Robo2Het showed similar 
axon patterning to the control mice, with axons crossing the nerve bridge in an 
organised way. Indicating no apparent defects in axonal pathfinding. E, F. In 
comparison, Slit3Het (E) and Robo1Het (F) sciatic nerves both display disrupted 
axon pathfinding. Axons attempt to cross the nerve bridge, however, many axons 
leave the nerve bridge in a disorganised manner (orange arrows), and do not enter 
the distal stump. H. The double mutant Robo1HetSlit3Het have a much more severe 
phenotype, with many axons appearing to leave the nerve bridge (white arrows) 
and few axons entering the distal stump. I. Axons entering the distal stump 14 days 
post-injury in a C57BL/6 control mouse. J. Noticeable fewer axons enter the distal 
stump in a double Robo1HetSlit3Het mutant in comparison to the control. K. 
Quantification of axons leaving the nerve bridge in the Slit/Robo mutants. A 
significant increase in axons leaving the nerve bridge can be observed in the single 
Slit3 and Robo1 mutants and a further significant increase can be seen in the 
Robo1HetSlit3Het mutant. L. Quantification of axons entering the tibial nerve in 
C57BL/6 control mice and Robo1HetSlit3Het mutant shows a significant decrease in 
axons entering the tibial nerve in the Robo1HetSlit3Het mutant compared to the 







9.2.2 Fibroblast migration patterns in Robo1Het mutants during peripheral nerve 
regeneration 
During peripheral nerve regeneration, fibroblasts fill the nerve bridge [Schröder et al., 
1993] that are involved in SC sorting. SC sorting is important for supporting 
elongating axons across the nerve bridge [Parrinello et al., 2010]. Therefore, we 
wanted to determine how fibroblast migration was affected in the Robo1Het mutant, 
as axon pathfinding is disrupted in this mutant [Figure 9.1].  
Robo1Cntrl and Robo1Het mice underwent sciatic nerve transection surgery, and 
seven days post-sciatic nerve transection the nerve was removed and longitudinally 
sectioned. The sections were stained with the primary antibody fibroblast marker 
fibronectin and Hoechst. In the Robo1Het mutant, clusters of fibronectin-positive cells 
appear to migrate away from the injury site. In comparison, in the Robo1Cntrl mice, 
fibronectin-positive cells appeared confined to the nerve bridge [Figure 9.2].  This 








B Robo1Het Ho Fibronectin 
A Robo1Cntrl Ho Fibronectin 
Figure 9.2: Robo1Het mice display disrupted fibroblast migration patterns 
seven days post-sciatic nerve transection.  Two-month-old Robo1Cntrl and 
Robo1Het mice underwent sciatic nerve transection surgery and nerves were 
removed seven post-sciatic nerve transection. Sections of nerves were stained 
with fibronectin and counterstained with Hoechst. A. Robo1Cntrl mice fibroblasts 
appeared confined to the nerve bridge, bridging the proximal stump and distal 
stump. B. In comparison, the Robo1Het sections reveal aberrant fibroblast 
migration (white arrows) away from the nerve bridge and the injury site. However, 
some Robo1Het mutant fibroblasts also crossed the nerve bridge from the 
proximal stump to the distal stump in a similar manner to the Robo1Cntrl mouse. 





9.2.3 Myelin clearance after sciatic nerve transection in Slit2, Slit3 and Robo1 
mutants 
During Wallerian degeneration SCs undergo reprogramming which results in the 
downregulation of myelin markers and the upregulation of markers of immature SCs 
such as ERK 1/2 and c-Jun [Arthur-Farraj et al., 2012; Harrisingh et al., 2004; Kim et 
al., 2013; Le et al., 2005; Napoli et al., 2012; Parkinson et al., 2008; Yang et al., 
2012].  During the reprogramming process, SCs must clear the myelin debris in the 
distal stump for successful regeneration to occur, they do this through myelinophagy 
and the recruitment of macrophages [Fex et al., 2013; Gomez-Sanchez et al., 2015; 
Jung et al., 2011]. c-Jun is a global regulator of SC reprogramming during 
regeneration, one mechanism by which c-Jun regulates reprogramming of SCs is by 
inhibiting the expression of the transcription factor Krox20 [Parkinson et al., 2008; 
Arthur-Farraj et al., 2012]. Ras/Raf/ERK signalling also drives the reprogramming of 
SCs, and within 48h of the activation of this pathway in SCs the complete loss of 
differentiation markers can be observed, revealing a central role of ERK1/2 signalling 
during regeneration [Harrisingh et al., 2002; Napoli et al., 2012] 
We wanted to determine if SC reprogramming and myelin clearance were affected in 
Slit/Robo mutants. To address this question, we performed a sciatic nerve 
transection on Robo1Het, Slit2Het and Slit3Het mutant mice and their littermate 
controls. Four or seven days post-sciatic nerve transection we removed the distal 
nerve stump tissue. The distal nerve stump tissue was then processed for western 
blotting. Myelin basic protein (MBP) and myelin protein zero (MPZ) primary 
antibodies were used to analyse myelin clearance. c-Jun and p-ERK1/2 primary 





Myelin protein levels, MBP and MPZ, in Robo1Het mice four days post-sciatic nerve 
transection did not appear different to Robo1Cntrl mice [Figure 9.3]. However, seven 
days post-injury both MPZ and MBP appeared to be present at slightly lower levels 
in the Robo1Het mice in comparison to Robo1Cntrl mice. However, Robo1Het mice did 
not appear to display any changes in c-Jun or p-ERK1/2 expression after sciatic 
nerve transection in comparison to Robo1Cntrl mice at either four or seven days. 
These results hints at a potential role in Robo1 in myelin clearance following sciatic 
nerve transection. However, further repeats need to be done to establish if there is a 
significant link between the downregulation of Robo1 and myelin clearance following 
injury.  
Levels of both MBP and MPZ did not appear different between the Slit2Het and 
Slit2Cntrl distal nerve stumps after sciatic nerve transection, at either four or seven 
days post-transection [Figure 9.3]. This result indicates that Slit2Het mice had no 
changes in the rate of myelin clearance after sciatic nerve transection in comparison 
to Slit2Cntrl mice. 
MBP was present at similar levels in both the distal stump from Slit3Het mice and the 
distal stumps from Slit3Cntrl mice at four days post-injury. However, at seven days 
post-sciatic nerve transection there appeared to be less MBP in the Slit3Het distal 
stump in comparison to the Slit3Cntrl distal stump. No differences could be observed 
in MPZ levels from the distal stumps from Slit3Het mice, at four or seven days post 
sciatic nerve transection, in comparison to distal stumps from Slit3Cntrl mice [Figure 
9.3]. This result indicates that MBP clearance may be accelerated in Slit3Het mice 
seven days after injury in comparison to Slit3Cntrl mice, however, more repeats need 
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Figure 9.3: Myelin clearance in Robo/Slit mutants. Two-month-old Slit2Het, Slit3Het 
and Robo1Het mice underwent sciatic nerve transection surgery with their control 
counterparts. At four and seven days post-sciatic nerve transection the distal stump 
was removed and prepared for western blotting. A. Western blotting results from 
Robo1Cntrl (+/+) and Robo1Het (+/-) mice. B. Western blotting results from Slit2Cntrl 






9.2.4 Functional recovery in Robo1 mutants after peripheral nerve injury 
One way to analyse recovery after a peripheral nerve injury is the analysis of gait. 
Gait is a direct reflection on the recovery of function to the affected limb. The static 
sciatic index (SSI) is a method of gait analysis; it is a simple measurement of toe 
spread and paw length that is a reliable measure of reinnervation after a sciatic 
nerve crush [Baptista et al., 2007]. The peroneal functional index (PFI) also analyses 
gait to give a measure of function, following a peroneal nerve lesion [Inserra et al., 
1998]. The peroneal nerve lesion does show recovery of function following 
transection due a relatively small gap, unlike the sciatic nerve transection [Baptista et 
al., 2007]. 
As Robo1Het mutants displayed disrupted axonal pathfinding and disrupted fibroblast 
migration, we wanted to determine if the functional recovery in Robo1Het mutants is 
affected after a peripheral nerve injury, in comparison to Robo1Cntrl mice. After a 
sciatic nerve transection the injury is too severe to regain any function without a 
repair, so we had to adopt a different injury approach [Baptista et al., 2007]. In 
comparison to a sciatic nerve transection, mice that have sustained a peroneal nerve 
cut or a sciatic nerve crush regain function within a matter of weeks [Menorca et al., 
2013]. Both these models can, therefore, be used to assess whether there is a 
change in functional recovery following injury. A crush model has a much faster 
recovery speed due to the maintenance of the Bands of Bugner that elongating 
axons can use as guidance to re-innervate their target [Menorca et al., 2013]. During 
a peroneal cut injury, the size of the bridge is considerably smaller than that of the 
sciatic nerve. The axons therefore have a small distance to transverse over the 





We performed a sciatic nerve crush or a peroneal nerve transection on Robo1Het and 
Robo1Cntrl mice. At time intervals, pre-injury and post-injury, we analysed the gait of 
the affected and unaffected limb to generate the SSI or PFI. We then compared the 
Robo1Het mutant with the Robo1Cntrl results, to determine if there were any significant 
differences in recovery. 
Our results for both the peroneal transection experiment [Figure 9.4] and the sciatic 
nerve crush experiment [Figure 9.5], revealed no significant differences in functional 
recovery between the Robo1Het and Robo1Cntrl mice at any time point. This indicates 


























Figure 9.4: Robo1Het and Robo1Cntrl mice have similar recovery patterns 
after a peroneal cut. Two-month-old Robo1Het and Robo1Cntrl mice underwent 
peroneal cut surgery. Before and after surgery the PFI was taken as a measure of 
function. Figure 9.3 shows a plot of the PFI data collected. Results reveal no 
significant differences (p=<0.05) in functional recovery at any time point after 
injury. This shows that Robo1Het and Robo1Cntrl mice re-establish function at a 





 displayed no significant differences, at
any time point, in functional recovery after a peroneal nerve cut





















































Figure 9.5: Robo1Cntrl and Robo1Het both recovered functionally at similar 
rates after sciatic nerve crush.  Two-month-old Robo1Het and Robo1Cntrl mice 
underwent sciatic nerve crush surgery. Before and at various time points after 
surgery, the SSI was taken as a measure of function. Robo1Cntrl and Robo1Het 
mice displayed no significant difference (p=<0.05) in function at any time point 
after injury. This indicates that Robo1Cntrl and Robo1Het had similar rates of 
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Our previous work had struggled to identify Slit1 in axons of the uncut nerve and the 
associated motor cell bodies [Figure 6.9]. However, we could strongly detect Slit1 in 
sensory cell bodies of the sciatic nerve [Figure 5.5], and Slit1 appeared to be 
expressed in some axons during regeneration [Figure 7.9], presumably sensory 
axons. It was therefore relatively unsurprising that in the Slit1KO mutant no 
regeneration defects were observed [Figure 9.1].  
In the Slit2 heterozygous mutant axons also crossed the nerve bridge similarly to 
that observed in the control [Figure 9.1]. We had previously observed Slit2 staining in 
axons and weak staining in surrounding cells in both the uncut and cut nerve [Figure 
3.5 and 7.10].  As Slit2 is expressed in the uncut nerve, it is surprising that in the 
mutant there are no changes in the regeneration pattern of axons. However, this 
could be potentially because Slit2 does not play a role in regeneration or that in the 
heterozygous mutant the allele present is sufficient to maintain function.  
Both the Slit3 and Robo1 heterozygous mutants have disturbed axon regeneration 
patterns in comparison to the control, with around 100 axons leaving the nerve 
bridge in comparison to their control counterparts where only around ten axons leave 
the nerve bridge [Figure 9.1]. This was an exciting and unsurprising result due to the 
strong expression of Robo1 and Slit3 during peripheral nerve regeneration in the cut 
nerve [Figure 7.3, 7.5 and 7.16]. This supports our theory that Slit3 positive 
macrophages surround the nerve bridge to direct Robo1 expressing cells towards 
the nerve bridge. Therefore, when there is loss of function in the perimeter or 
through the axons being less receptive to the perimeter then axons start to leave the 
bridge in a disorganised manner. This idea was further ratified through the 





axons, with around 200 axons leaving the nerve bridge in comparison to the single 
mutants [Figure 9.1] 
As we had previously shown that Robo2 was strongly expressed in axons of the 
proximal nerve stump [Figure 7.8], it was surprising that the nerve appeared to 
regenerate like that of the control with an insignificant number of axons leaving the 
nerve bridge [Figure 9.1]. As axons in the proximal nerve stump express Robo2 
[Figure 7.8] and a perimeter of Slit3 positive macrophages surround the nerve bridge 
[Figure 7.12 and 7.14], we thought it plausible that Robo2 would also act as a 
receptor for Slit3 and contribute to the guidance of axons across the nerve bridge 
and therefore when Robo2 was mutated guidance would be affected. However, 
axons appeared to cross over the nerve bridge and enter the distal nerve stump in 
an orchestrated manner. As we had also observed Robo2 in axons of the uncut 
sciatic nerve [Figure 3.4], it is plausible that Robo2 continues to be expressed in 
association with the role it plays in uninjured axons, which remains to be shown. 
Furthermore, with the mutant being heterozygous there is a potential that one allele 
is enough to coordinate correct migration of axons across the bridge.  
As we had previously observed axon migration disorganisation in Robo1 
heterozygous mutants, we wanted to explore if the migration pattern of other cells in 
the nerve bridge was disrupted in these mutants. We observed that fibroblasts in 
Robo1 heterozygous mutants appeared to migrate away from the nerve bridge in a 
disorganised pattern like that observed in axons [Figure 9.2]. This would suggest that 
Slit3 macrophages not only guide axons across the nerve bridge but also other cells 
involved in peripheral nerve regeneration. This is unsurprising as fibroblast, and SCs 





correct trajectories. Therefore, these cells themselves need to have the correct 
trajectories, and Slit3 positive macrophages may be a factor guiding them.  
During Wallerian degeneration, Robo1Het mice have some evidence of accelerated 
myelin clearance in the distal stump, in comparison to Robo1Cntrl mice [Figure 9.3]. 
However, it remains unclear as to how Robo1 could be contributing to the control of 
myelin clearance. In comparison, neither Slit3Het nor Slit2Het mice displayed 
significant changes in myelin clearance in comparison to control mice [Figure 9.3]. 
In functional tests, Robo1Het mice show no significant changes in rates of functional 
recovery in comparison to Robo1Cntrl mice [Figure 9.4 and 9.5]. This was a very 
surprising result as we had observed axons leaving the nerve bridge during 
regeneration in the Robo1Het mutant [Figure 9.1], we would, therefore, presume to 
observe delayed functional recovery in the Robo1Het mutants as less axons would 
reach their innervation sites. This may be due to the type of injury inflicted during the 
study, as the functional tests used a peroneal cut and sciatic nerve crush injury in 
comparison to a sciatic nerve cut which we used to observe axon regeneration 
patterns.   
In the crush study axons regenerate differently and do not have to migrate across a 
nerve bridge, instead following bands of Bugner created by SCs. As a nerve bridge 
does not exist in this type of injury Slit3 positive macrophages, do not need to guide 
Robo1 positive axons across the nerve bridge, and therefore there was no negative 
effects on functional recovery. This lack of a phenotype could also be due to the 
heterozygous nature of the Robo1 mutant.  
In the peroneal nerve injury model, the nerve bridge is relatively smaller than that 
observed in the sciatic nerve injury. Therefore, axons do not have as far to elongate 





normally in the Robo1Het mice following this injury model, it could suggest that 
signals from the distal nerve stump may be sufficient to guide axons in smaller 
injuries. Furthermore, axons did successfully cross the nerve bridge in the Robo1Het 
mutant following sciatic nerve transection it could be that these axons are sufficient 
to regain function. 
We have previously shown that there is a gene dosage effect in the Robo1 and Slit3 
mutants suggesting these models are reliable to assess the effects on peripheral 
nerve regeneration in Robo1/Slit3 heterozygous mutants [Figure 4.7]. However, we 
could have inhibited Slit/Robo function using other methods such as by placing an 
osmotic pump under the skin to deliver siRNA to the injury site. This would have 
inhibited the effects of Slit/Robo at the injury site potentially completely unlike in the 
heterozygous mutants were some functional Slit3/Robo1 proteins persist.  
The functional scores are both reliable methods to assess motor functional recovery. 
However, they do not assess sensory functional recovery. We could have used Von 
Frey hairs or a hot plate following injury; this would have determined if there were 








































Chapter 10: Discussion 























 Sciatic nerve L4-L5 DRG L4-L5 spinal cord 
Slit1 Only detectable via western blot +++ Dorsal neurons ++ 
Ventral neurons ++ 
Slit2 Axons ++  
Myelinating Schwann cells +++ 
Non-myelinating Schwann cells +++ 
Fibroblasts ++ 
++ Dorsal neurons + 
Ventral neurons ++ 
Slit3 Axons ++ 
Myelinating Schwann cells +++ 
Non-myelinating Schwann cells +++ 
Fibroblasts ++ 
++ Dorsal neurons ++ 
Ventral neurons ++ 
Robo1 Axons ++ 
Myelinating Schwann cells ++ 
Non-myelinating Schwann cells ++ 
Fibroblasts ++ 
Endothelial cells ++ 
++ Dorsal neurons ++ 
Ventral neurons +++ 
Astrocyte +++ 
 
Robo2 Axons ++ +++ Dorsal neurons ++ 
Ventral neurons ++ 
 
Key: 
+ low expression; 
++ medium expression; 
+++ high expression. 
Table 10.1 Summary table of Slit/Robo expression in the intact peripheral 






10.1.1 Robo1 and Robo2 expression in neurons of the adult peripheral nervous 
system. 
As the Slit/Robo signalling system has been shown to play a pivotal role in axon 
pathfinding during development, we wanted to examine whether Slit and Robo family 
members were also expressed in axons of the adult PNS [Brose et al 1990; Itoh et 
al., 1998; Kidd et al., 1999; Wong et al., 2001]. We identified Robo1 expression in 
both large calibre myelinated axon and small calibre non-myelinated axons in 
approximately 83% of axons [Figure 3.1, Table 10.1]. We also determined that 
Robo2 was expressed in 98% of axons of the sciatic nerve, agreeing with previous 
work that established that Robo2 was expressed in primary sensory axons in adult 
rats [Figure 3.4] [Yi et al., 2006; Zhang et al., 2010].   
As axons of the sciatic nerve express Robo1 and Robo2, we investigated whether 
the cell bodies of these axons also expressed Robo1 and Robo2. The cell bodies of 
sensory axons of the sciatic nerve reside in the L4-S3 DRG, and motor axon cell 
bodies reside in the grey matter of the L4-S3 spinal cord. Robo1 staining, on tissue 
samples of cell body regions, confirmed that Robo1 is expressed in both motor and 
sensory cell bodies of the sciatic nerve [Figure 5.3 and 6.3, Table 10.1]. The 
presence of Robo1 in motor and sensory cell bodies agrees with other studies, 
indicating that Robo1 is synthesised in cell body neurone [Li et al., 2017: Liu et al., 
2011; Jacobi et al., 2014; Zheng et al., 2012].  
Robo2 mRNA and protein expression have been previously documented in sensory 
cell bodies of L5-L6 DRG from rats [Bloechlinger et al., 2006; Yi et al., 2006; Zheng 
et al., 2012; Zhang et al., 2012]. In agreement with this work, we have also shown 
that Robo2 mRNA and protein is expressed in the cell bodies of L4-L5 DRG in adult 





mRNA and protein was expressed in the motor cell bodies of the L4-L6 spinal cord 
from C57BL/6 mice, which parallels previous work showing Robo2 mRNA 
expression in the cervical spinal cord of mice [Figure 6.7] [Jacobi et al., 2014]. 
Robo1 and Robo2 are chemorepulsive cues used by axons during development, 
therefore, it is possible that the expression of Robo1 and Robo2 in the cell body and 
axon of neurons plays a role in maintaining its structure by inhibiting aberrant 
sprouting [Brose et al., 1990; Itoh et al., 1998; Kidd et al., 1999].  
10.1.2 Robo1 and Robo2 expression in glial cells of the intact adult peripheral 
and central nervous system. 
We looked at the expression of Robo1 in SCs, astrocytes and oligodendrocytes. We 
confirmed that Robo1 is expressed in myelinating SCs of the sciatic nerve in mice, 
this finding is in agreement with Wang et al., (2013), who verified that Robo1 mRNA 
and protein were expressed in SCs in vitro and in vivo [Figure 3.2]. Furthermore, we 
quantified the number of SCs that Robo1 was expressed in and determined that 85% 
of SCs express Robo1. Wang et al., also showed that upon exposure to Slit-2N 
fragments cultured SCs were repelled and migrated away from the source of the 
fragment in vitro. This suggests that the expression of Robo1 in myelinating SCs in 
vivo could be playing a role in repelling SCs away from axons and maintaining the 
periaxonal space.  
A previous study did not detect the presence of Robo2 mRNA in cultured SCs [Wang 
et al., 2013]. Our results confirmed that Robo2 expression was confined to axons of 
the sciatic nerve expressed in an insignificant number of SCs [Figure 3.4]. This result 






Robo2 expression in the L4-L6 spinal cord of C57BL/6 mice was confined to the 
motor cell bodies of the grey matter. However, Robo1 was also present in non-NeuN 
positive cells in the L4-L6 spinal cord. We confirmed that Robo1 is not expressed in 
axons within the spinal cord, in agreement with previously published results [Figure 
6.4] [Liu et al., 2011]. We also confirmed that Robo1 was not expressed in 
oligodendrocytes of the L4-L6 spinal cord [Figure 6.5]. However, our work 
determined that Robo1 was expressed in astrocytes of the L4-L6 spinal cord [Figure 
6.6]. Previous work has shown that Sema3a expression by astrocytes is important 
during development of the CNS for influencing sensorimotor circuit formation and 
may also coordinate postnatal neural circuit refinement [Molofsky et al., 2012]. 
Sema3a is a ligand that can elicit a chemorepulsive or chemoattractive cue through 
its receptors neuropilins, this shared chemorepellent function with Slit/Robo 
signalling could implicate a similar potential role for Slit/Robo in the mouse spinal 
cord [Antipenko et al., 2003; Fiore and Püschel, 2003; Polleux et al., 2000]. 
10.1.3 Robo1 expression in the vasculature of the peripheral nervous system 
We also documented the expression of Robo1 in the vasculature of the sciatic nerve, 
this novel finding has not been previously reported, however, the expression of 
Robo1 has been previously seen in vascular endothelial cells in other tissues [Figure 
3.3, Table 10.1] [Enomoto et al., 2016; Rama et al., 2015; Wang et al., 2003].  
The role of Slit/Robo signalling in vascular tissue is unclear with some papers 
suggesting a pro-angiogenic role while others suggest an anti-angiogenic role [Jones 
et al., 2008, 2009; Urbich et al., 2009; Zhang et al., 2009; Zhou et al., 2011]. It is 
possible that the angiogenic effect of Slit/Robo signalling is tissue specific. In the 
adult, the vasculature of the PNS needs to be maintained to ensure functional units 





anti-angiogenic role to maintain the vasculature or be expressed as a pre-emptive 
pro-angiogenic marker to respond if the vasculature becomes damaged.  
10.1.4 Peripheral nerve anatomy in Robo1 mutant mice 
As we had observed Robo1 expression in both axons and myelinating SCs in the 
adult sciatic nerve, we wanted to determine if the morphology of the sciatic nerve 
was altered in Robo1Het mutant mice. No significant difference in axon diameters or 
G-Ratio could also be observed between the Robo1Het and Robo1Cntrl mice 
(p=<0.05), and linear regression line for G-ratio against axon diameter were similar; 
thereby determining that these parameters remain unchanged in the Robo1Het mice 
[Figure 4.1 and 4.2]. This result may be reflective of the heterozygous nature of the 
mutant, as one allele may be sufficient to maintain the structure of the sciatic nerve. 
A SC or neuron-specific inducible knockdown of Robo1 would fully elucidate the role 
of Robo1 in SCs or neurons in the adult PNS. 
10.1.5 Slit expression in neurons of the adult peripheral nervous system 
 
Slits act as the ligands for the Robo receptors;  upon Slit binding downstream 
signalling cascades are activated that result in chemorepulsion and this plays an 
important role in axon pathfinding during development [Brose et al., 1999; Kidd et al., 
1999a; Holmes et al., 1998; Huminiecki et al., 2002; Itoh et al., 1998; Long et al., 
2004; Nakayama et al., 1998; Sabatier et al., 2004]. Previous work has also 
confirmed the expression of the Slit ligands in the cell bodies of adult neurons but not 
in their associated axons [Bloechlinger et al., 2004; Jacobi et al., 2014; Li et al., 
2017; Wehrle et al., 2005]. Our work has identified that both Slit2 and Slit3 are 
expressed in 75% and 88% respectively in the sciatic nerve [Figure 3.5 and 3.6]. We 
could not detect Slit1 using immunohistochemistry, however, we able to identify Slit1 





protein is expressed at a very low level or that our immunohistochemistry antibody 
was not binding to the Slit1 protein in our uncut adult sciatic nerve transverse 
samples.  The Slits’ important role in controlling axonal pathfinding and sprouting 
during development could suggest a role in the maintenance of the axon structure in 
the adult.  
 
Slit1 and Slit3 expression have previously been documented in sensory cell bodies 
of the DRG in vitro and in vivo [Bloechlinger et al., 2004; Yi et al., 2006; Zhang et al., 
2010]. However, the expression of Slit2 in the same cells has not been determined. 
Our results confirmed that Slit1, Slit2 and Slit3 mRNAs and proteins were expressed 
in sensory cell bodies in neurons of the sciatic nerve in C57BL/6 mice [Figure 5.5, 
5.6 and 5.7]. 
The expression of Slit1, Slit2 and Slit3 have been identified in the cervical mouse 
spinal cord and rat thoracic spinal cord [Jacobi et al., 2014; Li et al., 2017; Liu et al., 
2011; Wehrle et al., 2005]. We have shown that Slit1 is expressed in a subset of 
motor neuronal cell bodies, of the grey matter, in the L4-L5 murine spinal cord 
[Figure 6.9]. We verified that Slit2 and Slit3 are present in all motor cell bodies of 
neurons of the sciatic nerve in C56BL/6 mice [Figure 6.10 and 6.13]. We also 
determined that Slit2 is not expressed in oligodendrocytes or astrocytes of the L4-L6 
region of the spinal cord in C56BL/6 mice [Figure 6.11 and 6.12]. We further 
confirmed that Slit3 is not expressed in axons of the spinal cord of the same region 
and is confined to the cell bodies [Figure 6.14]. 
Slit1-3 appears to be expressed in the cell bodies and axons of neurons of the sciatic 
nerve. This ligand could be secreted and be involved in maintaining the structural 





could also be secreted in autocrine nature to inhibit any aberrant sprouting in the 
intact adult nerve.  
 
10.1.6 Slit expression in glial cells of the adult peripheral nervous system. 
Previous work identified the expression of Slit3 mRNA in cultured SCs, whereas Slit2 
mRNA was determined to be expressed in SCs of peripheral nerves both in vivo and 
in vitro [Fujiwara et al., 2008; Tanno et al., 2005; Wang et al., 2013].  
Our results confirmed previous work, determining that both Slit3 and Slit2 are 
expressed in 97% and 78% of SCs respectively of the sciatic nerve of C57BL/6 mice 
[Figure 3.5 and 3.7]. Slit2 expression in SCs appeared much weaker than that 
observed in axons. In comparison, Slit3 expression levels were higher level in SCs. 
Moreover, the expression of Slit3 in myelinating and non-myelinating SCs differed 
with Slit3 expression highest in non-myelinating SCs.  
Our findings show that Slit2 and Slit3 are expressed in adult SCs, this expression 
may play a role in inhibiting aberrant sprouting of axons that express Robo1 in the 
sciatic nerve. As Slit3 is expressed higher in non-myelinating SCs, it may play a 
more critical role in signalling to sensory axons and maintaining the structure of 
them. 
 
10.1.7 Sciatic nerve morphology in Slit2 and Slit3 mutant mice 
As we had previously established that Slit2 and Slit3 are expressed in axons and 
SCs of adult peripheral nerves, we wanted to determine if there were defects in 
sciatic nerve anatomy in Slit2 or Slit3 mutants. As Slit2 homozygous mutants are 





animals (Slit2Cntrl) to establish any defects. Slit3 homozygous mutants (Slit3KO) are 
viable so were used in contrast to Slit3 control animals (Slit3Cntrl).  
Previously, Plump et al., (2002) determined that Slit2Het mutants had a few defects in 
axon pathfinding during the development of the optic chiasm but reported that most 
axons extended along their normal path [Plump et al., 2002]. The anatomy of the 
phrenic nerve was studied in Slit3KO mutants, but this study reported that the density 
and length of branches and sub-branches were unchanged [Yuan et al., 2003]. 
We have shown that the average myelin sheath thickness in Slit2Het mice and Slit3KO 
mice was not statistically different to their controls. Slit2Het and Slit3KO mice also had 
a similar abundance of groups of G-Ratios in comparison to their controls. Moreover, 
G-Ratio increased at a similar rate when plotted against axon diameter in both the 
Slit2Het and Slit3KO animals in contrast to their controls. Furthermore, the average 
axon diameter from sciatic nerves of Slit2Het and Slit3KO mutants was not significantly 
different from their controls [Figure 4.3, 4.4, 4.5 and 4.6].  
Our work appears in agreement with other studies, namely that no significant 
changes can be observed in nerve morphology in the Slit2Het or Slit3KO mice. This 
may be due to the heterozygous nature of the Slit2 mutant, as one allele may be 
sufficient to protect the mutant from any defects in nerve morphology and 
myelination. Furthermore, Slit2 and Slit3 have the same binding capacity for Robo 
receptors. This may mean that even if both alleles of one gene are mutated, such as 
in the Slit3 homozygous knockout, the other Slit may be able to compensate for the 
loss of the other. To fully elucidate the role of both Slit2 and Slit3 in maintaining the 
architecture of the peripheral nerve, a double Slit2 and Slit3 conditional null mutant in 

















 Our data within the sciatic nerve following sciatic nerve injury 
Slit1 Western blot data:  
Slit1 protein is only present in uncut nerve and proximal nerve stump. 
IHC results: 
Proximal stump axons ++ 
Slit2 IHC results: 
Proximal stump axons ++ 
Fragmenting distal stump axons + 
Unknown cells within the nerve bridge + 
Slit3 IHC results: 
Macrophages surrounding nerve bridge +++ 
Proximal stump axons + 
Schwann cells + 
Robo1 IHC results  
Proximal stump axons +++ 
Schwann cells proximal stump and tip +++ 
Bridge and distal tip ++ 
Distal stump + 
Proximal stump endothelial cells ++ 
Bridge endothelial cells + 
Fibroblasts ++ 
Robo2 IHC results: 
Proximal stump axons +++ 
Key: 
+ low expression; 
++ medium expression; 
+++ high expression. 
Table 10.2 Summary table of Slit/Robo expression in the regenerating 





10.2.1 Robo1 expression during regeneration of vasculature in the nerve 
bridge following sciatic nerve transection. 
Following nerve transection, one of the first structures to form between the nerve 
stumps is a web of newly created blood vessels. In rats, three days post-sciatic 
nerve transection, endothelial cells begin to migrate into the nerve bridge and by six 
days after sciatic nerve transection blood vessels in the nerve bridge are fully 
formed. In mice, there is a delay in vasculature formation, but blood vessel formation 
is completed by seven days [Cattin et al., 2015; Dun and Parkinson, 2015]. 
Endothelial cells migrate from both the proximal and distal stump to form the web of 
blood vessels, which SCs then use as a scaffold to migrate into the nerve bridge 
[Cattin et al., 2015].  
We previously established that Robo1 is expressed in blood vessel cells of the 
uninjured adult sciatic nerve [Figure 3.3]. Slit/Robo signalling has been shown to 
have both proangiogenic and antiangiogenic effects in various tissues; this suggests 
it could play a role in the formation of blood vessels across the nerve bridge. 
Therefore, we investigated the expression of Robo1 in newly formed blood vessels 
of the nerve bridge.  
We have shown that Robo1 continues to be expressed in endothelial cells of the 
proximal stump and the distal nerve stump, however, Robo1 is expressed at much 
lower levels in newly formed blood vessels in the nerve bridge [Figure 7.1, Table 
10.2]. This result suggests that the expression of Robo1 is not an important element 
for the formation of vasculature across the nerve bridge. The higher expression of 
Robo1 in the already established blood vessels of the proximal and distal nerve 





in the sciatic nerve. Indeed, Robo1 and Robo4 have been proposed to have a role in 
the maintenance of adult blood vessel integrity [Jones et al., 2009]    
10.2.2 Slit/Robo expression during regeneration in neurons following sciatic 
nerve transection. 
In mice, axons begin to elongate towards the distal nerve stump at four days post-
sciatic nerve transection [Dun and Parkinson, 2015]. During development, elongating 
axons of the CNS express Robo1 on their growth cones and respond to the Slit 
ligands [Brose et al., 1999; Kidd et al., 1998]. Moreover, we have previously shown 
that Slit2, Slit3, Robo1 and Robo2 are expressed in axons of the adult uninjured 
sciatic nerve [Figure 3.1, 3.4, 3.5 and 3.6]. Therefore, we wanted to determine 
Slit/Robo expression in elongating axons that were traversing the nerve bridge.  
Previous work has determined that Robo1 is upregulated in large calibre axons, and 
Robo2 is upregulated in large diameter sensory neurons after axotomy [Yi et al., 
2006]. Zhang et al., (2010) also reported that Slit1-Robo2 signalling promoted 
neurite outgrowth in DRG explants, suggesting a role for Slit/Robo signalling during 
axonal elongation following sciatic nerve transection. 
Our work has determined that Slit1, Slit2, Robo1 and Robo2 are all expressed in 
elongating axons of the proximal stump [Figure 7.3, 7.4, 7.8, 7.9, 7.10 and 7.16, 
Table 10.2]. Furthermore, fragmenting axons in the distal stump express Slit1, Slit2 
and Robo1 at very low levels. Moreover, both motor and sensory cell bodies of 
neurons of the sciatic nerve continue to express Slit1-3, Robo1 and Robo2 following 
sciatic nerve transection [Figure 8.1, 8.2, 8.3, 8.4 and 8.5, Table 10.2]. This suggests 






As axons express both ligand and receptor, axons could be signalling in an autocrine 
nature during regeneration. This autocrine signalling could be influencing axon 
regeneration by inhibiting aberrant sprouting or influencing axon pathfinding. Axons 
could also be signalling in a paracrine manner to surrounding cells, such as other 
Robo1 expressing axons. This signalling could be used to influence axon migration 
patterns to stop axons elongating towards one another.  
10.2.3 Slit/Robo expression in glial cells during peripheral nerve regeneration 
following sciatic nerve transection. 
SC reprogramming, migration and organisation is crucial for regeneration following a 
transection injury. SCs migrate into the nerve bridge, and form cords traversing the 
proximal and distal stump, elongating axons then use the cords for directional 
guidance across the nerve bridge towards the distal nerve stump [Chen et al., 2005; 
Parrinello et al., 2010; Son and Thompson, 1995].  
Previously, we have shown that Slit2, Slit3 and Robo1 are expressed in SCs of the 
adult sciatic nerve as have others [Figure 3.2, 3.5 and 3.7, Table 10.1] [Wang et al., 
2013].  Wang et al., (2013) also observed that Slit/Robo signalling could influence 
the migration of SCs in a chemorepellent manner. Furthermore, Tanno et al., (2005) 
found upregulation of Slit2 in SCs in the distal stump following sciatic nerve 
transection. 
Our findings show that Slit3 and Robo1 are expressed in SCs of the regenerating 
nerve [Figure 7.5, 7.6 and 7.17, Table 10.2]. Moreover, in the regenerating nerve 
Slit2 expression is present at low levels in cells surrounding axons in both the 
proximal and distal stump [Figure 7.11, Table 10.2]. These cells could potentially be 
SCs as other groups have confirmed the upregulation of Slit2 in SCs following sciatic 





As previous work has shown that Slit2-Robo1 signalling has a chemorepulsive effect 
on SCs in vitro, it is plausible that activation of the Robo1 receptor in SCs also has a 
chemorepulsive effect during peripheral nerve regeneration.  
Our findings have shown that SCs express Slit3 during nerve regeneration, and 
others have demonstrated that Slit2 is also expressed by the same cells [Figure 
7.17]. SCs may be signalling in a paracrine manner to Robo expressing cells such as 
axons and other SCs of the nerve bridge. This signalling may influence migration 
patterns of cells and/or may inhibit abhorrent sprouting of axons as they cross the 
nerve bridge.  
10.2.4 Robo1 expression in fibroblasts during peripheral nerve regeneration 
following sciatic nerve transection. 
We have previously shown that Robo1 is present in SCs and axons of the nerve 
bridge. However, there were still Robo1 positive cells in the nerve bridge that were 
not SCs or axons [Figure 7.3,7.4, 7.5 and 7.6, Table 10.2]. Following sciatic nerve, 
transection fibroblasts fill the nerve bridge and influence SC sorting [Parrinello et al., 
2010]. Moreover, we had previously shown that Robo1 is expressed in areas where 
fibroblasts are present in adult sciatic nerves. Therefore, we hypothesised that these 
other Robo1 expressing cells could be fibroblasts and investigated this theory.  
Our work strongly suggested that Robo1 was expressed in fibroblasts that fill the 
nerve bridge following sciatic nerve transection [Figure 7.7]. Furthermore, recent 
work by Dr Xin-peng Dun has confirmed that Robo1 is expressed in fibroblasts of the 
nerve bridge using vimentin and Robo1 antibodies on seven days post sciatic nerve 
sections to show co-localisation. As fibroblasts express Robo1 in the nerve bridge, 
Slit/Robo signalling could be influencing their migration patterns through 





it is unlikely that axons are the source of the Slit ligand that influences fibroblast 
migration. We and others have shown that SCs express Slit2 and Slit3 during 
peripheral nerve regeneration, and fibroblasts and SCs have been previously shown 
to interact with one another to influence the migration patterns of SCs. It is possible 
that Slits secreted by SCs could influence migration patterns of fibroblasts, or 
another source of Slits may be influencing fibroblast migration. 
10.2.5 Slit3 expression in macrophages during peripheral nerve regeneration 
after sciatic nerve transection. 
An important function of macrophages, hematogenous and resident, during 
Wallerian degeneration is to assist SC in phagocytosis of myelin debris [Brück, 1997; 
Gomez-Sanchez et al., 2015; Martini, Fischer, López-Vales, and David, 2008]. SCs 
recruit macrophages to the site of injury, through the secretion of pro-inflammatory 
factors such as galectin-1, MCP-1 and LIF [Tofaris et al., 2002; Horie et al., 2004]. 
Galectin-1 then becomes oxidised in the extracellular space and stimulates 
macrophages to stimulate SC migration and axonal elongation into the nerve bridge 
[Gaudet et al., 2009; Horie et al., 1999; Horie et al., 2004].   
Moreover, macrophages have also been shown to direct the migration of SCs and 
endothelial cells into the nerve bridge through the secretion of VEGF-A [Cattin et al., 
2015]. Furthermore, the administration of VEGF to DRG cultures induced axonal 
outgrowth and application of VEGF to the nerve bridge increased axonal regrowth, 
suggesting a possible role of macrophages in axonal elongation and stabilisation 
[Hobson et al., 2000; Sondell et al., 1999].  
Macrophages have been shown to aid axon elongation and stabilisation through the 
release of neurotrophic factors, such as nerve growth factor [Heumann et al., 1987; 





shown to express Slit3 in vitro, where it appeared localised to the plasma membrane 
and mitochondria [Tanno et al., 2007].  
As previously discussed, macrophages have a profound effect on nerve 
regeneration, and previously Slit3 has been detected in LPS stimulated 
macrophages. Therefore, we wanted to determine if Slit3 was expressed in 
macrophages during peripheral nerve regeneration.  
Our work determined that Slit3-positive macrophages surround the nerve bridge 
seven days post-sciatic nerve transection [Figure 7.12 and 7.13, Table 10.2]. The 
Slit3-positive macrophages surround the area that sprouting axons elongate through 
and SCs and fibroblasts migrate into, appearing to form a natural conduit around the 
nerve bridge [Figure 7.15, 7.16, 7.17 and 10.1]. Macrophages expressing Slit3 are 
also present inside the proximal tip and the distal stump at this time point. Staining 
using our Slit3 antibody on Slit3KO samples displayed no positive stain, thereby 
validating our results [Figure 7.18].  
We suggest a model whereby macrophages establish a perimeter around the nerve 
bridge and these cells produce Slit3 [Figure 10.1A]. Robo1 expressing fibroblasts 
and SCs then migrate into the nerve bridge from the proximal and distal nerve 
stumps and are maintained within the nerve bridge by Slit3 expressing 
macrophages, the SCs form cords within the nerve bridge via fibroblast sorting 
[Figure 10.1A]. Robo1 expressing axons then begin to elongate following the SC 
cords but also using the Slit3 macrophages perimeter as guidance to ensure they 
continue to elongate towards the distal nerve stump and not out of the nerve bridge 
[Figure 10.2B]. The macrophage perimeter is maintained until the axons have 
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Figure 10.1: Model of Slit3-Robo1 signalling involvement during peripheral 
nerve regeneration. Based on our findings we propose the following mechanism of 
Slit3-Robo1 signalling during peripheral nerve regeneration A. Slit3 positive 
macrophages surround the nerve bridge as Robo1 positive macrophages migrate 
into the nerve bridge from the proximal and distal nerve stumps. B. Robo1 positive 
SC form cords across the nerve bridge under the influence of Robo1 positive 
fibroblasts. Robo1 expressing axons begin to elongate using the SC cords to guide 
them across the nerve bridge. Robo1 expressing axons respond to Slit3 expressing 
macrophages in a chemo-repulsive manor to migrate through the nerve bridge 
instead of out of the nerve bridge in a misguided manner C. Robo1 expressing axons 






10.2.6 Axonal regeneration patterns in Slit/Robo mutant mice. 
Previous work has established that axons of the CNS in Slit/Robo mutants have 
abnormal trajectories and exhibit stalled growth during development [Bagri et al., 
2002; Plump et al., 2002; Long et al., 2004]. Axon pathfinding during peripheral 
nerve regeneration is essential for re-innervation of targets following sciatic nerve 
transection. We have previously identified the expression of Slit/Robos in the intact 
adult nerve and during peripheral nerve regeneration [Carr et al., 2017]. We then 
wanted to determine how axon regeneration patterns are affected in Slit/Robo 
mutants.  
Whole mount staining of sciatic nerves from control animals, 14 days post-sciatic 
nerve transection, showed axons leaving the proximal stump, crossing the nerve 
bridge and entering the distal stump. No axons appeared to diverge from their 
course towards the distal stump. Slit1KO, Slit2Het, and Robo2Het mutants had the 
same phenotype seen in the control mice, and nerve regeneration appeared normal 
[Figure 9.1]. In all three of these mutants, the number of axons leaving the nerve 
bridge was not statistically significant to the number of axons leaving the nerve 
bridge in the control mouse [Figure 9.1].  
This suggests that Slit1 may not be important for axonal pathfinding and elongation 
during peripheral nerve regeneration. However, due to the heterozygous nature of 
the Slit2 and Robo2 mutants, it is difficult to establish whether the lack of phenotype 
is due to one allele being able to compensate for any defects or that they are not 
involved during axonal pathfinding. 
In comparison, Robo1Het and Slit3Het single mutants both have a severely disrupted 
phenotype [Figure 9.1]. In these mutants, axons begin to elongate towards the nerve 





misguided fashion, tending to elongate away from the nerve bridge instead of 
towards the distal nerve stump [Figure 9.1 and 10.2].  
The Robo1HetSlit3Het double mutant had a more severe phenotype than that 
observed in any single or other double mutant [Figure 9.1]. Two hundred axons were 
counted leaving the nerve bridge in comparison to approximately 100 axons in the 
single Robo1Het or approximately 120 axons in the Slit3Het mutants. These axons left 
the nerve bridge and migrated away from the bridge instead of towards the distal 
nerve stump [Figure 9.1 and 10.2]. 
10.2.7 Fibroblast migration patterns in Robo1Het mutants during peripheral 
nerve regeneration 
Fibroblasts fill the nerve bridge during peripheral nerve regeneration and are 
involved in SC sorting [Parrinello et al., 2010; Schröder et al., 1993]. As fibroblast 
migration proceeds axonal elongation into the nerve bridge, and axonal elongation is 
disrupted in the Robo1Het mutant, we wanted to determine if fibroblast migration was 
also affected.  
In Robo1Cntrl mice fibroblasts appeared confined to the nerve bridge, bridging the gap 
between the proximal and distal stump. In comparison clusters of fibroblasts in the 
Robo1Het mutant appear to migrate away from the nerve bridge [Figure 9.2 and 10.2].  
Our results confirm that Slit3-Robo1 signalling plays a vital role in correct axon 
pathfinding during peripheral nerve regeneration and suggest a role in fibroblasts 
migration pathway control. We propose a model where Slit3 is secreted from 
macrophages surrounding the nerve bridge, and this directs elongating Robo1 
expressing axons and migrating Robo expressing fibroblasts, so they are maintained 





In the Robo1Het mutant axons and fibroblasts are less sensitive to the Slit3 
macrophage expressing perimeter so elongated and migrate out of the bridge 
[Figure 10.2A]. In the Slit3Het mutants the macrophage perimeter does not produce 
enough Slit3 to maintain some of the Robo1 expressing axons and fibroblasts within 
the bridge, so they elongate and migrate away from the bridge [Figure 10.2B]. In the 
Robo1HetSlit3Het mutant, the phenotype is exaggerated, and more axons and 
fibroblasts leave the nerve bridge because axons and fibroblasts are not as sensitive 
to the Slit3 perimeter and the macrophages are not producing as much Slit3 to 
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Figure 10.2: Slit3/Robo1 single and double heterozygous mutants have 
disrupted axon and fibroblast pathfinding during peripheral nerve 
regeneration. A. In Robo1Het mutants both axons and fibroblasts are less responsive 
to the chemorepulsive effects of Slit3 expressing macrophages. This results in axons 
and fibroblasts migrating out of the ring of Slit3 positive macrophages and out of the 
bridge. This results in uncoordinated axon pathfinding and streams of fibroblasts 
migrating out of the nerve bridge. B. In Slit3Het mutant’s macrophages surrounding 
the periphery of the nerve bridge express Slit3 at lower levels than in Slit3Cntrl mice. 
This reduces the strength of the chemorepulsive effect on Robo1 expressing axons, 
allowing them to elongate out of the nerve bridge. C. In Slit3/Robo1 double 
heterozygous mutants these two previous effects are combined. This results in a 
more profound effect as macrophages express Slit3 at lower levels and axons are 
also less able to respond to the Slit3 chemorepulsive cues due to expressing less 
Robo1; furthermore fibroblasts are also unable to respond as readily to the low levels 
of Slit3 present. This double mutant has an exacerbated phenotype where many 
more axons leave the nerve bridge and become disorganised due to the loss of Slit3-
Robo1 signalling.  
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10.2.8 Myelin clearance after sciatic nerve transection in Slit2, Slit3 and Robo1 
mutants. 
Having previously established that axonal and fibroblast migration is disrupted in 
Slit/Robo mutants, we wanted to determine if SC behaviour is also affected during 
peripheral nerve regeneration. During Wallerian degeneration, SCs undergo 
reprogramming to adopt a pro-regenerative state [Arthur-Farraj et al., 2012; 
Harrisingh et al., 2004; Kim et al., 2013; Le et al., 2005; Napoli et al., 2012; 
Parkinson et al., 2008; Yang et al., 2012]. To adopt the pro-regenerative state SCs 
must shed their myelin, a process that is carried out by SCs through myelinopaghy 
with the assistance of macrophages, which SCs recruit [Gomez-Sanchez et al., 
2015; Jung et al., 2011; Perry et al., 1995]. Upregulation of c-Jun and p-ERK has 
also been shown to be essential for the reprogramming of SC into a pro-regenerative 
state [Arthur-Farraj et al., 2012; Fontana et al., 2012; Napoli et al., 2012; Parkinson 
et al., 2008]. We wanted to determine if myelin clearance and c-Jun or p-ERK levels 
in the distal nerve stump were affected in Slit/Robo mutants following sciatic nerve 
transection.  
Slit2Het mutants had no changes in myelin clearance after sciatic nerve transection 
compared to Slit2Cntrl mice [Figure 9.3]. In comparison, Slit3Het mice appeared to have 
accelerated MBP clearance in the distal nerve stump seven days following sciatic 
nerve transection in comparison to Slit3Cntrl mice, but no changes in MPZ clearance 
at either four or seven days post-transection [Figure 9.3]. Robo1Het mice had slightly 
accelerated clearance of both MBP and MPZ in comparison to Robo1Cntrl mice seven 
days following sciatic nerve transection [Figure 9.3]. However, c-Jun and p-ERK1/2 





While western blots showed a trend in accelerated clearance of myelin in Robo1Het 
mutants the variations between samples was relatively high. The n number would 
need to be increased to make any deductions from these experiments.  
10.2.9 Functional recovery in Robo1 mutants after peripheral nerve injury 
As axonal pathfinding is severely disrupted in Robo1Het mutants, this may result in 
fewer axons reaching the distal nerve stump to elongate and reinnervate their target. 
If this were the case, then we would see a slower functional recovery in Robo1Het 
mutants. Therefore, we wanted to determine if functional recovery was affected. 
However, a sciatic nerve transection is a severe injury type where the function of the 
affected limb is only rarely fully regained. Therefore, a sciatic crush injury or peroneal 
cut injury was performed instead as these injuries are less severe and do show 
regain of function to the affected limb [Baptista et al., 2007].  We analysed gait as a 
measure of functional recovery following injury. We used the static sciatic index as a 
measure of reinnervation following a sciatic nerve crush [Baptista et al., 2007]. 
Following a peroneal cut injury, we used the peroneal functional index to give a 
measure of recovery [Inserra et al., 1998].  
Robo1Het mutants had no changes in functional recovery when compared to 
Robo1Cntrl mice in either functional test, indicating that Robo1Het mutants recover 
normally [Figure 9.4 and 9.5]. As we had observed disrupted axonal pathfinding 
following a sciatic nerve transection in the Robo1Het mutants this was a disappointing 
finding, however, these results can be explained.  
During a crush injury, a nerve bridge is not formed. Therefore, axons do not have to 
cross this area and do not rely on directional cues to guide them across the bridge. 
We have previously discussed that we believe Slit3-Robo1 signalling is required to 





axons are not relying on the Slit3-Robo1 mechanism and can regenerate 
comparatively normally.  
Functional recovery following a peroneal nerve injury in the Robo1Het mutant could 
be due to several factors. In the Robo1Het mutant following sciatic nerve transection, 
many axons had an aberrant path out of the nerve bridge, but axons also did 
transverse the nerve bridge to reach the distal nerve stump. It could be this group of 
axons that is providing motor reinnervation in the peroneal transection model. 
Furthermore, following transection axons can reinnervate 3-fold the number of 
muscles fibres in comparison to their uninjured counterparts [Fu and Gordon, 1995]. 
This increased number of reinnervation sites means that fewer axons can innervate 
the same number of muscle fibres following an injury which could account for the 
regain in function.  
10.2.10 Contribution of knowledge 
Previously, the complete expression pattern of Slit/Robo in the adult intact peripheral 
nervous system was partially elucidated to but not entirely. We have fully elucidated 
the expression pattern of Slit/Robo in uncut sciatic nerve in mice, consolidating this 
information while reconfirming some previous data and contributing novel findings to 
the field. Regarding the uncut sciatic nerve novel data includes: the expression of 
Robo2 is confined to neurons, Robo1 is expressed in endothelial cells and 
fibroblasts, Slit3 is expressed in neurons, fibroblasts, and both non-myelinating and 
myelinating SCs in varying degrees.  
Other novel data in the uncut adult sciatic nerve includes confirmation that in 





The role of Slit/Robo remains unknown, throughout the discussion we have 
postulated on the potential role in maintaining the structure of the sciatic nerve. 
However, this continues to be confirmed.  
Previously there was no evidence to show that Slit3 is expressed by macrophages 
that surround the nerve bridge. It had also not been previously demonstrated that 
SCs and axons that migrate into the bridge express Robo1 seven days post-injury. 
We have also shown that in single Robo1Het, Slit3Het mutants and double 
Robo1HetSlit3Het mutants axons have incorrect trajectories when elongating across 
the nerve bridge during regeneration.  However, we did not look at any of the 
downstream signalling pathways that are active that may control this co-ordinated 
migration.  
Furthermore, we have shown that fibroblasts migrate away from the nerve bridge in 
Robo1Het mutants. It is also not known if this uncoordinated migration is more severe 
in the Robo1HetSlit3Het double mutant. It is also currently unknown as to if SC 
trajectories are affected in the Slit3Het or Robo1Het mutants.  
We have established that motor functional recovery is not affected following either a 
sciatic nerve crush or a peroneal cut injury in Robo1Het mutants. However, we did not 
establish whether sensory functional recovery was affected following either a sciatic 
nerve crush or peroneal nerve cut.  
10.2.11 Weaknesses of the study 
Due to the embryological lethality of the Robo1 homozygous mutant, only 
heterozygous mutants could be used during this study. Moreover, all mutant mice 
were global knockouts causing every cell type to be affected. This means that the 
effects seen during peripheral nerve regeneration in the mutant mice were unspecific 





as macrophages and neurons, was the direct cause of the incorrect regeneration. 
This problem could be overcome with the production of inducible Slit/Robo cell-
specific knockouts. 
RT-PCR provides a good indication of mRNA expression within the tissue sample. 
However, this work is not genuinely quantitative and does not give a value of the 
expression. Fluorescence in situ hybridisation and qPCR could be used to confirm 
our RT-PCR and in situ results and fully elucidate to the expression of mRNA in the 
peripheral nerve samples before and after sciatic nerve transection.  
Immunohistochemistry can show expression location and intensity values within a 
tissue section, however, many factors can affect the expression pattern observed 
such as fixation method, antibody dilution and affinity, antibody detection systems. 
Varying protein isoforms and post-translation modifications can also mask or 
enhance the binding of the primary antibody to the protein, and this could potentially 
influence fluorescence intensity or detectability of the protein. We tried to minimise 
these confounding factors by using the same method for each antibody. We also did 
negative controls to determine any secondary antibody background to determine if 
the staining we saw was due to primary antibody staining or unspecific bind causing 
background. 
Another weakness of the study was the inability to assess functional recovery 
following a sciatic nerve cut injury, instead having to use a peroneal cut or a crush 
injury as these types of injuries do recover, and a sciatic nerve cut does not.  
Western blotting also has weaknesses that include the difference in antibody affinity 
and high background. Again, we tried to minimise these effects by using a standard 
protocol for all western blots that was adjusted to ensure complete transfer of 





method as the process does not give a quantifiable value of protein, rather a 
representation.  
10.2.12 Future directions 
Future directions that would address the weaknesses of this study could include the 
use of a tamoxifen-dependent Cre recombinases (CreER) LoxP system [Feil et al., 
2009]. This system could be harnessed to produce cell-specific Slit/Robo inducible 
knockouts. One inducible knockout of interest would be a Robo1 axon specific 
knockout. This would allow for tamoxifen pulsing at various time points throughout 
regeneration. This would establish if the loss of expression in these cells caused 
axons to regenerate with incorrect trajectories. It could then determine when 
precisely the expression of Robo1 was pivotal for the correct directional migration of 
axons. Tamoxifen pulsations could be administered at day 0, 2, 4, 6, 7, 8, 9, 10, and 
12 days post-injury the regenerating nerve would then be removed at 14 days post-
injury and whole mount staining performed to asses regeneration.  The same 
approach could be employed regarding SCs and fibroblasts to assess how Robo1 
contributes to their directional migration into the nerve bridge and at which time point 
this is pivotal.   
Another interesting future experiment would be to produce a macrophage-specific 
CreER inducible Slit3 knockout. A Slit3 flox/flox is in existence which could be 
utilised for this experiment [Kim et al., 2018]. This would determine if Slit3 expressing 
macrophages that surround the nerve bridge truly control the directional migration of 
Robo1 expression SCs, fibroblasts and axons. Again, the mouse could be 
administered tamoxifen at various time points following injury such as day 0, 2, 4, 6, 
7, 8, 9, 10, and 12 days post-injury. This would aim to establish a timeline of the 





qPCR could be used to assess the mRNA expression of Slit/Robos in uncut tissue 
and different regions of the cut nerve. This would give a quantitative value of 
Slit/Robo expression and enable critical evaluation of the expression patterns of 
Slit/Robo mRNA. Laser capture microdissection could also be harnessed to separate 
the macrophage conduit around the nerve bridge and then use this tissue for qPCR.  
To further confirm the expression pattern in the macrophages at the nerve bridge we 
could use fluorescence in situ hybridisation on longitudinal samples from 2-month-
old C57BL/6 mice seven days post-injury. This would enable us to observe Slit/Robo 
mRNA expression across the nerve bridge because currently, this data remains 
unknown.  
We only tested motor functional recovery following sciatic nerve crush and peroneal 
nerve cut in the Robo1Het mutant and did not test for sensory functional recovery 
[Figure 9.4 and 9.5]. It would be interesting to test sensory functional recover by 
testing with Van Frey hair following an injury to establish sensory axon reinnervation 
patterns. 
To further identify the role of Slit3 during regeneration Slit3 fragments could be 
embedded into a conduit and used on Slit3KO/Robo1Het mutants to assess if they 
increase the number of axons reaching the distal nerve stump. This may further 
confirm Slit3s directional capability in directing cells within the nerve bridge.  
10.2.13 Conclusion 
We can conclude that the intact adult sciatic nerve expresses a range of Slit/Robos 
[Carr et al., 2017], which may be involved in structural maintenance. We can also 
conclude that Slit3-Robo1 signalling plays a vital role in correct axon guidance 
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Material Source 
Acrylamide Bio-Rad Laboratories Ltd, 
Hertfordshire, UK 
Agar 30% low viscosity 
resin  
Agar scientific, Stansted, UK 
Agarose  Sigma-Aldrich, Missouri, USA 
Amersham Hyperfilm ™ 
ECL 
GE Healthcare Life Sciences, 
Little Chalfont, UK 
Ammonium Persulfate Sigma-Aldrich, Missouri, USA 
Bovine serum albumin  Sigma-Aldrich, Missouri, USA 
Chloroform Sigma-Aldrich, Missouri, USA 
Deionised Formamide Sigma-Aldrich, Missouri, USA 
Denhardts Sigma-Aldrich, Missouri, USA 
Deoxynucleotide 
triphosphates 
Roche, Welwyn Garden City, 
UK 
Devalex® M X-ray 





Sigma-Aldrich, Missouri, USA 
Diethylpyrocarbonate Sigma-Aldrich, Missouri, USA 
DIG-AP antibody  Roche, Welwyn Garden City, 
UK 
Dow-Corning® high-
vacuum grease  







Sigma-Aldrich, Missouri, USA 




All primers Eurofins, Camberley, UK  
Frame-Seal™ Incubation 
chamber  
Bio-Rad Laboratories Ltd, 
Hertfordshire, UK 
GelRed™ Biotium, Hayward, USA 
Glutaraldehyde Sigma-Aldrich, Missouri, USA 
Glycerol  Sigma-Aldrich, Missouri, USA 
Glycerol based Citifluor Citifluor, London, UK 
Glycine Sigma-Aldrich, Missouri, USA 
Green GoTaq 5x Buffer Promega, Southampton, UK 
Magnesium Chloride Sigma-Aldrich, Missouri, USA 
Maleic Acid Sigma-Aldrich, Missouri, USA 
Methanol VWR, Lutterworth, UK 
Magnesium chloride  Sigma-Aldrich, Missouri, USA 
Marvel milk powder  Premier foods, St Albans, UK 
NBT/BCIP Roche, Welwyn Garden City, 
UK 
Optimal cutting temperature 
(OCT) medium  
Scigen, Singapore 
PAP pen  Daido Sangyo, Tokyo, Japan 
Paraformaldehyde powder Sigma 
Polyvinylidene fluoride 
0.45µm transfer membrane 
(PVDF)  






Potassium Chloride Sigma-Aldrich, Missouri, USA 
Polyvinyl alcohol Acros organics - Thermo 
Scientific, Wilmington, USA 
QIAzol Lysis Reagent Qiagen, Manchester, UK 
Sodium dodecyl sulphate 
(SDS) 
Sigma-Aldrich, Missouri, USA 




Sigma-Aldrich, Missouri, USA 
Sodium Hydroxide Sigma-Aldrich, Missouri, USA 
Sodium phosphate dibasic Sigma-Aldrich, Missouri, USA 
Sucrose  Sigma-Aldrich, Missouri, USA 
SuperFrost®Plus slides  VWR, Lutterworth, UK 
Taq Polymerase Promega, Southampton, UK 
Tetramethylethylenediamine Sigma-Aldrich, Missouri, USA 
Tris-Base Sigma-Aldrich, Missouri, USA 
Tris-HCl Sigma-Aldrich, Missouri, USA 





























Figure 11.1: Control PCR and water controls. A. Control PCRs on DRG uncut samples 
for Slit1, Slit2, Slit3, Robo1 and Robo2 from 2-month old C57BL/6 mice. B. Water controls 























Figure 11.2: Original PCR gel Slit1 and Robo2 on DRG samples. Results from 
Slit1 and Robo2 primers on uncut and cut DRG samples from 2-month old 
C57BL/6 mice. Lane 1 shows cut 4 days post-injury, lane 2: uncut 4 days post 
injury. Lane 3: 7 days post-injury cut, lane 4: 7 days post injury cut. Lane 5: 10 
days post-injury injured side, lane 6: 10 days post-injury uninjured side. Lane 7: 
14 days post-injury injured side, lane 8: 14 days post injury uninjured.  
Slit1 Robo2 
Figure 11.3: Original gel GAPDH and Robo1 on DRG samples. Results from 
GAPDH and Robo1 primers on uncut and cut DRG samples from 2-month old 
C57BL/6 mice. Lane 1 shows cut 4 days post-injury, lane 2: uncut 4 days post 
injury. Lane 3: 7 days post-injury cut, lane 4: 7 days post injury cut. Lane 5: 10 
days post-injury injured side,lane 6: 10 days post-injury uninjured side. Lane 7: 14 
days post-injury injured side, lane 8: 14 days post-injury uninjured.  
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Figure 11.4: Slit3 PCR original gel on DRG samples. Results from Slit3 primers 
on uncut and cut DRG samples from 2-month-old C57BL/6 mice. Lane 1 shows 
cut 4 days post-injury, lane 2 uncut 4 days post injury. Lane 3: 7 days post-injury 
cut, lane 4: 7 days post-injury cut. Lane 5: 10 days post-injury injured side, lane 6: 
10 days post-injury uninjured side. Lane 7: 14 days post-injury injured side, lane 
8: 14 days post-injury uninjured.  
1    2    3    4    5   6    7    8  
Figure 11.5: Robo4 RT-PCR original gel on DRG samples. Results from Robo4 
primers on uncut and cut DRG samples from 2-month-old C57BL/6 mice. Lane 1 
shows cut 4 days post-injury, lane 2: uncut 4 days post-injury. Lane 3: 7 days 
post-injury cut, lane 4: 7 days post-injury cut. Lane 5: 10 days post-injury injured 
side, lane 6: 10 days post-injury uninjured side. Lane 7: 14 days post-injury 
injured side, lane 8: 14 days post-injury uninjured.  













Figure 11.6: Slit2 RT-PCR original gel from DRG samples. Results from Slit2 
primers on uncut and cut DRG samples from 2-month-old C57BL/6 mice. Lane 1 
shows cut 4 days post-injury, lane 2: uncut 4 days post injury. Lane 3: 7 days 
post-injury cut, lane 4: 7 days post-injury cut. Lane 5: 10 days post-injury injured 
side,lane 6: 10 days post-injury uninjured side. Lane 7: 14 days post-injury injured 
side, lane 8: 14 days post-injury uninjured.  
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Robo1 
Figure 11.7: Slit1 original RT-PCR from uninjured and post-sciatic nerve cut 
spinal cord samples. Lane 1, 3 and 5 are all samples from uninjured spinal cord 
samples. Lane 2, 4 and 6 are all samples from spinal cord samples post-sciatic 
nerve cut. Slit1 RT-PCR experiments on samples from uninjured and post-sciatic 
nerve cut spinal cord samples 4, 7, 10 and 14 days post-injury from 2-month-old 
C57BL/6 mice..   
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Figure 11.8: Slit2 original RT-PCR from uninjured and post-sciatic nerve cut 
spinal cord samples. Lane 1, 3 and 5 are all samples from uninjured spinal cord 
samples. Lane 2, 4 and 6 are all samples from spinal cord samples post-sciatic 
nerve cut. Slit2 RT-PCR experiments on samples from uninjured and post-sciatic 
nerve cut spinal cord samples 4, 7, 10 and 14 days post-injury from 2-month-old 
C57BL/6 mice..   
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Figure 11.9: Robo1 original RT-PCR from uninjured and post-sciatic nerve 
cut spinal cord samples. Lane 1, 3 and 5 are all samples from uninjured spinal 
cord samples. Lane 2, 4 and 6 are all samples from spinal cord samples post-
sciatic nerve cut. Robo1 RT-PCR experiments on samples from uninjured and 
post-sciatic nerve cut spinal cord samples 4, 7, 10 and 14 days post-injury from 2-
month-old C57BL/6 mice.  
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Figure 11.10: Robo2 original RT-PCR from uninjured and post-sciatic nerve 
cut spinal cord samples. Lane 1, 3 and 5 are all samples from uninjured spinal 
cord samples from 2-month-old C57BL/6 mice. Lane 2, 4 and 6 are all samples 
from spinal cord samples post-sciatic nerve cut from 2-month-old C57BL/6 mice. 
Robo2 RT-PCR experiments on samples from uninjured and post-sciatic nerve 
cut spinal cord samples 4, 7, 10 and 14 days post-injury.  
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Figure 11.11: Robo4 original RT-PCR from uninjured and post-sciatic nerve 
cut spinal cord samples. Lane 1, 3 and 5 are all samples from uninjured spinal 
cord samples from 2-month-old C57BL/6 mice.  Lane 2, 4 and 6 are all samples 
from spinal cord samples post-sciatic nerve cut from 2-month-old C57BL/6 mice. 
Robo4 RT-PCR experiments on samples from uninjured and post-sciatic nerve 
cut spinal cord samples 4, 7, 10 and 14 days post-injury.  
1   2  3   4  5   6 
4 Days 
1   2  3  4   5   6 1   2   3  4   5   6 
1   2   3  4  5  6 







Figure 11.12: Robo1 original western blot films. A. P-ERK results uninjured 
sciatic nerve and 4 days and 7 days post-injury distal nerve stumps from 
Robo1Cntrl and Robo1Het mice. B. GAPDH results uninjured sciatic nerve and 4 
days and 7 days post-injury distal nerve stumps from Robo1Cntrl and Robo1Het 
mice. C. c-Jun results uninjured sciatic nerve and 4 days and 7 days post-injury 
distal nerve stumps from Robo1Cntrl and Robo1Het mice. D. MBP results uninjured 
sciatic nerve and 4 days and 7 days post-injury distal nerve stumps from 
Robo1Cntrl and Robo1Het mice. E. MPZ results uninjured sciatic nerve and 4 days 












Figure 11.13: Slit3 original western blot films. A. MBP results uninjured sciatic 
nerve and 4 days and 7 days post-injury distal nerve stumps from Slit3Cntrl and 
Slit3Het mice. B. MPZ results uninjured sciatic nerve and 4 days and 7 days post-
injury distal nerve stumps from Slit3Cntrl and Slit3Het mice. C. GAPDH results 
uninjured sciatic nerve and 4 days and 7 days post-injury distal nerve stumps 








































Figure 11.14: Slit2 original western blot films. A. MBP results uninjured sciatic 
nerve and 4 days and 7 days post-injury distal nerve stumps from Slit2Cntrl and 
Slit2Het mice. B. MPZ results uninjured sciatic nerve and 4 days and 7 days post-
injury distal nerve stumps from Slit2Cntrl and Slit2Het mice. C. GAPDH results 
uninjured sciatic nerve and 4 days and 7 days post-injury distal nerve stumps 










Figure 11.15: Slit1 original western blot films. A. Slit1 results from C57BL/6 
uninjured sciatic nerve and the proximal nerve stump, the nerve bridge and the 
distal nerve stump 7 days post-injury. B. GAPDH results from C57BL/6 uninjured 
sciatic nerve, the proximal stump, the nerve bridge and the distal stump 7 days 
post-injury.  
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